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Photoreactive groups have been used in photoaffinity labelling of chemical 
macromolecules via the generation of highly reactive species upon short wave light 
irradiation. One of the most efficient photoreactive functional groups is 
trifluoromethyl aryldiazirine (TFMAD). This compound was synthesised as part of 
the work discussed in this thesis, making use of microwave irradiation to shorten 
reaction times (Chapter I). An investigation of properties allowed the development 
of three different applications for conjugation to biomolecules. The first application 
consisted of the development of an approach for generation of small-molecule 
microarrays, where a 2,000 compound library was immobilised onto the glass 
surface through carbene insertion. The microarray was then used to screen for 
potential binders to beta-transducin repeat containing protein (β-TrCP1) allowing 
the reduction of possible candidates to less than 25 compounds (Chapter II). The 
second application was the synthesis of two probes to allow the selective delivery of 
active compounds inside specific organelles or cells. The diazirine moiety was used 
as a rapid way to covalently capture a number of cargos. The approach allowed a 
peptoid and an anticancer drug to be conjugated to the two probes and their cell 
penetrability properties and therapeutic effect were studied, respectively (Chapter 
III). Finally, the insertion properties of TFMAD were used to develop approaches to 
attach DNA onto microspheres and the efficiency of this delivery system was 
evaluated (Chapter IV). 
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Chapter I: 




1.1. Introduction  
Photophores are stable reagents that become highly reactive species 
when activated by UV light, often forming new covalent bonds with surrounding 
molecules. These may be biopolymers or surfaces with typically few, if any, 
restrictions on selectivity towards different functional groups. Their use adds 
variation and opportunity for studying systems where little is known.  
This chapter introduces the most common photoactivatable groups, 
describes how they work and looks at their reactivity and applications. Finally, it 
focuses on the synthesis, properties and behaviour of the trifluoromethyl 
aryldiazirine photophore, which is the photoactivatable group that has been used 
in this thesis. 
1.1.1. Photoactivatable Reagents 
Photoprobes are important tools used in drug discovery and drug 
development.1-4 For example, photoactivatable groups have been widely used in 
photoaffinity labelling approaches, a method that is based on the chemical 
modification of biological macromolecules (i.e. proteins). It is an efficient and 
reliable tool used to identify, isolate and characterise novel biological molecules 
as well as to identify potential drug targets, particularly when the target 
molecule is unknown. This method also helps to define relationships on 
biomolecules within an assembly, and to provide information on the spatial 
relationship between components in complex systems.1, 5  
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One important feature of this technique is the preparation of an 
effective probe. The photoaffinity probe incorporates a photoactivatable group in 
its structure which is activated by light when complexed to its target. Until they 
are photolysed, photosensitive functional groups are relatively non-reactive in 
typical thermochemical processes. Because they are stable in the dark, reagents 
designed with a photophore can be assessed for their bioactivity before being 
used in highly controlled photoactivated reactions.  
Upon activation, photoactivatable groups generate highly reactive 
species which allows formation of a new covalent bond between the ligand and 
the target molecule. In addition, the probe often incorporates a reporter group in 
order to identify and facilitate the isolation of the labelled molecule. These 








Figure 1.1: Schematic representation of photoaffinity labelling approach. In this case, the 
probe consists of a high affinity compound that has been derivatised with a photoreactive 
group and reporter group. Once the complex between probe and protein has ocurred, the 
sample is irradiated leading to the formation of a covalent bond between them. Then, the 
reported group is used to identify or purify the adduct. 
Photoactivatable reagents form short-lived, high-energy intermediates 
upon UV irradiation. Thus, an important feature of these reagents is that they 
should be activated at wavelengths that do little or no damage to the other 
components of the system. In general, this means that irradiation at 
wavelengths absorbed by proteins and nucleic acids (<300 nm) should be 
avoided. In addition, photolysis should be highly efficient; that is the reagent 
should have a high extinction coefficient (ε) and the reactive group should be 
formed in high quantum yield (Ф).  
The most common photoactivatable functional groups are 
benzophenones, aromatic azides and aromatic diazirines generating reactive 
intermediates such as ketyls, nitrenes, and carbenes. 
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1.1.1.1. Ketyl-Reactive Species: 
Acetophenones, benzophenones and anthraquinones form highly reactive 
species after exposure to UV light (ranging from 340 to 360nm).11-13 The 
photoactivatable group of these reagents are conjugated carbonyl functionalities 
which can be excited by UV light, generating an nπ* triplet state (Figure 1.2).14 
In the exited state the molecule can interact with weak C-H σ-bonds, resulting in 
hydrogen abstraction to form a ketyl radical. The ketyl readily recombines with 
the alkyl radical generated in the substrate, forming a new C-C bond (Scheme 
1.1). Unreacted excited species rapidly relax to the ground state, as a result, 
conjugated ketones usually need quite long irradiation times,15, 16 which can be 
problematic for some applications. However, they can be manipulated in 
aqueous solutions as they do not react with water or bulk nucleophiles.12  
 
Figure 1.2: Generation of nπ* triplet state after excitation with UV light. 
 
 
Scheme 1.1: Conjugated carbonyl excited by UV light form a triplet excited state that 
abstracts a hydrogen atom from a donor yielding two radicals which subsequently couple. 
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1.1.1.2. Nitrene-Reactive Species: 
Nitrenes are highly reactive species generated by azide photolysis. They 
can insert non-specifically into different chemical bonds of target molecules, 
including addition reactions to double bonds and insertion reactions to bonds at 
C-H and N-H sites. 
One of the most widely applied photolabelling reagents are phenyl 
azides.17, 18 Their popularity is mainly due to the ease of their synthesis and 
commercial availability. Although phenyl azides possess high stability, the 
nitrenes generated are much less reactive than many other classes of nitrenes. 
For example, photolysis of phenyl azides in hydrocarbon solvents at room 
temperature gives almost none intermolecular C-H insertion products.19, 20 This 
lack of reactivity may in part be due to the ring expansion of the generated 
singlet phenyl nitrene after photolysis forming azirine and dehydroazepine,21, 22 
23 which tends to be intercepted by a nucleophile such as an amine or undergo 
polymerisation to form poly-1,2-azepines24 in the absence of a nucleophile 
(Scheme 1.2).  
 
Scheme 1.2: Photolysis of phenyl azides at 250 nm produces phenyl nitrenes which insert 
into different chemical bonds or they can undergo a ring expansion forming dehydroazepine 
which reacts with nucleophiles such as amines and thiols to form substituted azepines or 
polymerise to form poly-1,2-azepines. 
New azide reagents that promise an improved series of photolabels are 
perfluorophenyl azides (PFPA). They give higher yields of C-H insertion than their 
non-fluorinated analogues, possibly due to the higher reactivity of the nitrenes 
by favouring triplet state formation and consequently lacking the side reaction of 
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the singlet nitrene ring expansion (Scheme 1.3). Moreover, its photolysis can 
be conveniently monitored by 19F NMR. However, all 4-substituted 
perfluorophenyl azides have UV absorption maxima around 260 nm which can 
damage biomolecules. Fortunately, photolysis tends to be complete before 
appreciable photolytic damage takes place due to the greater molar absorptivity 
and photochemical liability of the photoreactive reagent relative to 
biopolymers.25 
 
Scheme 1.3: Photolysis of perfluroinated azides produce singlet and triplet nitrenes, without 
ring expansion, which they undergo C-H insetion to form secondary amines or radicals by 
proton atom abstraction followed by radical coupling. 
1.1.1.3. Carbene-Reactive Species: 
Diazo and diazirine compounds undergo irreversible nitrogen liberation 
upon UV irradiation forming short-lived and highly reactive carbenes that react 
rapidly with the surrounding chemical environment.26 Carbenes insert non-
specifically into chemical bonds, preferably addition reactions to double bonds27 
but also insertion reactions into C-H and O-H bonds28, 29 (Scheme 1.4).  
 
Scheme 1.4: Photolysis of diazo or diazirine compounds generate carbenes which react 
non-specifically with the surrounding molecules. 
Although diazo compounds were one of the first photoactivatable 
reagents to be used, their photolysis properties are not ideal for photoaffinity 
labelling for several reasons. Firstly, they generally possess a strong absorption 
band in the ultraviolet (<300 nm, ε ≈ 104 M-1cm-1) and a very weak band at 
longer wavelengths (340 nm, ε ≈ 11 M-1cm-1).5 Irradiation at >300 nm must 
thus be prolonged to achieve complete photolysis which can damage biological 
samples, however it has been shown that photolysis at 254 nm can be achieved 
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in a reasonable time-frame without causing damage to proteins if care is taken.30 
They are not very stable but it is known that they are stabilised by electron 
withdrawing substituents at the α-position to the diazo carbon. The diazoacetyl 
compound family is one of the most stable.31 
Secondly, the carbene formed after irradiation can undergo Wolff 
rearrangement yielding a ketene as a major product (Scheme 1.5). This fact is 
one of the reasons why nowadays diazoacetyl compounds are seldomly used for 
photoaffinity labelling.32, 33 
 
Scheme 1.5: Formation of ketene from carbene by Wolf rearrangement. 
Finally, diazoacetyl compounds have very low stability. They are unstable 
at low pH and they have been seen to react in the dark towards protein 
functional groups. For instance, modification of histidine occurred in an acid-
catalysed rather than a light-induced process with the percentage yield 
depending on the pH. 33, 34 In addition, like phenyl azides, diazo compounds are 
susceptible to reduction by a number of thiols used commonly as protective 
agents for proteins.35 However, the two diazo reagents, diazotrifluropropionyl 
(1)36 and p-toluenesulfonyldiazoacetyl (2),37 are considerably improved in these 
respects and are stable in 1 M hydrochloric acid.  
 
Scheme 1.6: Structures of diazotrifluoropropionyl and p-toluenesulfonyldiazoacetyl group. 
 On the contrary, the use of diazirines as stable carbene precursors has 
increased dramatically over the past twenty years and these reagents are rapidly 
becoming the most popular photophores for photoaffinity labelling and biological 
applications. They have also become important in radical chemistry to prepare 
heterocyclic compounds.38, 39 
Among diazirines, trifluoromethyl aryldiazirines appear to come closest to 
satisfying the chemical and biological criteria required for an optimal 
photoreagent.40-44 The diazirine functionality is remarkably stable under a range 
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of different physical and chemical conditions and it is rapidly photolysed at 350 
nm to generate a carbene capable of reacting with the full range of functional 
groups, including paraffinic C-H bonds.  
1.1.2. Trifluoromethyl Aryldiazirine Photophores 
Diazirines were first synthesised and characterised in the early 1960s.45-47 
These unsaturated species (3) are three-membered heterocycles featuring an 
azo group and an sp3 hybridised carbon atom.   
 
The most outstanding property of diazirines is their ability to form highly 
reactive carbenes with concomitant liberation of nitrogen upon suitable 
activation via exposure to light, pyrolysis or ultrasonification.48 In addition to 
reactions with nucleophilic groups, carbenes are capable of reacting via insertion 
into saturated and unsaturated hydrocarbons including aromatic systems.49 
Reaction with carbenes involve the formation of stable carbon-based bonds 
under most of the conditions necessary for further studies.50  
 
Figure 1.3: Structures of a) dialkyldiazirines and b) 3H-diazirines. 
The first diazirines to be prepared were dialkyl diazirines and               
3H-diazirines (Figure 1.3), the latter being extremely difficult to synthesise in 
acceptable yields since they have low stability. The problem of these diazirines is 
their susceptibility to undergo intramolecular rearrangement by 1,2-hydrogen 
migration51 (Scheme 1.7). Adamantanediazirine, a constrained caged ring, and 
3-halodiazirines have been prepared as they can not rearrange to olefins. 
However, adamantanediazirines are not exempted of intramolecular 
rearrangements52, 53 and 3-halodiazirines were found to have a potentially 
explosive nature and they are typically only utilised for structural and kinetic 
studies.48 
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Scheme 1.7 : Examples of unwanted photolysis products by intramolecular rearrangement. 
a)  Rearrangement of carbenes from alkyl diazirines to give olefins. b) Adamantanediazirine 
carbenes undergo intramolecular insertion.  
A more recent addition to the diazirine family were 3H-3-aryldiazirines 
described by Knowles et al.,54 which were found to be relatively stable to 
intramolecular rearrangements. However, a serious problem of this family is the 
high percentage of diazo isomer generation when irradiated, which can vary 
between 30 and 70%.54, 55 Lastly, Brunner et al.42 introduced the trifluoromethyl 
aryldiazirines family which properties come close to satisfying the criteria 
required for photoprobes while rearrangement to the linear diazo form is less 
significant. 
Photolysis of trifluoromethyl aryldiazirines can be conducted at 
wavelengths that biomaterials are inert to, thus preventing any unwanted 
photochemical or structural changes in the target receptor.54 They are readily 
photolysed to produce highly reactive carbenes, in high quantum yield, whose 
life-time is on the nanosecond time-scale, so that no reactive species are left 
after photolysis. Although a certain proportion of trifluoromethyl aryldiazirines 
undergo isomerisation to its linear diazo isomer upon photolysis (Scheme 
1.8)42, the resulting diazo species (6) are stable under the conditions used to 
decompose trifluoromethyl diazirines and the biological environments, therefore 
not giving undesired intermediates.42 This stability is enhanced by the 
introduction of the trifluoromethyl group which decreases the ability to undergo 
rearrangement and increase the stability of the corresponding diazo derivative 6, 
which becomes a precursor of carbene 5 with the use of a shorter wavelength 
(302 nm) or with longer irradiation times at 365 nm.42, 56 An additional 
advantage of the trifluoromethyl group next to the diazirine ring is that all 
compounds generated from the photolysis are suitable for 19F NMR analysis.  
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Scheme 1.8: Photolysis of aryl(trifluoromethyl)diazirines generates a carbene which react 
non-specifically with surrounding molecules. Simultaneously, the diazo isomer form is also 
generated and with further irradiation also becomes a precursor of carbenes. 
Despite the strained ring structure of diazirines, these systems possess 
excellent chemical and thermal stability, being far more stable than their linear 
diazo isomers. Aryldiazirines have been shown to be stable towards a wide range 
of reagents; they are resistant to dilute acids and strong bases, oxidising agents 
and mild reducing agents such as sodium borohydride.10, 44, 57, 58 Such 
information is of great importance in designing synthetic strategies. Diazirines 
are also stable under physiological conditions including the presence of thiols, 
which attack azides and diazo compounds,42 and can be stored for long periods 
of time.31, 59 The reason why these systems have not been employed as widely 
as other photophores (such as azides) is the lack of commercial availability of a 
wide range of trifluoromethyl ketones used as starting materials in addition to 
the often complex synthesis required.60 
1.1.3. Diazirine Reactivity 
Carbenes are neutral molecules that have divalent carbons and react in 
various ways to complete their valence shells. The typical reactions of carbenes 
are shown in Scheme 1.9. Besides reacting with nucleophilic groups, carbenes 
are capable of reacting by insertion with saturated hydrocarbons and by addition 
to unsaturated hydrocarbons including aromatic molecules.26 
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Scheme 1.9: Typical reactions of carbenes. 
 Carbenes can be classified as either being in a triplet or a singlet state, 
depending on whether the nonbonding electrons are of the same or opposite spin 
(Figure 1.4). The bonds in triplet carbenes are formed from sp orbitals, with 
unpaired electrons being in two equivalent p orbitals and possessing a linear 
structure (H-C-H angle of 125-140º). The singlet carbene assumes sp2 
hybridisation, with the two unshared electrons in an sp2 orbital. The p orbital is 
unoccupied. The R-C-R angle is contracted slightly from the normal 120º 
because of the electronic repulsions between the unshared electron pair and the 
electrons in the two bonding orbitals (H-C-H angle of 102º). 
 
Figure 1.4: Two varieties of carbenes: singlet carbenes have no unpaired electrons, spin 
multiplicity zero and they are diamagnetic, whereas triplet carbenes have two unpaired 
electrons, a total spin of one and they are paramagnetic. 
The spin states of carbenes are important since singlet and triplet 
carbenes not just have different geometries but also different chemical 
reactivities. Singlet carbenes are believed to be involved in rearrangements to 
fully bonded species, stereospecific reactions with σ and p bonds and the 
addition of nucleophiles. In contrast, triplet carbenes take part in abstractions, 
non-stereospecific additions to double bonds and radical-like reactions.26  
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Although carbenes are extraordinarily reactive, they exhibit an 
appreciable degree of selectivity in reactions with various functional groups. This 
selectivity depends upon the molecular structure of the carbene. For example, a 
photogenerated singlet methylene reacts with nucleophiles more readily than 
with C-H bonds, even when the number of C-H bonds is much higher than for 
example O-H bonds.28, 61, 62 On the other hand, carbenes such as :CF2 react with 
alkenes substituted with groups with a variety of  electronic properties, and do 
not insert at all into C-H bond.49  
The selective reactivity of trifluoromethyl aryldiazirines used in this thesis 
have been explored in just one detailed study in the literature.63 The study 
showed that trifluoromethyl aryl carbenes generated in alcoholic solutions, 
preferably inserted into O-H groups, accounting for around 70% of insertion 
products. This behaviour could be explained by singlet methylene formation. On 
the other side, the insertion degree of C-H bonds gradually decreases as 
methylene and methyl groups move away from the hydroxyl group. Different 
preferable selectivity towards methylene or methyl groups was not seen in this 
study, but when methine groups were present, insertion was preferred over 
methylene or methyl groups wherever its position was. This tendency can be 
explained via application of triplet carbene as an intermediate: the carbene’s 
rate-limiting abstraction of a hydrogen atom produces a radical pair which give 
the formal insertion product.64 Thus, it is clear that the trifluoromethyl 
aryldiazirine group generates both singlet and triplet carbenes. 
Selectivity of carbenes also varies between thermal and photolysis 
generation and also between photogenerated carbenes in solution or in solid 
phase.64 Kanoh et al.63 studied the reactivity of trifluoromethyl arylcarbenes in a 
semi-solid state (photolysis in solution at -196 ºC) demonstrating that the 
insertion reactions in the solid state is less selective since C-H and O-H insertion 
products were formed in close to equivalent amounts. 
1.1.4. Applications 
The majority of applications for photophores have been directed to 
photoaffinity labelling techniques to investigate structural and functional 
properties of biological systems.3, 5, 32, 65-67 These labelling reagents can be 
divided into three main classes: firstly, probes designed to report on general 
properties of a system, for example, small apolar molecules or lipids which 
partition into membranes and label selectively integral proteins upon 
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activation;40, 68-71 secondly, affinity labelling reagents intended to interact with 
label components (receptors) in a specific, functionally relevant manner; and 
thirdly, heterobifunctional photocross-linkers, containing a photoactivatable and 
a thermal reactive function, preferentially connected via a cleavable linker to 
study the spatial relationship between components in complex systems, or to 
make macromolecular affinity probes. 
 Photoreactive groups have also been used for producing reactive 
(bio)polymers. Polymers of biological or synthetic origin have been modified to 
feature photolabile groups along the polymer chain which have been used to 
covalently immobilise bioactive ligands onto it and simultaneously covalently 
bind it to the substrate surface.48 Photoreactive amino acid analogues have been 
synthesised72, 73 to allow reactive peptides to be made by standard solid-phase 
techniques as well as photoreactive proteins.  This allows the study of structural 
properties from the interaction of peptides with proteins74 and protein-protein 
interactions within cells.75 Similarly, photoreactive DNA have also been prepared, 
which retain the ability to form double strand.76, 77 The photoreactive DNAs are 
useful tools for analysing the interactions between nucleotides and proteins, such 
as transcriptional complexes and regulators,78-82 chromatin structure,83 and 
chromatin-remodeling complexes.84 
 Finally, photoreactive groups have been used for modification of inert 
surfaces. One method is the pretreatment of the surface to achieve a reactive-
functionalised surface capable of attaching different biomolecules. Another 
method is the preparation of biomolecules containing a photoreactive group at a 
specific position. By positioning the photoreactive group on specific positions, the 
molecule can be bound onto the surface with the desirable orientation. These 
two methods have been used to modify different surfaces or particles, including 
polymer-base microplates,85 slides29, 86-90 and beads.91, 92  
1.2. TFMAD Synthesis 
 For all the advantages previously mentioned, the photoactivatable 
trifluoromethyl aryldiazirine reagent was selected for this thesis. Trifluoromethyl 
aryldiazirines (TFMAD) are generally prepared from the corresponding 
trifluoromethyl acetophenone in a four step sequence: oximation, tosylation, 
diazirinylation and oxidation to form the diazirine ring.41, 43, 44, 72, 93, 94 The main 
drawbacks of its application are the number of steps involved and the difficulty in 
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preparing trifluoromethyl acetophenones. In addition, a tether is usually 
introduced into the ring to allow further functionalisation for latter applications.  
The synthetic target chosen for this thesis was {4-[3-(trifluoromethyl)-
3H-diaziren-3-yl]phenoxy}acetic acid (4). This compound contains a carboxylic 
acid group, which would be used later on and could be safely protected with the 
bulky tert-butyl group while the diazirine ring was generated. 
 
Figure 1.5: {4-[3-(trifluoromethyl)-3H-diaziren-3-yl]phenoxy}acetic acid  (TFMAD).  
 The synthesis started with the alkylation of 4-hydroxybenzaldehyde 8 
(Scheme 1.10) with t-butyl bromoacetate giving t-butyl(4-formyl-
phenoxy)acetate 9 using microwave irradiation. Trifluromethyl acetophenone 
was synthetised in two steps: introduction of the trifluromethyl group by reacting 
the aldehyde with Ruppert’s reagent95 and oxidation of the resulting alcohol 10 
with Dess-Martin periodinane to give 11. Next, oxime 12 was prepared with 
hydroxylamine hydrochloride in pyridine which was subsequently tosylated with 
p-toluenesulfonyl chloride to give 13. Both reactions were performed under 
microwave irradiation which shortened reaction times and improved the yields. 
Formation of diaziridine 14 was accomplished by treating the tosylated oxime 
with liquid ammonia overnight at high pressure. Iodine was used for the 
oxidation of 14 to give trifluromethyl aryldiazirine 15.  Finally, the t-butyl group 
was removed with 50% trifluoroacetic acid in DCM. This synthetic route allowed 
the synthesis of 4 with a reasonable overall yield of 21%. 
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Scheme 1.10: Synthetic route for TFMAD 4 synthesis. 
This synthetic route was slightly modified when it was scaled up (Scheme 
1.11). Although Ruppert’s reagent and Dess-Martin oxidation gave good yields 
on small scale, Dess-Martin oxidation was very temperamental and lower yields 
were achieved when large amounts were required.  
For the large scale synthesis, 4-bromophenol was used as starting 
material, the bromo group allows the introduction of the trifluoromethyl acetate 
group by Grignard or nBuLi reaction. Both reactions were carried out with        
N-(trifluoromethyl)piperidine as an electrophile56, 93, 94, 96 under different reaction 
conditions. Although nBuLi reactions worked better than Grignard reagent, the 
yields were very poor. One way to improve the nBuLi reaction yield was the 
protection of the phenol. Finally, different electrophiles were tested and the best 
yields were found when trifluoromethyl ethylacetate was used.  
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Scheme 1.11: Large amount synthesis of TFMAD 4 photophore (about 1 gram). 
Thus, the synthetic route started by protecting the phenolic OH of 4-
bromophenol 16 with trifluoromethylsilane group and reaction with nBuLi and 
trifluoromethyl ethylacetate to give 18 as the deprotected alcohol in 68% yield. 
The rest of the synthesis was carried out as previously described in scheme 1.10 
giving 4 in overall 35% yield. 
1.3. Photochemical Properties 
As introduced in section 1.1.2, photolysis of diazirine ring leads to the 
generation of the diazo compound as well as the desired carbene. TFMAD and its 
diazo isomer can be differentiated from each other by their characteristic UV-Vis 
spectra and 19F NMR.42, 72, 97 These two techniques were used to characterise the 
synthesised TFMAD photophore 4, to evaluate its reactivity and determine the 
optimal irradiation time for its complete photolysis in solution and in solid phase. 
1.3.1. Spectrophotometric Measurements 
For this study, a 3.54 mM solution of TFMAD 4 in deuterated methanol 
was introduced into a quartz cuvette and irradiated with a UV light lamp (UVP, 
B100AP, 100 W), which emits monochromatic light with a wavelength of 365 nm 
above 10 cm for different periods of time. The photolytic process is summarised 
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in Scheme 1.12, where diazirine 4 is photolysed, losing nitrogen to generate a 
carbene 5 and partially rearranging to its linear diazo isomer 6. The carbene 
reacts with deuterated methanol to form presumably compound 19 while the 
diazo isomer generates carbene upon further irradiation.  
 
Scheme 1.12: Photolysis of TFMAD leads to the generation of carbene species, which gives 
product 19 after insertion into the O-D bond of d4-methanol. Its diazo isomer is a precursor of 
carbene with further irradiation. 
Consistent with the spectral properties of other trifluoromethyl 
aryldiazirienes,40, 42, 72 the TFMAD photophore 4 showed characteristic absorption 
at around 360 with a maximum at 371 nm with an extinction coefficient of      














Figure 1.6: UV-Vis spectra of the reaction products from photolysis of TFMAD 4. A solution 
of 4 in methanol was irradiated for increasing periods of time (in minutes) as indicated.  
Chapter I 
The Trifluoromethyl Aryldiazirine Photophore         17 
 
Photolysis Decay 



























The wavelength region between 410 and 480 nm have been expanded as 
it corresponds to the characteristic diazo absorption (Figure 1.6).40-42, 72 
Although the diazo characteristic band is 10 times lower than that of the 
diazirine absorption due to a low molar extinction coefficient, a band with 
maximum intensity at 441 nm could be observed to increase with the decrease 
of the diazirine band. The UV-Vis spectra also showed the decay of the diazirine 
characteristic band with a maximum at 371 nm within 12 min with a half-life of 
ca. 495 seconds (8.25 min) for a 3.54 mM solution following apparent first-order 







Figure 1.7: Representation of the decay of a 3.54 mM solution of 4 in methanol as a function 
of time of photolysis at 365 nm. 
This study was useful in that it characterised the synthesised diazirine, 
determining its maximum absorption wavelength and extinction coefficient and 
confirmed its photoisomerisation to the linear diazo form.  
1.3.2. NMR Studies 
NMR studies are very useful to study the reactivity of diazirines. 1H- and 
19F NMR have been used to determine the irradiation time necessary for 
complete photolysis of samples in solution and in solid state. Furthermore, all 
compounds generated from the photolysis of TFMAD bear a trifluoromethyl group 
that makes them suitable for the estimation of the formation of different species 
by 19F NMR.  
1.3.2.1. Photolysis in Deuterated methanol 
A solution of compound 4 in deuterated methanol (1.5 mL, 3.5 mM) 
containing trifluoroacetic acid as a reference standard was introduced into a 
glass vial and exposed to a 365 nm UV irradiation at room temperature. At 
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different times, aliquots of the solution were taken for 1H and 19F NMR analysis. 
After 40 minute exposure, complete consumption of the starting material was 
observed. This could be seen by both, 1H and 19F NMR, although 19F NMR was 
much clearer.  
In the 1H NMR, the two aromatic signals of the starting material were 
indicative of the reaction progress as seen in Figure 1.8 (For the complete NMR 
spectra, see Appendix I). The most deshielded signal disappears with an 
increase in the irradiation time to form a new signal at a lower field. The other 
aromatic signal experienced a reverse effect, not as drastic as the former, 
becoming a more shielded signal. After 40 minutes irradiation, there was no 






































Figure 1.8: Expanded view of the aromatic region from the monitored photoreaction of 
TFMAD 4 in CD3OD as determined by 
1H NMR.  
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19F NMR showed the complete disappearance of the TFMAD 4 resonances 
at -66.7 ppm in 40 min (Figure 1.9).  The resonance peak for the diazo form 5 
was expected at -58 ppm,45, 99, 100 however, there was no trace of it. The reason 
for that was the use of trifluoroacetic acid as a reference standard (resonance 
peak at -78 ppm). Although it is well established that diazirine decomposition is 
unaffected by acid,31 the decomposition of the diazo compounds is acid 
catalysed.101 For example, one way for the diazo and the diazirine absorption 
bands identification in the UV spectra was the use of acid. A solution of diazirine 
that had been irradiated for 2 min was treated with acetic acid, the diazo 
compound band was eliminated, but the diazirine absorbance band was 
maintained, and a new product was identified by NMR examination 
corresponding to trifluorobenzyl acetate derivative 20 (Scheme 1.13).54  
 
Scheme 1.13: Suggested products of the photolysis of TFMAD 4 in presence of TFA. 
In other words, by using trifluoroacetic acid as a reference standard 
during photolysis, the formed diazo isomer 5 was rapidly reacted with TFA to 
form 20 (Scheme 1.13). As a result, resonance of diazo compound was not 
detectable and two new signals corresponding to the formed adducts were 
observed in this study. This was supported by the decrease in intensity of 
trifluoroacetic acid resonance peak (Figure 1.9). The product peaks have not 
been identified but it is reasonable to think that peak at -79 ppm could 
correspond to the product formed when the diazo compound reacts with 
trifluoroacetic acid as here a trifluoromethyl group would be next to an ester 
(trifluorobenzyl trifluoroacetate, 20) and the peak at -77 ppm would correspond 
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to the adduct formed from the carbene with methanol 19, which have been 
reported in the literature for other TFMAD derivatives.100, 102 
Figure 1.9: Expanded view from the monitored photoreaction of TFMAD 4 in CD3OD as 
determined by 19F NMR. The blue arrow points the diazo isomer 5 resonance; the red, 
TFMAD 4 compound resonance and the green, TFA external standard resonance as shown 
in Scheme 1.13. 
1.3.2.2. Photolysis in Solid State 
The reactivity of carbenes in solution or solid phase differs highly. This 
fact has already been seen by carbenes derived from parent diazo compounds in 
solidified organic molecules.64 Recently, another group has studied the reactivity 
of trifluoromethyl aryldiazirines in a semi-solid state and highly concentrated 
states with 7 different alcohols.63 They demonstrated that photolysis of diazirine 
in solution gave O-H insertion products in more than 70%, whereas solid phase 
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Another advantage of carbenes generated from photolysis in the solid 
state is that they are not quenched by reacting with water or buffer components 
coexisting in the media, making the yields of cross-linking more efficient and 
random toward functional groups due to the low mobility of molecules. 
To find out the conditions and the time necessary for irradiating samples 
in the solid state, the same studies performed before in methanol were carried 
out with a dry sample consisting of biotin and TFMAD 4 in a mole ratio of 10:1 
(Scheme 1.14), but this time without TFA as an external standard. Six identical 
solutions of TFMAD 4 and biotin in methanol were prepared in 1 mL glass vials 
and solvent was evaporated until complete dryness. The vials were irradiated 
above 10 cm and every 10 minutes one of them was removed from the light, 
dissolved in deuterated methanol and analysed by 1H and 19F NMR. 
 
Scheme 1.14: A sample of biotin:TFMAD (10:1) was irradiated at 365 nm in a solid state for 
different periods of time to give several conjugated products. 
The changes in 1H NMR were quite similar to those achieved previously. 
The same effect on the two aromatic doublets was seen as shown in Figure 
1.10, which was the clearest change for determining the irradiation time for 
complete photolysis. As before, photolysis was almost completed at 30 min and 
finished at 40 min.  
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Figure 1.10: Expanded view of the aromatic region of 1H NMR at different irradiation times. 
19F NMR also showed that photolysis of the diazirine derivative in solid 
phase was complete within 40 minutes as in solution phase. Unlike in solution 
phase, the diazo isomer resonance appeared with short irradiation times and 
disappeared with further irradiation periods (Figure 1.11). From this, two 
conclusions could be extracted. Firstly, the use of trifluoroacetic acid was the 
responsible for the absence of the diazo isomer form in solution studies as 
hypothesised. And secondly and more importantly is the fact that the diazo 
isomer decreases after longer irradiation times with only tiny traces observed 
after 40 min irradiation. Thus, no short UV wavelength lamp (302 nm) needs to 
be used to rapidly decompose the diazo form (as has been recommended for 
samples with high percentage of diazo isomer form).99  
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Figure 1.11: Expanded view of the full 19F NMR spectra (Figure 1.13). The blue arrow 
points to the signal corresponding to the diazo isomer byproduct from photolysis of TFMAD 4 
and the red one shows the signal corresponding to TFMAD 4. The rest of signals are biotin-
TFMAD conjugated products as shown in the sturcture. 
19F NMR also showed that large amounts of conjugate product were 
formed, all corresponding to the chemical shift region of the trifluoromethyl 
group (Figure 1.12) and no other signals outside this region were observed 
(Figure 1.13). Some of the peaks, for example peak -77 ppm, are multiplets 
instead of singlets, suggesting the formation of different products without 
inducing large changes to the electronic environment of the trifluoromethyl 
group. This fact is in agreement with the non-specificity of the reaction.  
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RCH2F CH3F CF3CR3 -70 to -55
CF3-O- -70 to -55
CF3-CO- -90 to -70
CF3-CF2- -95 to -80
Type shift ranges (ppm)
a) b)
 
Figure 1.12: a) 19F spectrum showing the typical chemical shift ranges for each type of 
signal; b) Table specifying the values of CF3- shift ranges. 
 
 
Figure 1.13: 19F NMR of TFMAD 4 before and after irradiation in dry conditions in the 
presence of biotin for different periods of time. The blue arrow points to the signal 
corresponding to the diazo isomer by-product 6 from photolysis of TFMAD. The red arrow 
shows the signal corresponding to TFMAD 4. The other signals are biotin-TFMAD 
conjugated products.  
If 19F NMR signals are integrated, the relative integration ratios can be 
used to represent the percentage of each product formed. Thus, taking the 
multiplet at -77 ppm as one signal, Figure 1.14 was obtained. The peak with 
the highest percentage was at -77.6 ppm which accounts for 72% of the total 
adducts formed. The next two highest percentages corresponded to peaks -68.2 
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and -79.9 ppm with 9 and 7.5%, respectively. Peak -84.8 ppm, which 
contributed in 4%, could correspond to the adduct 21 as its chemical shift was in 
the range of CF3- next to an ester (Figures 1.14 & 1.15). Finally, the rest of 
contribution on the adduct percentage is shared equally between two signals at  
-84.8 and -68.3 ppm. 
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Figure 1.14: Representation of the percentage of each adduct formed in Scheme 1.14 at 
different irradiation times. 
 
 
Figure 1.15: Probable conjugated structure for the resonance at -84.8 ppm. 
 In conclusion, this study showed that within 40 minutes the photolysis of 
diazirine in solid state was completed with the formation of a large quantity of 
different products as a result of the non-specificity of the reaction. Moreover, it 
was also clear that despite the formation of the diazo form, it disappeared within 
the irradiation time determined for the complete photolysis of TFMAD 4. 
 
Chapter I 
The Trifluoromethyl Aryldiazirine Photophore         26 
1.4. Conclusions 
Trifluoromethyl diazirine photophore 4 was synthesised in good overall 
yield of 35%, from a synthetic route consisting of nine steps where reaction time 
were shortened by using microwave-assisted reactions. The characterisation and 
the study of the photo-reactive properties of photophore 4 allowed the 
determination of the irradiation time necessary for complete photolysis under 
different conditions, such as in solution or solid phase. The non-selective 
reactivity of the carbene generated was also observed. Moreover, the 
introduction of a carboxylic group would allow the presence of this moiety to 
other structures or surfaces, where photo-crosslinking strategy is needed for the 
application development. 
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2.1. Introduction   
A recent development in the area of high-throughput screening is the use 
of microarrays; a flexible and versatile platform that has been applied to the 
analysis of DNA, RNA, proteins, cells and tissues.103 Microarrays represent a 
powerful and advantageous alternative to existing high-throughput techniques, 
and DNA microarrays have become an essential tool in many areas.103-106 
Although small-molecule microarrays have recently been receiving growing 
recognition for the identification of molecules capable of binding to biologically 
relevant targets;107 there still remains a need to find new approaches to convert 
this techniques into a routine and essential tool such as DNA microarrays. 
2.2. Small-Molecule Microarrays 
A small-molecule microarray consist of a microscope slide on which very 
small amounts of different molecules, such as peptides, drug-like molecules, 
natural products or sugars, have been captured in an ordered manner through a 
variety of immobilisation reactions. In this way several thousands or even tens 
of thousands of molecules can be addressed in parallel for interactions with a 
biological target of interest, which for example have been fluorescently labelled 
(Figure 2.1). Protein-compound interactions are then monitored by a 
microarray scanner with high sensitivity that rapidly quantitates the fluorescence 
of each microspot. Since arrays are addressable, the identity of small molecules 
interacting with the protein is revealed by their location without further analysis.  
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Figure 2.1: Small molecule-protein interactions on a microarray surface. Each spot 
contains one compound type and just those spots where there is small molecule-protein 
interaction will be visible. 
 
The advantages of microarrays as a screening tool are the ability to mass-
produce large numbers of arrays, the ability to perform massively parallel 
binding assays, and the high sensitivity of detection that result from 
concentrating molecules to a microspot while using only tiny amounts of 
compound. Despite all these advantages, several factors may affect the success 
of the small-molecule microarray screen, such as the quality of the compound 
library, the choice of target, and the sensitivity and specificity of the signal. 
2.3. Microarray Surfaces 
Regarding the chemical nature of the surfaces, there is a huge range on 
offer depending on the desired application and the compounds to be 
immobilised. Both the molecular structure of the spacer and the nature of the 
reactive group on a given surface determines the properties towards probe 
immobilisation, such as the density of immobilised probes, their molecular 
arrangement, the accessibility by the target, and the prevention of non-specific 
binding of the target. The surface chemistry also determines the spot 
morphology and the distribution of spotted probe on the surface which depends 
on the wettability and the surface tension. 
The most widely used substrates for microarray manufacturing are based 
on microscope glass slides with standard dimensions, typically 25 by 75 mm and 
about 1 mm thick. Glass surfaces are reasonably flat, transparent, resistant to 
high temperatures and easy to handle, but more importantly, there is a wide 
range of well established protocols for the modification of their surface properties 
to allow immobilisation of the desired compound or to prevent/reduce non-
specific binding of proteins, cells or DNA.  
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2.3.1. Surface Activation  
Organosilanes are a versatile class of reagents widely used to attach 
different functionalities onto the glass slide.108-112 They consist of an organic arm 
which contains the functional or reactive group that is wanted on the surface. 
This alkyl chain is attached to the central silicon atom, which also can have up to 
three hydrolysable groups attached to it. They have been shown to efficiently 
react with available surface silanols of inorganic substrates and pack to densities 
that render any remaining surface silanols essentially nonreactive (Scheme 
2.1).113 
 
Scheme 2.1: Reaction of monofunctionalised organosilane with a glass surface in order to 
modify the surface with the desired functional group R.  
Assemblies of monoalkoxy (or chloro) silanes (R(CH3)2Si-X) attach 
covalently to the surface through one bond per molecule due to its single 
hydrolysable group (Scheme 2.1). However, microarray technology tends to use 
di- and trialkoxy silanes (RCH2-Si(OEt)3) to form close-packed monolayers which 
attach covalently to the substrate with higher density of reactive groups on the 
surface (Scheme 2.2).114-116  
 
Scheme 2.2: Monolayer formation with trimethoxysilanes bearing a desired functional group 
(R) for surface functionalisation.  
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As the success of the microarray experiment depends on the uniformity 
across the entire substrate by ensuring identical coupling of compounds at each 
microarray location,117 steric control of the reaction conditions is essential for the 
formation of a single monolayer.118 Reactions can be carried out in aqueous 
solution, entirely in organic solvents, organic solutions containing a small 
amount of water, and even in the vapor phase. The choice of reaction strategy 
often is governed by the inorganic reactive groups on the silane.  
Glass slides have also been coated with polymers (e.g. agarose or 
polyacrylamide or PEG-based hydrogels) to provide a three dimensional 
architecture with greater capacities of immobilisation and thus enhanced 
detection sensitivities.119 Some of these slides have been commercialised such as 
HydroGelTM (PerkinElmer Life Sciences) and CodelinkTM (Amersham Biosciences) 
slides. 
Alternatively, glass slides coated with gold can easily be functionalised by 
self-assembled monolayers (SAMs) of thiolates. These arrays are based on the 
ability of thiols to spontaneously organise themselves on gold surfaces. The 
advantages of these surfaces are the prevention of non-specific interactions 
between the biological target and the surface120 and the photosensitivity of the 
Au-S bond, which can be cleaved by exposure to ultraviolet light, allowing 
molecules attached onto the gold surface to be detected by mass 
spectrometry.121 In addition, surface plasmon resonance (SPR) can be used as a 
detection method to analyse low affinity interactions between small molecules 
and proteins.87, 122 
2.3.2. Spacers 
Screening microarrays can be problematic due to steric hindrance or 
congestion with the surface.123, 124 While it has been demonstrated that a small 
molecule-protein interaction is possible with small molecules attached directly to 
the glass surface,125 it has generally been noted that higher sensitivity and 
better signal-to-noise ratios are obtained when spacers are used.86, 126-128 
Spacers separate the glass surface from the small molecule giving flexibility and 
making them more accessible to the biological target. They also reduce protein 
adsorption and cell adhesion, reducing background noise.129, 130 Alternatively, 
dendrimers have also been used to increase the separation between the small 
molecule and the surface while increasing the loading capacity of the            
surface.126, 131, 132 
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2.4. Immobilisation Strategies  
One of the most critical steps in small-molecule microarray preparation is 
perhaps the decision over the way in which a large variety of small molecules will 
be efficiently immobilised at specific locations on the surface while maintaining 
the binding properties of the molecules. Efforts over the past decade have 
introduced a plethora of options for the immobilisation which they have been 
extensively reviewed133-138 and they can be classified into two types: 
chemoselective or non-specific immobilisation strategies.  
In chemoselective approaches, a small molecule library is designed in 
which all members contain a specific functional group which is required for the 
specific-coupling reaction towards a functional group displayed on the solid 
support. Thus, compounds with other functional groups will not be immobilised 
onto the surface (Figure 2.2). Consequently, this strategy is suitable for 
synthetic compounds that can be designed for the specific application, but 
general libraries or natural products cannot be attached unless modified. 
 
Figure 2.2: Chemoselective immobilisation of small molecules. A library of compounds is 
prepared with a specific functional group A that is able to selectively react with the functional 
group B on the surface. Compounds not containing functional group A will not be able to be 
immobilised onto the solid support and after washing they will be removed.  
In addition, site-specific immobilisation chemistries facilitate the directed 
and uniform presentation of small molecules across the arrays by specific 
reaction between the chemical group incorporated into the library during the 
synthesis and a complementary group on the slide. Therefore, part of the 
molecule is used to link it to a spacer for the specific-coupling reaction to take 
place. If the binding protein recognises the portion that is used for linking, the 
binding protein will not bind to the small molecule on the slide and information 
would be lost (Figure 2.3a and b). 
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Figure 2.3: Possible situations within a microspot: a) chemoselective immobilisation where 
the recognised part of the small molecule by the protein is accessible; b) chemoselective 
immobilisation where the binding site of the compound is facing the slide surface; and c) 
non-specific immobilisation of small molecules provokes a heterogeneous display of 
orientations which decrease the fluorescence intensity as just a few molecules are 
recognised by the target protein. 
In contrast, using a non-selective coupling reaction, small molecules are 
randomly attached onto the solid support exhibiting all potential interaction sites 
to the biological probe (Figure 2.3c). The advantage is that no binding 
interaction is lost although the sensitivity of this strategy is lower.  
The different approaches for microarray preparation can also be classified 
into two different methods, where libraries are built in situ by solid phase 
techniques or are spotted onto the surface once they have been synthesised. 
2.4.1. In situ Synthesis 
This immobilisation method applies solid phase techniques for the in situ 
generation of combinatorial libraries of small molecules (mainly linear polymers) 
at specific positions over planar solid supports. The resulting libraries can be 
then screened for active compounds while still bound to the solid support used 
for their synthesis. Light-directed synthesis and SPOT-synthesis are the two 
different techniques for this method.  
2.4.1.1. Light-Directed Synthesis: 
Light-directed in situ synthesis was initially developed for peptide 
synthesis139 but is now widely used for the synthesis of DNA. This method 
enables the production of peptide libraries on microarray slides by using amino 
acids with photolabile protecting groups (e.g. nitroveratryloxycarbonyl, NVOC) as 
a building block and photolithographic masks to selectively deprotect this          
N-terminal protecting group (Scheme 2.3). 
a) b) c) 
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Scheme 2.3: Representation of light-directed synthesis. On a derivatised glass surface with 
amino groups protected with a photolabile protecting group, light is exposed through a 
photolithographic mask that allows the light through only at specific positions. Where light 
have gone through, the building blocks have been deprotected and are available to react 
with the next building block. A second mask is then applied and other positions are 
deprotected and reacted with other building blocks. By repeating the process and changing 
the masks a linear polymer library can be built. 
In order to improve the microarray density, new methods have been 
developed such as the use of polymeric photoresist films to construct the 
masking pattern on selected regions of the substrates or the use of digital 
micromirror devices to avoid the cost of photolithographic masks. These 
methods have been used to prepare oligonucleotide,140 peptoid141, 142 and cyclic 
peptide143 microarrays.  
2.4.1.2. SPOT-Synthesis: 
The SPOT-synthesis, developed by Frank et al.,144 is an easy and flexible 
method for parallel chemical synthesis on membranes.145, 146 SPOT-synthesis is 
used for the synthesis of different peptides or peptide mixtures at clearly defined 
positions on a modified cellulose membrane by manually or automated 
dispensing of N-terminally and side chain-protected amino acids plus coupling 
agents to defined positions. After the coupling reaction is complete, the whole 
membrane is washed and the N-terminal protecting group is deprotected prior to 
the next coupling cycle.  
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This method requires no specialised infrastructure to synthesise the 
library immobilised onto the support and experimental procedures are simple. 
The mean spot size is ca. 60-times larger (6 mm in diameter) than microarrays 
prepared by other techniques, due to higher volumes of reagent spotted and the 
solid support wicking ability, and they are usually called macroarrays. As a 
result, macroarrays displays three orders of magnitude more compound than 
microarrays (nanomoles vs. picomoles) and thus, the spots are sufficiently large 
that they can be cleaved from the membrane and submitted to routine analysis 
or transferred to a microtiter plate where several solution phase assays can be 
carried out.145  
These peptide macroarrays have been used namely to study protein-
protein and protein-peptide interactions147 and for epitope mapping of 
antibodies.148-150 SPOT method applications and SPOT synthesis optimisations 
have been reviewed.151-153 Recent advances in the field have expanded this 
technique beyond peptidic systems into the complexity of small-molecule 
synthesis, including the use of microwave assisted organic reactions and 
multicomponent reactions.154 The chemical structures accessed to date are 
1,3,5-triazines,155 cyclic peptidomimetics,156 1,3,5-hydantoins,157 natural product 
fragments,158 chalcones,159 and α-acyl amino amides,160 with purities reported as 
good to excellent.  
2.4.2. Microspotting 
As an alternative to in situ synthesis, molecules can be immobilised onto 
the surface after their synthesis. The advantages of microspotting over in situ 
synthesis are the wider scope of small molecules to be immobilised, the ability to 
check compound purity before use, and the efficient generation of many copies 
of the same chip from a stock solution.  
2.4.2.1. Covalent Immobilisation: 
 For covalent attachment onto the surface, small molecule libraries need 
to be designed to include a common handle with a specific functionality, which 
can be used to ligate small molecules to an appropriately functionalised surface. 
Several immobilisation strategies have been used for the covalent attachment of 
molecules onto surfaces and they can be classified into selective and non-
selective immobilisation reactions (Table 2.1). 
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Table 2.1: Covalent immobilisation approaches where SM stands for small molecule 
(Continued).  
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Table 2.1: Covalent immobilisation approaches.  
2.4.2.2. Photochemical Immobilisation 
Several approaches for light-dependent biomolecule immobilisation on 
surfaces have been developed as it offers the prospect of facile and addressable 
attachment of substrates with the possibility to structure surfaces by light 
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Table 2.2: Photoimmobilisation strategies. 
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Typical photoselective methods are the thiol-ene photoreaction181, 186 and 
Diels-Alder reactions.122, 187-189 Both strategies are compatible with most 
functional groups and are carried out under mild conditions. Alternatively, the 
use of photoreactive groups as an anchor for immobilisation of compounds onto 
surfaces is usually classified as a non-selective method as slides are derivatised 
with photosensitive groups which after activation with UV light immobilise 
proximal molecules in a random manner.87, 88 In addition, the same strategy has 
been used for selective immobilisation where the photoreactive moiety has been 
introduced to the compound library and then used to attach those molecules to 
any type of surface.190 
2.4.2.3. Non-Covalent Immobilisation 
The different non-covalent immobilisation methods use small molecules 
tagged with biotin, lipophilic or fluorinated chains or peptide nucleic acids which 
are retained onto a functionalised surface by strong interactions.  
a) Ligand-Receptor Pairing 
These approaches use small-molecule libraries that have been tagged 
with biotin and are attached onto an avidin/streptavidin-coated surface by non-
covalent interactions (Scheme 2.4).191 Avidin also provides a molecular layer 
between the glass surface and the proteins interacting with the immobilised 
molecules which eliminates blocking procedures and minimise non-specific 
binding on the glass surface. Overall, this method is highly robust and flexible 
and it has been used for the successful preparation of peptide173, 192, 193 and 
carbohydrate194 microarrays.  
 
Scheme 2.4: Biotinylated small molecules are immobilised onto a pre-coated  surfaces with 
a monolayer of streptavidin or avidin. 
b) Physisorption Using Lipophilic or Fluorous tags 
This method consists of a small molecule tagged with a tail having specific 
physical properties which adhere to a surface by physical absorption. This 
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method has been applied using two different tags: hydrocarbons and 
fluorocarbons. 
The first approach was used for the preparation of carbohydrate arrays 
where carbohydrates bear a long saturated hydrocarbon chain, between 13 and 
15 carbons, were spotted on a hydrophobic surface (Scheme 2.5). It was seen 
that they were resistant to aqueous washings.176, 195 
 
Scheme 2.5: A C12-hydrophobic alkyl-functionalised glass surface is used to immobilise 
molecules labelled with a lipophilic tag of the same length by physisorption. 
The second approach uses the unique properties of fluorinated alkanes, 
which have prompted the development of perfluorocarbon chains linked to small 
molecules as a handle for purification.196 Fluorous tags are hydrophobic and 
lipophilic, preferring to be in a fluorous phase. In addition, fluorous tags are 
relatively unreactive and often contain a small aliphatic linker designed to 
insulate the molecule from the electron withdrawing effects of the fluorous chain. 
Carbohydrate microarrays were prepared using fluorous chemistry where 
sugar derivatives with fluorous tags linked to the anomeric position were 
synthesised and spotted onto a fluorous-modified glass slide (Scheme 2.6). The 
study showed that a single C8F17 tail was sufficient enough to attach molecules to 
a fluorinated surface and able to withstand washing with buffer solutions, even in 
the presence of detergents, with high reproducibility.197 As a result, several 
groups have used this approach,197-204 although as discussed in this thesis there 
are a number of precautions necessary. 
 
Scheme 2.6: Small molecules functionalised with a fluoroalkyl chain were spotted and 
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c) Self-Assembling Immobilisation 
In this method, a small molecule is covalently tethered to a peptide 
nucleic acid (PNA) tag whose sequence encodes the structure of the molecule 
and localises it to a specific site upon hybridisation to an oligonucleotide array 
containing complementary sequences (Scheme 2.7).205, 206 
 
 
Scheme 2.7: The PNA tags address each substrate from a library to a predefined location 
on the oligonucleotide microarray through hybridisation, thus allowing the deconvolution of 
multiple compounds from solution. 
An advantage of PNA-encoded libraries compared to covalent 
immobilisation of small molecules is the possibility to carry out the bioassay in 
solution prior to the read out by hybridization onto the microarray. In addition, 
compounds bound to a protein in solution can be selected from the unbound 
ones prior to hybridisation by size-exclusion filtration or gel separation, which 
simplifies the screening (Scheme 2.8). The methodology and validation of this 
approach has been described for profiling proteolytic activity from single 
proteases and from those in crude cell lysates as well as clinical blood 
samples.206, 207 
 
Scheme 2.8: A PNA-tagged library is incubated with the target proteins and then the 
compounds that have been recognised by the proteins are separated form the ones that are 
not bound by different techniques and hybridised onto a DNA microarray to know their 
identity. 
A drawback of these approach is when large PNA-tagged compound 
libraries are hybridised and screened as they involve a broad range of melting 
temperatures, variations in hybridisation efficiency, differences in concentrations 
between library members and variations across the microarray itself in terms of 
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DNA synthesis. To minimise this, dual colour approaches have been developed 
for profiling tyrosine kinases208 and proteases.209-211 
2.5. Printing Technologies 
There are many aspects to take into account when printing. Firstly, 
microarray spots should be small and discernible from each other and be 
deposited in a grid-like fashion, at equal distances from each other. Secondly, 
the size and the shape of the spots is also important, they should contain equal 
amounts of material. For this reason, it is important to control the humidity 
level, as high humidity may cause spots to smear whereas low humidity may 
cause the rapid evaporation of solvents from printed spots, which can cause 
changes in concentration across the spot as well as evaporation of solvents from 
the source plate.  
Two methods for microarray fabrication are photolithography and 
mechanical microspotting. Photolithography methods are used for in situ 
synthesis of small-molecules onto the slide surface (Section 2.4.1), while 
mechanical microspotting consists of the deposition of pre-synthesised 
compounds onto the surface by contact or inkjet methods.  
 Contact deposition methods are based on a high precision robot that 
holds one or more pins which are dipped into wells containing the solutions of 
the desired material and pins are then brought in contact with the slide surface 
where they deliver the sample as a small spot. When moving the pins away from 
the surface, the adhesion forces between sample and substrate lead to retention 
of small volumes on the substrate. Thus, the main factors affecting this printing 
are the viscosity and surface tension of the liquids, the wetting characteristics of 
both substrate and pins, and parameters controlling the robot. External factors 
such as humidity and temperature can also affect the quality of printing.212 
There are various pin technologies available for microspotting (Figure 
2.4). Solid pins need to be re-dipped for sample loading after each deposition, 
thus spot size and sample delivery is dependent on the number of stamps per 
spot. Alternatively, split pins have a reservoir capacities ranging from 0.25 to 
1.25 µL and therefore, there is no need of dipping into the solutions repeatedly. 
Another way to circumvent re-dipping is the pin and ring technology, where a 
small ring is dipped into the sample solution. The surface tension of the sample 
is used to form a fluid layer within the ring. A solid pin is pushed through the 
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fluid layer and the trapped sample is deposited onto the surface. After retraction 
of the pin the fluid film is still intact and fluid is replenished from the ring.213  
 
Figure 2.4: Representation of the diferent pins available: a) solid pins; b) split pin; and c) pin and ring. 
In inkjet deposition, extremely small volumes (pL) of solution are 
deposited without contact between the dispensing tip and the surface. Although 
contact deposition requires less probe solution and results in smaller spots that 
can be packed more densely on the microarray surface, inkjet printing allows a 
mild deposition on fragile substrates and better control of the quantities of liquid 
delivered, allowing a wider range of spot sizes to be printed.214 Piezoelectric 
printing and syringe-selenoid methods are the most common variations of this 
method. 
In piezoelectric printing, the target solution is drawn into a glass capillary 
which is surrounded by a piezoelectric crystal. Application of voltage to the 
crystal results in a slight conformational change, squeezing the capillary and 
creates a pressure wave which propagates through the glass into the liquid. In 
the nozzle region the pressure wave accelerates and a small liquid column leaves 
the nozzle, breaks off and forms a droplet which flies freely through the air 
(Figure 2.5). The liquid delivery is controlled by the duration and amplitude of 
the voltage applied to the piezo material allowing very rapid spotting times. The 
ejected droplet size mainly depends on the size of the nozzle. However, this 
deposition method is prone to problems caused by air bubbles, which can cause 




a) b) c) 
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Figure 2.5: Cross sectional view of the fluid channel and nozzle, illustrating the mechanism 
of droplet ejection. When an electric field is applied, the piezoelectronic crystal undergoes 
distortion, implying the rapid expansion and contraction, which provokes a pressure pulse in 
the fluid channel that causes a drop to be ejected from the nozzle. 
2.6. Detection Methods  
 Screening of small-molecule microarrays generally involves the binding of 
a protein target to the immobilized compound which needs to be detected.215 
The existing detection techniques can be classified into two different methods: 
a) Labelling methods  
The preferred method of detection is fluorescence detection because 
these methods are extremely sensitive, simple, have very high resolution, and 
are compatible with standard microarray scanners. A disadvantage of labelling 
proteins with fluorophores is a reduction of the quantitative accuracy of the 
assay, as incorporation of the label may alter the binding properties of the 
proteins.216 However, other detection methods have been used with reporter 
groups such as alkaline phosphatase, radionuclides126 or epitope tags155, 217 
which in turn can be detected by secondary reagents. Moreover, functional 
assays for substrates of enzymes have also been applied and the modification of 
the immobilised compounds is detected with fluorescent quench assay209, 218 or 
radiolabel assay.126 
b) Label-free detection methods:    
Although direct protein labelling detection methods are still widely used, 
non-labelling methods are evolving as a viable complement to traditional 
labelled-based throughput screening efforts.219 Label-free technologies offer a 
number of distinct advantages. First, they are non-invasive and require minimal 
manipulation of reaction components. This enhances the potential for measuring 
biologically meaningful data. Second, label-free methods do not suffer from 
potential assay artefacts such as compound autofluorescence or quenching as no 
fluorescent dye or label is involved. Finally, they can be used to characterise the 
affinities, kinetics, and other properties of molecular binding interactions. The 
most common label-free detection methods are atomic force microscopy 
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(AFM),220 and surface plasmon resonance (SPR),87, 122, 221 reflectometry,216, 222-224 
interferometry,129 and oblique-incidence reflectivity difference (OI-RD) 
microscopy.225 
2.7. Applications  
Microarrays of small molecules have already been successfully applied in 
important areas ranging from protein profiling to the discovery of therapeutic 
leads. Therefore, they represent a way forward in high-throughput exploration 
and in combining their vast potential towards medicinal and diagnostic 
applications. 
2.7.1. Protein-Binding Assays 
Small-molecule microarrays have proven to be useful tools in the 
discovery of new protein-small molecule interaction.138, 226 In chemical genetics 
research, they are routinely used for identifying small molecules that can 
selectively modulate either a given protein function or a specific biological 
phenotype,227 and in general drug discovery research, they are used for 
searching potential “hits” for therapeutic targets. Direct binding assays using 
microarrays have identified small-molecule ligands of varying affinities for many 
purified proteins, including transcription factors (Hap3p, Ure2p),165, 228 
immunoglobulins (TNF-α),229, 230 proteases,207, 231, 232 histone deacetylases,199 
calcium-binding proteins (Calmodulin),166 kinases,233, 234 and HIV integrase.235 
Fragment-based low-affinity microarray screening technology has been 
developed to allow the rapid experimental characterisation of protein-binding 
properties and the identification of potential ligands. In this platform, low-
complexity drug fragments or pharmacophores, selected from pharmacophores 
models or virtual screening approaches, are immobilised on microarrays and 
incubated with the protein or proteins of interest. Binding of the protein to 
specific molecules on the array is detected and quantified by wavelength shifts of 
the surface plasmon resonance. A surface plasmon resonance imager is used to 
record the mass change, which depends on the amount of protein binding to the 
chemical surface, creating protein-ligand affinity fingerprints. After SAR analysis, 
the first generation of “hit” compounds and analogues are synthesised and 
tested, and lead candidates can be further optimised. Graffinity Pharmaceuticals 
have applied this technology to the search of novel fragments binding to    
FVIIa22, 236 and Neri et al. found binders with submicromolar dissociation 
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constants against bovine carbonic anhydrase and human serum albumin.237 
Alternatively, Carlson et al. used this approach for the differentiation of proteins 
based on their binding patterns.238  
A similar approach is that of small-molecule binding environments 
microarrays where combinations of pharmacophores are immobilised and 
screened against a protein of interest. Osada et al. used this technology to find a 
novel bivalent ligand for carbonic anhydrase II (CAII) with high affinity.239  
Some potential applications to small-molecule microarrays have been 
limited by challenges in protein biochemistry involving expression of large 
proteins, solubility, post-translational modification state, activity and yield. For 
that reason, this technology has been extended to the use of proteins from crude 
cell lysates. Bradner et al. incubated small-molecule microarrays with cellular 
lysates containing overexpressed epitope-labelled proteins from mammalian 
cells. Detection of small molecule–protein interactions was achieved by 
treatment of the microarrays with fluorescently labelled antibodies that interact 
with the epitope tag.217 Osada et al. also used their small molecule-based 
binding environments microarrays to screen cellular lysates to identify important 
moieties for fragment binding to the Shble protein.240 
2.7.2. Protein Specificity Profiling 
Enzyme assays are one of the most popular applications for 
characterisation of kineases and proteases. Such assays are also highly sensitive 
since they allow intrinsic signal amplification owing to multiple turnovers by the 
enzyme.241 Various microarray-based approaches can be examined in that 
respect, namely functional annotation,171, 242 substrate fingerprinting126, 161 and 
inhibition fingerprinting.243, 244 
Functional enzymatic assays with small-molecule microarrays have been 
developed where surface-bound reporter group translates enzymatic activity into 
fluorescent readouts. For example, the use of a coumarin substrate immobilised 
on glass slides in a screen of hydrolytic enzymes has been reported by several 
groups.204, 218, 242 Hydrolysis of the non-fluorescent coumarin–substrate 
complexes results in the fluorescent coumarin being unmasked and indicates 
substrate-dependent enzyme profiles.  
Profiling of tyrosine kinases have been developed by several groups using 
different approaches. Lam et al. studied the non-receptor tyrosine kinase x-SRC 
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using [γ33P]ATP as the phosphoryl donor to label peptide substrates in order to 
improve the resolution of the radiolabelled microarray.126 Houseman et al. 
studied the same protein by three different detection methods and found three 
inhibitors.187 Bradley et al. screened a 10,000-membered PNA-tagged peptide 
library against tyrosine kinease and ATP and peptides that were phosphorylated 
were detected using a primary/secondary antibody approach.208  
Protease profiling has been carried out by means of a PNA self-sorting 
approach. Bradley et al. used DNA microarrays to self-sort a 10,000 PNA-tagged 
peptide library where each library substrate incorporated a FRET system in order 
to interrogate Chymopapain and Subtilisin.209, 210 Winssinger et al. used a PNA-
tagged compound library which was labelled with a single fluorescein molecule 
and used to probe the presence or absence of functionally active cysteine 
proteases by incubation in solution. The fluorescence intensity of a particular 
microarray feature is a direct reflect of the amount of the corresponding 
functional protein present in the sample (Scheme 2.9).206  
 
Scheme 2.9: Screening of PNA-encoded libraries. Individual small molecules are tethered to 
a unique fluorecently labelled PNA sequence, which encodes both their synthetic history and 
their location following hybridisation to an oligonulceotide microarray. The library of PNA-
encoded small molecules were incubated with a protein mixture of interest, passed through a 
size-exculsion filter to separate the small molecule-PNA adducts bound to a micromolecule 
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2.7.3. Diagnostic Applications 
Recent studies suggest that small-molecule microarrays are useful tools 
in the discovery of biomarkers for various illnesses, such as autoimmune 
diseases.245, 246 Peptide microarrays have been used for antibody detection, 
where a collection of referenced sera permitted the demonstration of a large gain 
in sensitivity and specificity compared to the standard ELISA tests.168 The ligands 
indentified could be used for a variety of therapeutic and diagnostic 
applications.247 Alternatively, carbohydrate microarrays have been extensively 
used for serum antibody profiling. Human serum contains a wide variety of 
carbohydrate-binding antibodies, and the population of these antibodies changes 
as a result of disease, exposure to pathogens, and vaccination.248  
Alternatively, Disney et al. developed a small-molecule microarray to 
study the binding of ligands to the surface of a variety of pathogens, from Gram-
negative bacteria (P. aeruginosa and E. coli) to fungi (C. albicans). These studies 
have identified a pathogen “fingerprint” for ligand recognition which can be used 
for a variety of therapeutic and diagnostic applications.249 Small-molecule 
microarrays have also been used for the simultaneously and quantitatively 
detection of three veterinary drug residues in foodstuff: Chloramphenicol, 
Clenbuterol, and Tylosin.250 
2.8. Aim of the Project 
The aim of this project was to broaden the scope of small-molecule 
microarray technology to encompass any compound library. We envisaged 
achieving this by developing a generic approach for the immobilisation of 
compounds onto glass slides (microarrays).  The immobilisation would be 
possible by using the photoreactive diazirine derivative 4 (chapter I) to 
functionalise the glass surface via two different strategies. Either the covalent 
attachment of 4 onto the surface using standard solid phase coupling chemistry, 
or alternatively, by physisorption using fluorine chemistry. Small-molecule 
libraries could then be printed onto the treated slides to provide close contact 
between the compound and the photoreactive group. Activation of the 
photoreactive group by irradiation would generate a carbene, which would react 
with the small molecules in a non-selective manner. We planned to apply this 
technology to the immobilisation of a 2,000 member compound library and 
utilise it for the biological screening of β-TrCP1.  
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2.9. Microarray Fabrication 
For the development of the small-molecule microarray approach, the first 
step was the preparation of photoreactive surfaces which were prepared by two 
different strategies, compared and optimised. 
2.9.1. Strategy I: Photospacer Covalent Immobilisation 
Strategy I was based on the covalent immobilisation of the photospacer 
onto the slide surface. As the TFMAD photophore 4 obtained in chapter I 
contained a carboxylic acid group, it could be attached to an amino-
functionalised surface by standard solid phase coupling conditions. However, 
instead of derivatising the whole slide with this photophore, a masking process 
was carried out to localise the probe in order to reduce the non-specific 
interactions between the target probe and the surface. Once the photoreactive 
slide was prepared, solutions of small molecules could be dispensed and 
immobilised by UV irradiation (Scheme 2.10). 
 
Scheme 2.10: Glass slides were printed with drops of 20% sucrose in water and then 
treated with tetrahydrooctyl-1-trimethoxysilane (TFCS) to functionalise the slide with fluorous 
chains everywhere except where sugar had been printed. Removal of sucrose with water 
allowed derivatisation of the surface with amino groups which were reacted with the 
preactivated photospacer. Slides were then used for small molecule printing and 
immobilisation by UV light. 
2.9.1.1. Surface Preparation 
The first step of this strategy consisted of a masking treatment of the 
glass surface in order to create a pattern which prevents non-specific 
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interactions with proteins or cells. In this case, masking was created by spotting 
a concentrated sugar solution (20% sucrose in water (w/v)) onto pre-cleaned 
glass slides. The slide was then derivatised with tridecafluoro-1,1,2,2-
tetrahydrooctyl-1-trimethoxysilane (TFCS) except at the masked positions where 
the sugar had been deposited. As a result, once the sugar was dissolved in water 
and washed away, localised areas with free hydroxyl groups could be converted 
to other functionalities (Scheme 2.11).  
OH OH OH OHOHOH
sucrose
OH OH OH OHOHOH
sucrose





Scheme 2.11:  The masking process consitst of 3 steps: first, a solution of sucrose in water 
is printed on a precleaned slide and let to dry. TFCS is used to modify the surface which 
interacts with the alcohol groups on the sucrose where the masking have been done. Finally, 
the slide was washed, firstly with acetone to remove excess TFCS, and then with water to 
dissolve the mask. 
The free hydroxyl groups were reacted with a solution of 2%                 
3-aminopropyl trimethoxysilane (APTMS) in acetonitrile to convert them into 
amino groups. These amino groups were further functionalised by dispensing a 
solution of the photospacer with HOBt/DIC in DMF to give the final photoreactive 
slide (D, see Scheme 2.10). After extensive washing in DMF, slides were kept in 
the dark until small molecule printing.    
2.9.1.2. Photospacer Synthesis 
To optimise the distance of the small molecule from the glass surface and 
maximise sensitivity, three different length photospacers were synthesised by 
solid-phase synthesis. For this purpose, it was essential to synthesise compound 
23 and Fmoc-protected spacer 27. 
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The acid-cleavable linker 23 was readily prepared in 2 steps from 
hydroxybenzaldehyde (Scheme 2.12). Firstly, alkylation of the phenol was 
carried out with ethyl 4-bromobutyrate under microwave irradiation at 120 ºC to 
give 22. Subsequent hydrolysis with sodium hydroxide and reduction of the 
aldehyde to an alcohol with sodium borohydride was carried out in a single pot 
reaction to give 23 in an overall yield of 83%. 
 
Scheme 2.12: Synthetic route to 4-[4-(hydroxymethyl)phenoxy]butanoic acid 23. 
The Fmoc-8-amino-3,6-dioxaoctanoic acid was synthesised by a slightly 
modified procedure of Visitin et al.251 (Scheme 2.13). The amino group of       
2-(aminoethoxy)ethanol was di-protected with benzyl bromide to give 24. Then, 
the alcohol was alkylated with bromoacetate in the presence of sodium hydride 
to give 25. Deprotection of the benzyl group was performed by hydrogenation 
on palladium. Final protection of the amino group with Fmoc chloride gave 27 
with an overall yield of 49% and a spacer unit ready for use in Fmoc chemistry 
on a solid support.  
 
Scheme 2.13: Synthesis of Fmoc-8-amino-3,6-dioxaoctanoic acid spacer unit 27. 
The assembly of building blocks to prepare the photospacer started with 
the covalent attachment of the linker to aminomethyl resin by standard solid 
phase coupling conditions (Scheme 2.14). Saponification was performed with 
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aqueous sodium hydroxide to eliminate oligomers formed during the reaction. 
The spacer unit was then attached to resin 28 by esterification. The success of 
these couplings was monitored by the colorimetric Malachite Green test, which 
indicated incomplete coupling when beads were green after washing and gave 
colourless beads when the coupling was completed. Deprotection of the Fmoc 
group was carried out with 20% piperidine in DMF and reaction completion was 
monitored by a ninhydrin test. At that point, one third of the resin was separated 
and reacted with TFMAD 4. The first photospacer was cleaved from the resin 
with a standard acidic cocktail to give PS1. Another spacer unit was coupled to 
the rest of the resin with subsequent Fmoc deprotection. The resin was divided 
into two parts, one was reacted with TFMAD 4 and cleaved to give PS2 and the 
cycle was repeated with the other half to give PS3. By this method, 
photospacers with one, two or three units of the PEG spacer were prepared with 
high purity (Figure 2.6). 
 
Scheme 2.14: Synthesis of photospacers by solid phase synthesis.  
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Figure 2.8: Photospacers synthesised with different PEG spacer lengths. 
2.9.1.3.  Experimental Validation 
To validate the robustness and sensitivity of the developed method, the 
strong interaction between Biotin and Streptavidin was used as a model. Biotin 
was printed on the photoreactive slide and immobilised by irradiation for 40 min 
with UV light at -196 ºC. After washing, the slide was incubated with 
fluorescently labelled Streptavidin for 1 h at 37 ºC. If the photospacers were able 
to immobilise biotin, fluorescently labelled Streptavidin would be detected just at 
those locations where biotin had been immobilised (Scheme 2.15). 
 
Scheme 2.15: Representation of the validation strategy performed. Biotin was printed at the 
same positions of the photospacer. Slides were dried and cooled to -196 ºC and then 
irradiated with a UV lamp for 40 min. After washing, the slides are incubated with            
Cy5-labelled Streptavidin for 1 h at 37 ºC. Slides are washed and scanned using a Cy5 filter. 
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The experiment was designed as follows. Each sample was printed in 
quadruplicate (2x2 spots) and the experiment was duplicated on the same slide 
(Figure 2.7). Negative controls were printed in the first and fifth column where 
either photospacer or Biotin was printed and treated under the same conditions. 
Each photospacer was deposited in different columns, from shorter to longer 
length spacer, and rows were printed with different concentrations of Biotin 
solutions, ranging from 100 mM to 0.1 mM. Figure 2.7 corresponds to the slide 
scanned image (La Vision BioTech, Bielefeld, Germany). 
 
 
Figure 2.7: Scan of the experimental validation slide with a Cy5 filter. The experiment was 
duplicated in two grids. In each grid,  negative controls were printed in the first and the fifth 
column, where green squares correspond to only photospacer PS1 printing and red squares 
to only biotin solution printing. Columns 2 to 4 and 6 to 7 contain a different photospacer 
each, ranging from shorter (PS1) to longer (PS3) spacer lenght and each row corresponds to 
the printing of different concentration of Biotin solutions on top of the photospacer. The slide 
was irradiated, washed, incubated with Streptavidin-Cy5 and scanned. 
The results showed that the spacer length and the concentration of 
printed small molecule solutions were important factors for the assay sensitivity. 
On one side, it was clear that the longer the photospacer the better was the 
signal, where the signal could be detected down to 1 mM of printed solution. On 
the other side, no signal was detected when 0.1 mM biotin solutions were printed 
and minimal for 1 mM concentration. However, 10 mM and 100 mM solutions 
gave good signal-noise ratios. As a result, further studies were carried out with 
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2.9.2. Strategy II: Fluorous Tag Physisorption 
Rather than using a covalent reaction to immobilise the photospacers 
onto the slide surface, photospacers tagged with a perfluoroalkyl chain could be 
adhered to a fluoroalkylated surface by fluorous affinity. The strategy would 
simplify slide preparation, without the need of masking steps or amino 
functionalisation (Scheme 2.16). 
 
Scheme 2.16: Glass slides treated with TFCS were printed with photospacers tagged with 
the same fluoralkyl chain and immobilised by fluorous affinity. After washing, small 
molecules were printed at the same photospacer locations and covalently immobilised by 
carbene reactions after UV activation. 
2.9.2.1.  Fluorous Tagged Photospacer Synthesis 
Fluorinated tagged photospacers were synthesised by coupling the 
photospacers PS1, PS2 and PS3 with 1-amino-1H,1H,2H,2H-perfluorodecane, 
using PyBOP and DIEA and purified via a fluorous silica column (Scheme 2.17).  
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Positive controls were also synthesised for this strategy. 
Carboxyfluorescein and biotin were derivatised with the same fluorous tag and 
reaction. All products were obtained with yields between 60 and 75% (Figure 
2.8). 
 
Figure 2.8: Fluorous tagged compounds prepared for strategy II. 
2.9.2.2. Preparation and Manipulation of Fluorinated Slides 
Preparation of slides for this strategy was simpler than for strategy I, in 
which pre-cleaned standard glass slides were functionalised with TFCS and 
printed with fluorous tagged photospacers. 
In order to find the optimal conditions for manipulation, different 
strategies for printing and washing the slides were assessed. Thus a 10 mM 
solution of fluorous tagged Fluorescein 33 in DMF was used to print different 
numbers of drops per spot onto the fluorinated slide. Once printed solutions 
were dried, spot size and morphology were investigated as well as solvents for 
slide washing after printing and drying methods such as centrifugation or 
nitrogen. As shown in Figure 2.9, when slides are washed in water the spots 
remained exactly as before and with the same range of intensities. However, if 
the washing was performed with sonication for 1 min some shadows could be 
seen surrounding the spots indicating compound movement. Slide drying by 
centrifugation showed the worst results and it was clear that fluorine affinity was 
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not strong enough to survive this treatment. As expected, organic solvents 
completely washed away the fluorous tagged compound from the slide; however 







Figure 2.9: Scan of fluorous tagged Fluorescein 33 printed slides after different washing and 
drying techniques: a) slide without washing; b) slide washed with water for 10 minutes and 
then 1 minute sonication; c) slide washed with DMSO; e) slide washed with water for 10 
minutes; f) slide washed for 10 minutes in water and then dried by centrifugation; g) slide 
washed with ethanol.  
To assess the ability of fluorous tagged photospacers once adhered onto 
the surface to capture Fluorescein the following experiment was carried out. A 
fluorinated slide was printed with a solution of 10 mM of FPS1 in DMF with 
different number of drops. Slides were left to dry overnight and then a solution 
of 10 mM carboxyfluorescein in DMF was printed at the same position with the 
same number of drops as the photospacer. Slides were left to dry and then 
irradiated for 40 min at 365 nm. Scanning of the slide was done before and after 
washing twice with a 10% MeOH solution in water for 10 min (Figure 2.10). As 
anticipated, the intensity of the spot decreased after washing due to the removal 
of exces fluorescein, however, the spot shape and homogeneity was still good. 
The results showed that a fluorous tagged photospacer was attached to the 
surface and it remained after washing and that it was capable of capturing 
carboxyfluorescein. In addition, signals were detected with as less as 2 drops per 





Figure 2.10: Scan of carboxyfluorescein immobilised onto a surface printed with FPS1. 
From left to right, increasing drop number of FPS1 solution printed. a) slide without wash; b) 
slide washed with 10% MeOH in water. 
 A second method used for immobilisation of compounds consisted of 
mixing FPS1 and carboxyfluorescein prior to solvent evaporation and irradiation. 
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The sample was then redissolved in DMF and printed onto a fluorinated slide with 
the same number of drops as the previous experiment. The slide was left to dry 
and then washed before scanning. Although this strategy seemed to work, the 





Figure 2.11: A carboxyfluorescein and FPS1 were irradiated for 40 min and then dissolved 
in DMF to make a 10 mM solution and printed onto a fluorinated slide. 
In conclusion, these experiments established the best way to immobilise 
compounds by fluorous tag physisorption onto fluorinated slides. Firstly, slides 
could be washed in water without fear of compound diffusion but when washed 
with organic solvents compounds were completely washed away. Secondly, slide 
quality was superior when no sonication or centrifugation was applied. And 
finally, the simpler and the better signal-to-noise ratio and spot morphology was 
achieved when irradiation was performed over the slide after spotting of both the 
photospacer and the small molecule to be immobilised.  
2.9.2.3. Experimental Validation 
To determine the sensitivity of this strategy and the optimal photospacer 
length, a validation experiment was carried out. As for strategy I, every 
structure was printed in quadruplicate and the experiment was duplicated within 
the slide. The left array was printed with 8 drops/spot and the right one with 10 
drops/spot of a photospacer solution. The controls used were the same as before 
where only one of both, photospacer (FPS3) or the small molecule, was printed 
and highlighted with green and red squares, respectively. From left to right, the 
three different photospacers were printed, and from top to bottom the 
concentration of the small molecule increases. This experiment was carried out 
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Figure 2.12: All photospacers were printed using a 10 mM solution in DMF. Green squares 
show where FPS3 photospacer had been printed and red squares where 10 mM solution of 
Fluorescein. The left grid was printed with 8 drops/spot and the right one with 10 drops/spot 
of both photospacer and carboxyfluorescein solutions. After printing, the slides were left 
overnight and then irradiated for 40 min at 365nm, washed with water and scanned with a 




Figure 2.13: Photospacer length and sensitivity experiment by immobilising Biotin. Detection 
of Biotin was carried out by incubation of Cy5-labelled Streptavidin for 1 h at 37 ºC. After 
washing, slides were scanned using a Cy5 filter. 
Unlike strategy I, the shortest fluorous tagged photospacer FPS1 gave 
the best results and intensive signals could be detected when the lowest 
concentrations of small molecule were used. Fluorous tagged photospacers FPS2 
and FPS3 signal was detected when the small molecule concentration was at 
least 10 mM or higher. Thus, the sensitivity of strategy II seemed to be higher 
than strategy I as signals could be detected at lower concentrations of the small 
molecule solutions. 
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In conclusion, strategy II has some advantages over strategy I. Firstly, 
the preparation of slides for strategy I is longer, involving an additional printing 
step for the masking process. Moreover, each slide needs to be specially 
prepared for each designed experiment, making sure that the photospacer and 
the small molecule to be immobilised are printed at the same position where the 
masking was disposed. On the contrary, slides prepared by strategy II involve 
only one step without printing and do not need the removal of slides from the 
printer station until all processes are completed. In addition, when the 
experiment is finished there is the possibility to wash the slides with organic 
solvents and reprint them.  
2.10. Printing of a 2,000 Compound Library 
A small-molecule microarray was prepared by strategy II to screen a 
library of 2,000 compounds. For statistical reasons, each compound had to be 
assessed in triplicate. As a consequence, a small-molecule microarray needed to 
be designed where at least 6,000 spots could fit into the printing area. Thus, a 
SciFlexarrayer printer was used to achieve higher spot density on the slide 
instead of the Microdrop printer used for previous experiments. In addition, the 
Sciflexarrayer software allows programming of the printing method in a simple 
manner which is an important advantage when 6,000 spots need to be 
deposited.  
2.10.1. SciFLEXARRAYER printer 
In order to see if the preliminary experiments could be extrapolated to 
the SciFlexarrayer technology the following experiment was carried out where an 
array of 5x5 spots was printed with FPS1 and used to immobilise biotin. In 
addition, the experiment was used to determine the best photospacer:biotin 
ratio by printing a different number of drops/spot in each column. Column 1 
corresponded to 1:1 ratio, column 2 to 2:1, and up to 5 times more photospacer 
than Biotin. Each condition was replicated five times. The positive control 
corresponded to the printing of a 2 mM solution of fluorous tagged Biotin 32 and 
the negative control corresponded to a 10 mM Biotin solution. The slides were 
left to dry and then irradiated for 40 min at 365 nm and washed extensively 
before incubation with Streptavidin-Cy3 for 1 h at 37 ºC, washed and scanned 
with a Cy3 filter (Figure 2.14). 
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Figure 2.14: Scanning of a slide generated using strategy II and a SciFlexarrayer printer in 
order to optimise the amount of photospacer to be used for a 10 mM small molecule solution 
(Biotin). The different photospacer:Biotin ratios (columns 1 to 5) were produced by 
depositing the same volumes of FPS1 but varying the number of printing times, ranging from 
5:1 ratio in the first column to 1:1 ratio in the fifth column.  Each ratio was quintupled (rows), 
generating a 5x5 grid. The same volume of a 10 mM Biotin solution was printed equally 
everywhere. The negative control consisted in an extra column (green rectangle) where a 10 
mM Biotin solution was printed without previous photospacer printing. A 2 mM fluorous 
tagged Biotin 32 solution was used as a positive control (red rectangle).  
The experiment showed that the strategy II could be performed with the 
SciFlexarrayer printer and that a large excess of photospacer did not give a 
better signal, the 5:1 ratio giving the lowest intensity. The 3:1, 2:1 and 1:1 
ratios gave high fluorescent signals, with the 2:1 ratio the most intensive. 
However, the 1:1 ratio was used for the development of the small-molecule 
microarray as the spots were smaller, showed high intensity and required less 
photospacer.  
2.10.2. Slide Reuse 
The reuse of the printed slides was studied with the biotin printed slide 
used in the previous section (Figure 2.14). The fluorescence mean data of each 
spot was analysed before and after water washings at 70 ºC (for 1 or 2 h) to 
induce protein denaturation and to wash away the Cy3-labelled Streptavidin. 
Subsequently, the slide was incubated again with Streptavidin-Cy3 and 
fluorescence data was compared in order to determine how well the washing 
steps were performed and if the slide was still functional after the washing step 
in comparison with the first incubation of the slide with Streptavidin-Cy3 (Figure 
2.15 and Graph 2.1).  
 a) b) c) d) 
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Figure 2.15: Scanning of the same slide in Figure 2.14 where a 10 mM Biotin solution was 
immobilised by different amounts of photospacer-Ftag generating a grid of 5x5 (5 different 
ratios (columns) by 5 replicates of each condition (rows)) on a Genetix Scanner after a) first 
incubation with Streptavidin-Cy3 (the same as Figure 2.14); b) washing for 1 h at 70 ºC; c) 
washing for 2 h at 70 ºC; and, d) repeated incubation with Streptavidin-Cy3. Red squares 
correspond to the area where Biotin-Ftag was printed and green squares were Biotin 
solution was printed without previous photospacer printing. 
 
Graph 2.1: Intensity values of each spot condition after each treatment: yellow bars 
correspond to the first incubation with streptavidin-Cy3; light blue to wash treatment at 70 ºC 
for 1 h; dark blue to wash treatment at 70 ºC for 2 h; and orange bars show means after the 
slide have been incubated for a second time with Streptavidin-Cy3. Mean is shown as an 
average of 5 spots and x-axis represents the different ratios of Biotin:FPS1 photospacer. 
The results showed that intensity decreased after washing for 1 h at      
70 ºC. After a second wash at 70 ºC for 1h, the intensity further decreased to 
half and re-incubation of the slide with Streptavidin-Cy3 restored the 
fluorescence achieving the same or higher values than the first hybridisation. 
In conclusion, the data indicate that after washing the entire signal was 
removed but fluorescent signals could be restored after protein re-incubation 
with the same intensity values of the first incubation. Thus, printed slides 
already used for binding assays can be reused. In addition, degradation of 
immobilised compounds under washing conditions can be spotted when intensity 
is not restored to initial values after washing and re-incubation. 
1:1 1:2 1:3 1:4 1:5 1:1 1:2 1:3 1:4 1:5 1:1 1:2 1:3 1:4 1:5 1:1 1:2 1:3 1:4 1:5 
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2.10.3. Spectum Library 
The 2,000 compounds (Spectrum collection of MicroSource Discovery 
Systems, Inc. (Gaylordsville, CT)) encompass a wide range of biologically active 
compounds. Approximately 50% of the library consists of known drugs. Natural 
products with unknown biological properties make up 30% of the library and the 
remaining 20% of the compounds represent non-drug enzyme inhibitors, 
receptor blockers, membrane active compounds, and cellular toxins.  
2.10.4. Beta-Transducin Repeat Containing Protein 
Beta-Transducin Repeat Containing Protein (β-TrCP1) is an F box protein 
which interacts with Skp1 through the 40 amino acid F box motif and with 
substrates through C-terminal protein-protein interaction domains consisting of 
seven WD40 repeats. The F-box domain subunit, together with the adaptor 
protein Skp1, the scaffold protein Cullin1, and the RING-domain protein RBX1, 
makes up the SCF complex (Skp1-Cul1-F-box protein) or E3 ubiquitin ligase. All 
known SCFβ-TrCP1 substrates contain the DSGØXS destruction motif (Ø 
representing a hydrophobic and X any amino acid) in which the serine residues 
are phosphorylated by specific kinases. The binding of β-TrCP1 results in 











Figure 2.16: Diagrammatic drawing showing the SCF complex and how it recognises its 
substrate for degradation by the proteasome. (Ub)n, polyubiquitn; P, phosphate group; E1 
and E2, ubiquitin E1 and E2 enzymes; Cul1, RBX1,Skp1, and Fbox protein, SCF complex 
components. 
β-TrCP1 is implicated in various cancers, by being overexpressed or 
having mutations. β-TrCP1 controls the stability of proteins involved in 
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transcription, including β-catenin253 and IkB.254 For example, the degradation of 
IkB is an essential step for releasing  the transcription factor NFkB (Nuclear 
Factor-kB) which translocate to the nucleus and bind their cognate DNA binding 
sites to regulate the transcription of a large number of genes, regulating and 
activating key molecules that are associated with diseases ranging from 
inflammation to cancer.254, 255 Thus, finding molecules that interact with β-TrCP1 
could help to study and regulate its activity in cancer cells where it is 
overexpressed. 
2.10.5. Microarray Experiments 
A small-molecule microarray was prepared by printing 8 drops per spot of 
10 mM FPS1 solution in DMF (53 rows x 114 columns = 6,042 spots). The 
SPECTRUM library (2,000 compounds) was then printed in triplicate, spotting 8 
drops per spot of 10 mM compound solutions, and then irradiated (Figure 
2.17). 
 
Figure 2.17: Image of the prepared small-molecule microarray following strategy II (6,042 
spot/slide with an average spot diameter of 200 µm). 
This small-molecule microarray was used to screen ligands for β-TrCP1. 
Compounds that interact with the target protein were detected by incubating the 
microarray with an anti-β-TrCP1 primary mouse antibody which was recognised 
by a secondary antibody containing a fluorescent label (Cy3-conjugated Donkey 
anti-Mouse IgG secondary antibody). 
To eliminate assay false positives, non-specific interactions from the 
antibodies used for the assay towards the small molecules immobilised onto the 
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array were investigated. Firstly, the small-molecule microarray was incubated 
with the Cy3 conjugated donkey anti-mouse IgG secondary antibody and the 
comparison of fluorescence before and after incubation was evaluated. No false 
positives were detected as a result of the interaction between the secondary 
antibody and the immobilised compound library. 
Secondly, incubation of the small-molecule microarray with the two 
antibodies used for the assay was investigated in order to detect possible         
non-specific interactions between the first antibody and the compound library. 
The slide was first treated with monoclonal mouse anti-β-TrCP1 for 4 h and 
subsequently incubated with the secondary antibody as previously. Slides were 
washed and dried and finally scanned with a Cy3 filter with a microarray scanner 
(Genetix 4200AL, Axon). Fluorescence intensities before and after the antibody 
binding clearly showed the existence of non-specific interactions. In order to 
eliminate these false positives, the fluorescence data collected from this assay 
was used as the background to be substracted from the posterior binding assay 
experiments with β-TrCP1. 
Finally, the binding assay of β-TrCP1 was carried out by incubation of the 
protein with the small-molecule microarray at 4 ºC overnight and subsequent 
incubation with antibodies (Figure 2.18).  
 
Figure 2.18: Fluorescence image of the microarray after incubation with β-TrCP1 and 
primary and secondary antibodies. Each compound of the library was printed in triplicate in 
different positions of the slide.  
 
After the first set of data was collected, the slide was washed at 70 ºC for 
1 h with water and the bioassay was carried out for a second time. Data were 
collected and the process was repeated, thus giving three sets of data for 
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binding. Data treatment generated a list of binders, with many compounds seen 
in all three lists (Table 2.3). Some of the compounds found as potential binders 
had been already assessed by fluorescence polarisation solution assays and 
showed inhibition activity towards β-TrCP1. This was indicative of a good assay 
performance and background correction. 
 Binding Assay 1 Binding Assay 2 Binding Assay 3 
1 Rutilantinone Pyrromycin Pyrvinium Pamoate 
2 Pyrromycin Pyrvinium Pamoate Pyrromycin 
3 Derrubone Doxorubicin Fenofibrate 
4 Quinacrine Hydrochloride Dehydrovariabilin  Grayanotoxin I 
5 Chlorhexidine Bisanhydroturilantinone Phloretin 
6 Pyrimethamine Fenofibrate Dichlorophene 
7 Doxorubicin Rutilantinone Benzbromarone 
8 Thioridazine Hydrochloride Dichlorophene Pimozide 
9 Grayanotoxin I Naphazoline Hydrochloride Auraptene 
10 Pyrvinium Pamoate Hexachlorophene Hexachlorophene 
11 Tyrothricin Bithionate Sodium Pararosaniline Pamoate 
12 Purpurin Auraptene Gentian Violet 
13 Perillyl Alcohol Pararosaniline Pamoate Pomiferin 
14 Tannic Acid Tannic Acid Tannic Acid 
15 Daunorubicin Benzbromarone Bithionate Sodium 
16 Thiostrepton Daunorubicin 3,4'-Dimethoxyflavone 
17 Indapamide Gentian Violet 1,4,5,8-tetrahydroxy-2,6-
Dimethylanthroquinone 
18 Epirubicin Hydrochloride Gambogic Acid Amide Pyrimethamine 
19 Aristolochic Acid 3,4'-Dimethoxyflavone Pachyrrhizin 
20 Hexachlorophene Probucol Tyrothricin 
21 Bithionate Sodium Trazodone Hydrochloride Thioridazine Hydrochloride 
22 Bisanhydrorutilantinone Dibutyl Phthalate Aristolochic Acid 
23 Dehydrovariabilin Pyrimethamine Resveratrol 
24 Dichlorophene Gossypol Gossypetin 
25 Pimozide Pomiferin Gossypol 
 
Table 2.3: 25 first hits of the 3 binding assays carried out where those compounds that are 
in all three assays in these positions have been highlighted. 
  In order to reassess potential binders found from the whole library 
screens, a “short list” of 80 compounds was generated (Appendix II). This list 
was built up of putative ligands found in the first positions of the three binding 
assays and compounds that showed no activity (as negative controls). These 
compounds were spotted again in quadruplicate and in 6 different grids 
distributed along the slide and screened against β-TrCP1 (Figure 2.19).  
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Figure 2.19: Scanning of one of the six grids with quadruplicates of the 80 printed 
compounds after incubation with β-TrCP1. 
The top 10 potential binders identified for β-TrCP1 are shown in Table 
2.4. These compounds were analysed by fluorescence polarisation solution assay 
to determine their inhibition activity towards β-TrCP1. The fluorescence 
polarisation assay consists of a modified sustrate with a fluorophore for the 
target protein (β-TrCP1), in this case β-catenin was modified with fluorescein. 
The fluorophore is excited with polarised light. Only fluorophores parallel to the 
light absorb and are excited. The excited state has a lifetime before the light 
emission occurs. During this time the labelled fluorophore molecule rotates and 
the polarisation of the light emitted differs from the excitation plane, giving a 
fluorescence polarisation response as mP (milli-polarisation level). The rotational 
speed of a molecule is dependent on the size of the molecule. The basic principle 
is that the substrate is small and rotates rapidly (low polarisation), however, 
when the labelled compound binds to a larger molecule, its rotation slows down 
considerably and its fluorescence becomes polarised. As a result, when a 
molecule which can displace the substrate form the target is added, the 
inhibition activity can be measured as a change in polarisation (mP). 
 
 
Compound mP (10 µM) % inhibition mP (100 µM) % inhibition Conclusion 
 4’-Methoxy Chalcone 110.3 10.2 112.6 6.5   Inactive 
 Curcumine 232.2 - 261.2 -   Fluorescent 
 Trazodone HCl 110.4 10.0 111.5 8.3   Inactive 
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 Tyrothricin 116.1 - 251.3 -   Fluorescent 
 Grayanotoxin I 111.0 9.1 107.8 14.2   Inactive 
 Dehydrovariabilin 108.8 12.6 109.2 12.0   Inactive 
 Derrubone 111.1 9.0 108.3 13.5   Inactive 
 Dichlorphene 105.3 18.4 97.5 30.9   Weakly active 
 Thiostrepton 110.3 10.2 110.6 9.8   Inactive 
 Gambogic Acid Amide 114.5 - 144.6 -   Fluorescent 
Table 2.4: Top 10 potential binders identified after screening the 80 selected compounds 
from SPECTRUM library and the results from fluorescence polaritsation solution assays in 
mP values and percentage of inhibition for each concentration.  
The results from the solution assay showed that one compound was 
weakly active with 30% of inhibition activity at a 100 µM concentration and the 
rest were inactive or could not be determined as a result of the intrinsic 
fluorescence of the compound.  
2.11. Conclusions 
The experiments presented demonstrated two different ways to 
immobilise compounds in an array format by means of carbene insertion 
chemistry. Both methods use fluorinated surfaces which avoid or limit non-
specific interactions of proteins with the glass surface, and thus improve the 
signal-to-noise ratio. Comparison of the two methods suggested that the second 
strategy, in which the slide surface was functionalised with TFMAD 4 by non-
covalent interactions using a fluorous surface, was more sensitive as it could 
detect lower concentrations of printed small molecules and involved a much 
simple surface preparation procedure. In addition, it was shown that the slides of 
immobilised compounds could be re-used several times with simple washing 
away of the protein that was being interrogated under de-naturing conditions.  
Once the approach was optimised, a 2,000 compound library was 
immobilised and screened against β-TrCP1, a protein with oncologic interest. The 
β-TrCP1 screens produced a ranking of 25 molecules that would bind and 
potentially act as inhibitors or inducers of β-TrCP1. These compounds were re-
printed and reassessed again to obtain the top 10 “hit” list. These compounds 
were analysed by fluorescent polarisation based assays in order to detect 
displacement of the natural β-TrCP1 ligand. The assay identified one of the 
compounds as weakly active with 30% of inhibition activity towards β-TrCP1 at 
100 µM concentration. However, three of the top ten hits could not be analysed 
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in depth due to their intrinsic fluorescence. This highlights one of the weaknesses 
of the affinity based assays in that compounds might well bind to the target, but 
actually be totally passive with respect to β-TrCP1 inhibition (i.e they could bind 
in non-responsive positions).  
Although the results reported have not identified potent inhibitors for     
β-TrCP1, the approach developed could be a useful tool for the screening of 
other libraries of compounds where potential binders could be found or for the 
screening of other proteins of interest. However, more experiments would be 
needed to make this approach a reliable tool for protein screening.  
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Chapter III: 
3. Fluorescent Probes for Cargo Attachment 




3.1. Introduction  
Many biologically active compounds, including various large molecules, 
need to be delivered intracellularly to exert their therapeutic effect. These 
compounds need to be sufficiently soluble in the intracellular media and at the 
same time sufficiently hydrophobic to allow membrane penetration as the 
lipophilic nature of the biological membranes restricts direct intracellular 
translocation. As this is difficult to accomplish, several carrier-mediated delivery 
systems have been developed.256, 257 One of these approaches involves tethering 
molecules to peptides that can translocate through the cellular membrane, 
thereby enhancing delivery into the cell.258  
3.1.1. Cellular Membrane 
The cellular membrane is a complex fluidic phospholipid bilayer embedded 
with proteins that control the intracellular flux of compounds circulating 
extracellularly due to its selective permeability (based predominantly on ionic 
charge, hydrophobicity, and size).259 The phospholipid bilayer is arranged such 
that the polar ends of the molecules form the outermost and innermost surface 
of the membrane while the non-polar ends mingle at the center of the 
membrane (Figure 3.1). Other complex lipids are also present in lesser amount 
such as cholesterol, which makes the membrane less permeable to most 
biological molecules and adds rigidity. Lipids allow diffusion control across the 
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membrane: prevent loss of polar compounds such as proteins, acid or ions but 





Figure 3.9: Schematic representation of a) the phospholipid structure that makes up the lipid 
bilayer and b) the cellular membrane and its components. 
Membrane proteins allow numerous cellular functions to occur such as 
transport, cell signalling, and adhesion. Channel proteins form pores for the free 
transport of small molecules and ions to pass through without coming in direct 
contact with lipid interior. Carrier proteins facilitate diffusion and active transport 
of specific molecules and ions that cannot cross on their own. For cell signalling, 
receptor proteins bind to specific molecules such as hormones and cytokines, 
this interaction triggering a series of membrane and intracellular events that 
alters the activity of the target cell. Finally, cell adhesion molecules are 
important in the cell’s ability to recognise “self” and in cell-to-cell interactions. As 
a result of this complexity, selective substances cross the cytoplasmic membrane 
of eukaryotic cells by different transport methods such as simple diffusion, 
osmosis, active transport, endocytosis, and exocytosis. 
The complexity and the selective permeability of the cellular membrane 
represent a challenge for drug development as foreign materials such as nucleic 
acids and proteins are not able to translocate the cellular membrane alone and 
require a delivery vehicle. The principal delivery vehicles being explored include: 
microspheres,260 cationic lipids,261 polymers262 and dendrimers,263 multi-walled 
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3.1.2. Cell-Penetrating Peptides 
A strategy for promoting cellular delivery of poorly permeable materials 
into cells is based on the conjugation to cell-penetrating peptides which enhance 
translocation across the cellular membrane, while organelle specific targeting can 
also be mediated by specific peptides. The mechanism of translocation occurs by 
a non-toxic process, apparently independent of membrane receptors although 
the mode of action is still subject to debate.266 Cell-penetrating peptides are 
short peptides of less than 30 amino acids and are classified into two structural 
types: polycationic or amphiphatic.  
Polycationic peptides are highly rich in basic residues (lysine and arginine) 
such as the TAT peptide (GRKKRRQRRRPPQ),267-269 and they posses an overall 
positive charge. Short oligomers sequences made of Arginines267, 269 or Lysines270 
have also been shown to enable or enhance uptake of agents into the cells that 
do not enter or do so poorly.  
In contrast, amphiphatic cell-penetrating peptides consist of sequences 
with an alternating pattern of polar and non-polar residues, such as transportan 
(GWTLNSAGYLLGKINLKALAALAKKIL),271 penetratin (RQIKIWFQNRRMKWKK),266 
and MAP (model amphiphatic peptide) (KLALKLAKALKAALKLA),272, 273 and they 
exhibit the ability to be arranged in amphipatic α-helical structures.  
The use of peptides with cell-penetrating properties as delivery carriers 
allows modifications of the peptide sequence to yield carriers addressing 
different cellular subdomains and/or able to transport various types of cargoes. A 
cargo can be bound to the cell-penetrating peptide covalently or through either 
electrostatic or hydrophobic interactions, and its molecular weight can be several 
times greater than the cell-penetrating peptide.274  
Details on the nature of cell-penetrating peptides, their proposed 
mechanisms of translocation, and their involvement in the delivery of therapeutic 
agents have been reviewed recently.258, 265, 275 In addition, a range of 
peptidomimetics, such as peptoids276-279 and β-peptides280, structurally inspired 
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3.1.2.1. Peptoids as Delivery Agents 
Peptoids are N-alkylated Glycine derivatives in which the amino acid side 
chains are shifted from the α-carbon to the amino functionality (Figure 3.2).  
 
Figure 3.2: schematic comparison between a peptide (a) and an oligomer of N-substituted 
Glycines or “peptoid” (b) sequence, showing the similarity of spacing of the side chains, and 
the lack of stereochemistry of the peptoid monomers. 
Like peptides, peptoids are prepared by standard solid phase techniques 
as a succession of building blocks linked together by amide bonds and the 
distance between two consecutive side chains is the same in both structures.277, 
278, 281, 282 However, peptoids are achiral peptidomimetics (except for any chirality 
found in any side chain). The advantage of peptoids, as for peptides containing 
D- and β-peptides, is that they are resistant to proteolysis, and are therefore 
advantageous for therapeutic applications.283 Since the secondary structure of 
peptoids does not involve hydrogen bonding, they are not typically denaturated 
by solvent, temperature, or chemical denaturants such as urea.  
Peptoids inspired on cell-penetrating peptides, such as polyArginine or 
polyLysine, have been shown to have good cell permeability characteristics in a 
wide range of cell lines, with the ability to transport a variety of drugs and cargo 
molecules into cells and tissues.279, 282, 284, 285 Hybrids of polyLysine-like peptoids 
with peptide localisation sequences have shown the ability of intracellular 
targeting.286, 287  
3.1.3. Nuclear Localisation Sequences 
The nuclear envelope or nuclear membrane is a double membrane that is 
continuous with the endoplasmatic reticulum. It encloses the genetic material in 
eukaryotic cells and serves as a physical barrier, separating the contents of the 
nucleus from the cytosol.  
Transport of proteins to the nucleus, as opposed to some other cellular 
compartments,288, 289 is unique because of the presence of pore complexes in the 
nuclear membrane. Nuclear pore complexes represent discontinuities in the 
phospholipid bilayers of the double nuclear membrane that are potentially 
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nuclear membrane, but a selective mechanism regulates the entry of larger 
proteins.290  
The selectivity of large nuclear protein import resides in nuclear 
localisation signals (NLS), which are present only in nuclear proteins. Transport 
signals are specifically bound and recognised by importins in the cytoplasm, and 
the resulting complexes cross the nuclear envelope (Figure 3.3).291, 292 They can 
be located almost anywhere in the amino acid sequence and generally consist of 
a short sequence (typically four to eight amino acids) that varies for different 
nuclear proteins but is rich in Lysine and Arginine residues, and usually contains 
Proline. In many nuclear proteins this sequence is split into two blocks of two to 
four amino acids, with the blocks separated from each other by about ten amino 
acids. These blocks are thought to form loops on the protein surface.293  
 
Figure 3.3: Schematic representation of nuclear import. The process starts when proteins or 
cargos bearing a nuclear localisation singal (NLS) are recognised by importins and form a 
complex that localises to the nuclear envelope and docks at the nuclear pore. Once 
translocation through the pore is executed using ATP, the complex is destabilised and 
dissociated,  facilitating cargo release.  
Nuclear localisation signals were first indentified in the large viral protein 
T-antigen, encoded by the SV40 virus and needed for viral DNA replication in the 
host cell nucleus.294 This signal comprises a highly basic stretch of amino acids 
(126PKKKRKV132) containing five consecutive positively charged residues.295 There 
is an absolute requirement for a positive charge at the position of the second 
Lysine, with the next three positive charges having less effect on transport.294, 296 
Since then, several nuclear localisation signals have been identified, together 
with their import receptors that recognise and bind them.297-300 
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NLS peptides coupled by way of covalent linkers have already been 
demonstrated to confer nuclear localisation on a variety of proteins, e.g., BSA 
and ferritin,296 and even molecules as large as IgM.301 In addition, the NLS 
sequence conjugated with a different classes of biomaterials, such as 
nucleotides,302 peptidic materials303 and drugs,304 have also been reported as an 
efficient and very specific mechanism for transporting cargos into the nucleus. 
Thus, NLS may have applications in drug delivery, where the therapeutic agent 
in question has its specific target site of action within the nucleus, for example 
some anticancer drugs. 
3.1.4. Colchicine & Anticancer Drugs  
The water-soluble alkaloid Colchicine (Figure 3.4) is extracted from the 
bulb of meadow saffron or Colchicum. Colchicine blocks or suppresses cell 
division by inhibiting mitosis, the division of a cell's nucleus. Specifically, it 
inhibits the development of spindles as the nuclei are dividing by binding to 
tubulin, one of the main constituents of microtubules.305 Normally, the cell would 
use its spindle fibers to line up its chromosomes, make a copy of them, and 
divide into two new cells with each daughter cell having a single set of 
chromosomes. With Colchicine present, the spindle fibres do not form, and so 
the cell cannot move its chromosomes around.306 The cell may end up copying 
some or all of the chromosomes anyway, but cannot parcel them out into new 
cells, and so it never divides. 
 
Figure 3.4: Colchicine anticancer drug structure. 
Since one of the defining characteristics of cancer cells is a significantly 
increased rate of mitosis, cancer cells are significantly more vulnerable to 
Colchicine poisoning than normal cells are. Unfortunatelly, the therapeutic value 
of Colchicine against cancer is limited by its toxicity against normal cells. 
However, Colchicine is nowdays used to treat gout and familial Mediterranean 
fever as it also has anti-inflammatory effects, by inhibiting neutrophil motility 
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and activity, and the deposition of uric acid crystals which is a vital aspect of the 
mechanism of gout.307-310  
The crucial role of the mitotic spindle in cell division has been identified as 
an important target for anticancer drug development.311, 312 However, drug 
delivery in cancer chemotherapy has two main limitations. Firstly, the selectivity 
of chemotherapeutic agents for cancer cells is often low. As a consequence, the 
drug does not reach a given concentration close to the tumor cells and higher 
doses of anticancer drugs must be given resulting in unacceptable toxicity to 
normal tissues. Secondly, the water solubility of the chemotherapeutic agent 
must be high in order to gain access to tumor cells surfaces via the circulatory 
system as well as good lipid solubility to allow penetration of the cancer cell 
plasma membrane upon arrival at the cell surface. These two solution properties 
are often difficult to design into the same drug molecule. Consequently, there is 
a need for a new method of administration that could concentrate the drug close 
to the tumour site.  
Several solutions have been proposed for increasing the efficacy of 
chemotherapy while reducing adverse effects. On one side, carrier systems have 
been used to enhance cell penetrability and solve solubility problems.313 And, on 
the other hand, folic acid has been conjugated to anticancer drugs to generate 
high specificity of these drugs to cancer cells by receptor-mediated endocytosis 
as a result of the overexpression of folate receptors on cancer cells, which in 
turn also reduces permeability barriers due to drug solubility.314, 315 
3.1.5. Flow Cytometry 
Flow cytometry is a powerful technique that allows the measurement of 
multiple parameters of individual particles in heterogeneous samples. When a 
sample in solution is injected into a flow cytometer, the particles are randomly 
distributed in a three-dimensional space and ordered into a stream of single 
particles that can be interrogated by the machine’s detection system. This 
process is managed by the fluidics system.  
Essentially, the fluidics system consists of a central channel/core through 
which the sample is injected, enclosed by an outer sheath that contains faster 
flowing fluid. The difference in fluid velocity creates a massive drag effect on the 
narrowing central chamber, called hydrodynamic focusing, which creates a single 
line of particles (Figure 3.5). Then, each particle passes through one or more 
laser beams. The light that emerges from each cell passing through a laser beam 
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is captured. Light scattering or fluorescence emission provides information about 
the particle’s properties.  
 
Figure 3.5: Overview of a typical flow cytometry setup. 
Light that is scattered in the forward direction is collected by a detector 
known as the forward scatter channel (FSC) and its intensity equates to the 
particle’s size and can also be used to distinguish between cellular debris and 
living cells. The side scatter light (SSC) is collected at 90º to the excitation line 
and provides information about the granular content within a particle. Both FSC 
and SSC are unique for every particle, and a combination of the two may be 
used to differentiate different cell types in a heterogeneous sample. On the other 
hand, fluorescent measurements taken at different wavelengths can provide 
quantitative and qualitative data about fluorescently-labelled cells. The data 
gathered can be analysed statistically by flow cytometry software to report 
cellular characteristics such as size, complexity, phenotype, and health. 
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3.2. Aim of the Project 
The aim of this project was to develop a general method for cellular 
delivery. Probes were prepared incorporating the TFMAD photophore (Chapter 
I) in order to capture any desired cargo and a fluorescent dye to allow probe 
detection by microscopy and flow cytometry. One of the probes also contained a 
nuclear localisation sequence (PKKKRKV) to mediate intracellular delivery 
(Scheme 3.1). Cargos were covalently bound to the probe by irradiation at 365 
nm. Optimal conditions for cargo capture were determined by using a peptoid as 
a model cargo and comparing the cell penetrability abilities of each sample. 
Probes were characterised by their cellular uptake efficiency, their toxicity and 
cellular localisation, and finally, they were applied to study their effect on the 
improvement of delivery efficiency and therapeutic effect of a cancer drug. 
 
Scheme 3.1: Schematic representation of photoreactive probes prepared in this chapter. 
Both probes contained 6-(5)-carboxfluorescein dye linked by a PEG spacer to the 
photoreactive compound TFMAD 4. The only difference between them was the presence of 
the NLS sequence (PKKKRKV). 
3.3. Probe Synthesis 
Probe synthesis was achieved via solid phase using Fmoc-Lys(Dde)-OH. 
The orthogonality of the Dde and Fmoc protecting groups allowed the selective 
substitution of the two amino functionalities, thus introducing branches for 
functionalisation.316  
Dde-OH 34 was prepared from dimedone and acetic acid in the presence 
of DCC and DMAP in DMF (Scheme 3.2). Dde-OH 34 was successfully 
condensed to the side chain residue of Fmoc-Lys-OH using microwave irradiation 
and the presence of catalytic amounts of TFA to give Fmoc-Lys(Dde)-OH 35 with 
an overall yield of 69%. 
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Scheme 3.2: Preparation of Fmoc-Lys(Dde)-OH. 
 The synthesis of the first photoprobe started with the loading of 
aminomethyl polystyrene resin with the Rink Amide linker under microwave 
irradiation for 20 min at 60 ºC followed by Fmoc deprotection with 20% 
piperidine in DMF. Fmoc-Lys(Dde)-OH was then coupled to the resin under the 
same conditions and Dde deprotection was carried out with hydroxylamine 
hydrochloride and imidazole. To the free amino group on the side chain was 
coupled TFMAD (Scheme 3.3).  
 
Scheme 3.3: Synthetic route to photoreactive probe 41. 
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After TFMAD photophore coupling, deprotection of the Fmoc group and 
subsequent PEG coupling was performed to separate the photophore and the 
dye. Fmoc deprotection and 6-(5)-carboxyfluorescein coupling were carried out 
with a subsequent resin wash with 20% piperidine in DMF before final acidic 
cleavage from the resin. The probe was obtained in 64% overall yield. 
 
 
Scheme 3.4: Synthetic route of NLS photoreactive probe 46. 
The NLS photoreactive probe was synthetised following the same strategy 
(Sheme 3.4). Aminomethyl polystyrene resin was loaded with the Rink linker 
and Fmoc deprotection was carried out. The cycle was repeated seven more 
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times in order to build the NLS sequence (PKKKRKV). After that, Fmoc-Lys(Dde)-
OH was introduced and the same procedure as before was used to give the 
probe in 24% yield. 
MALDI-TOF mass spectra of the NLS photoreactive probe showed the 
molecular mass of the probe with nitrogen loss [(Probe-N2)+H]
+· as a result of 
the laser beam (nitrogen laser) used for sample ionisation that triggers the 
carbene generation by nitrogen liberation. It also showed the mass of the 
conjugate product between the NLS photoreactive probe and sinapic acid (SA) 
used as a matrix for sample ionisation (Figure 3.6). 
 
Figure 3.6: Mass spectra of NLS photoreactive probe 46. 
3.4. Time-Dependent Cellular Uptake 
The time dependence of the fluorescein-tagged designed probes to enter 
cells was tested with HeLa cells and analysed by flow cytometry. Probes (10 and 
20 µM solutions prepared using the extinction coefficient of                          
5(6)-carboxyfluorescein were tested in triplicate, using untreated cells and cells 
incubated with 5(6)-carboxyfluorescein as a negative control. Cells were 
analysed at different times using 0.4% Trypan Blue to quench any extracellular 
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Figure 3.7: Representation of the cell population after 8 h of cellular uptake. a) NLS 
photoprobe 46, b) photoprobe 41, c) carboxyfluorescein, and d) all samples together. 
 
Graph 3.1: Flow cytometry analysis of cellular uptake versus time. Samples were analysed 
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Fluorescence intensity increased in a non-linear manner over time 
(Graph 3.1) pointing to a protein-mediated uptake mechanism, with rapid 
accumulation within the first 1 h, typically giving half the final uptake after 6h for 
experiments using the 10 µM probe. As expected probe cellular uptake was 
dependent on the concentration and was non-toxic to cells.  
Both probes showed considerable cell-penetrating properties after 8 h 
incubation with a 50-fold or a 10-fold increase in mean fluorescence relative to 
the untreated cellular control or to cells treated with 5(6)-carboxyfluorescein, 
respectively.  
3.5. Probe Cytotoxicity 
The cytotoxicity of the two photoprobes was evaluated in HeLa cells 
exposed to increasing concentrations of each probe for 24 h (Graph 3.2). MTT 
assays use 3-(4,5-dimethylthiazol-2-yl)-2,5-dipheyltetrazolium bromide, a 
tetrazole which is converted by healthy cells to purple formazan crystals. Once, 
dissolved, the absorbance of the formazan produced can be measured (λ = 570 
nm) and related to the cellular viability (taking untreated control cells as 100% 
viable).318 
 
Graph 3.2: Evaluation of toxicity of photoprobe 41 and 46 toward HeLa cells using MTT 
assays for 24 h (n = 6).  
No substantial cytotoxicity was noted in HeLa cells using photoprobe 41 
at concentrations up to 100 µM (viability was generally more than 90% in all 
cases). NLS photoprobe 46 showed a slight toxicity effect for concentrations 
higher than 50 µM. The experiment demonstrated that concentrations used for 
the present study (10 and 20 µM) were not cytotoxic. 
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3.6. Nuclear Localisation 
Intracellular localisation of both probes was investigated in HeLa cells 
using fluorescence microscopy. HeLa cells were incubated with both 
photoprobes, washed, fixed with a solution of 4 % paraformaldehyde and the 
nuclei stained with Hoechst-33342 prior to analysis by microscopy. Differences in 
fluorescent patterns were observed for both probes. Photoprobe 41 was localised 
in the cytoplasm with some “spot” accumulations (Figure 3.8). On the other 
hand, co-localisation of the photoprobe 46 fluorescence emanating from the 
nucleus along with Hoechst-33342 could be observed, with perceptible 
accumulation in the nucleolus (Figure 3.9).  
 
Figure 3.8: Microscopic images of HeLa cells incubated with photoprobe 41 at 50 µM for 2h: 
(a) 40 x, and (b) 20 x magnified. On the right, FITC fluorescence images form 41; on the left, 
fluorescence images of DAPI dye staining the nucleus; and middle image is a merge of both 
images.  
 
Figure 3.9: Microscopic images of HeLa cells incubated with photoprobe 46 at 50 µM for 2h: (a) 40 x, 
and (b) 20 x magnified. On the right, FITC fluorescence images form 46; on the left, fluorescence 
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Although further microscopy studies would be useful, the results strongly 
suggested that probe 46 localised into the nucleus as a consequence of the NLS 
presence unlike probe 41 which localised into the cytoplasm.  
3.7. Enhancing Cellular Uptake 
In order to establish the capacity of capture, an experiment was carried 
out where the probe was activated in the presence of a 9-mer lysine peptoid 
(Figure 3.10) with activation of the TFMAD photophore in the solid state 
(Scheme 3.5). This peptoid has the ability to deliver cargos into cells, so if the 
linkage between the probe and the peptoid was successful, cells would be even 
more rapidly labelled with carboxyfluorescein. 
 
Figure 3.10: Peptoid used in this study. 
 
 
Scheme 3.5: Peptoid and fluorecently labelled probes were mixed together, the solvent was 
evaporated and the sample irradiated at 365 nm for 40 min, forming different peptoid-probe 
conjugates which would display a higher degree of penetrability into cells. 
The experiment consisted of mixing different ratios of photoreactive 
probes and peptoid in order to find the best conditions for cross-linking. In a 96 
well-plate, solutions of peptoid and photoreactive probe were mixed (mole 
ratios: 3:1, 2:1, 1:1, 1:2 and 1:3 (peptoid:probe)). Samples were evaporated 
and after irradiation for 40 minutes at 365 nm, redissolved in PBS. Negative 
controls were also prepared by activation of the photoprobe without peptoid. 
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All samples were analysed by MALDI-MS to demonstrate formation of 
peptoid-probe conjugates. Spectra were quite similar for all samples, all showed 
a mass 2287 Da which correspond to the adduct formed from probe and the 
peptoid and thus demonstrate the adduct was formed. A peak 1711 Da was 
present in all samples (being the most intensive peak) suggesting the formation 
of probe-probe adducts (Figure 3.11).  
 
Figure 3.11: MALDI-MS spectrum of a solution 1:1 peptoid-probe after irradiation. 
To assess the capture reaction efficiency of the cell-penetrating peptoid 
derivatives generated, experiments were carried out with HeLa cells. Solutions of 
10 µM peptoid-probe conjugate were added to cells and incubated for 8 h. The 
same volumes of negative control samples were used. After incubation, cells 
were washed, trypsinised and analysed by flow cytometry (Graph 3.3). All cells 
treated with peptoid-probe conjugate solutions showed a 70 - 90% labelling of 
the whole population, except for the ratio 1:3, which despite containing the 
highest amount of probe, showed just 50%. In addition, HeLa cells treated with 
different concentrations of irradiated probe alone were not labelled at all 
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Graph 3.3: Cellular uptake of peptoid-probe adducts in HeLa cells (8 hours, n = 3). Graph a) 
showing the percentage of labelled cells and b) the fluorescence mean intensity relative to 
untreated cells. 
Fluorescence values suggested that 1:1 and 1:2 were the best ratios for 
conjugation. Furthermore, the mean fluorescence observed in cellular uptake 
studies for a 10 µM photoprobe solution incubated for 8 h with HeLa cells was 
20-fold and 51-fold higher than for untreated cells with probe 41 (Graph 3.1) 
and peptoid-probe 41 conjugate (Graph 3.3), respectively. Therefore, peptoid 
conjugation increased the cellular uptake properties of probe 41. 
 In summary, these experiments confirmed that molecules could be 
captured by the synthesised photoreactive probe and that the best ratio for 
conjugate preparation was an equimolar quantity of probe and cargo (peptoid).   
3.8. Colchicine Adduct Toxicity 
In order to assess the potential use of these molecules as carriers for 
drug delivery, the delivery of an anticancer drug was evaluated. Conjugates of 
Colchicine with the NLS photoprobe 46 or photoprobe 41 were prepared (ratio 
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1:1) as previously described for peptoid capture. Colchicine itself was used as a 
positive control. 
HeLa cells were treated with concentrations of 10, 1, and 0.1 µM of the 
Colchicine-probe conjugates. After 24 hours, cells were washed and MTT assays 










Graph 3.4: MTT assay results from 3 independent assays (n = 5).  
Results suggested that the IC50 of Colchicine for this assay was between 1 
and 10 µM as cell viability decreased from 65% to 20%, respectively. Colchicine-
probe adducts also showed the same behaviour but with a small increase in 
effectiveness (although statistically unchanged). Images of the effect of the drug 
and its derivatives are shown in Figure 3.12. 
 
Figure 3.12: Images of cells after 24 h incubation with a) photoreactive probe-Colchicine 
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Although the Colchicine IC50 values did not decrease by orders of 
magnitude, the study showed that increasing the uptake and localising the drug 
into the nucleus probably had an effect on Colchicine effectiveness.  
3.9. Conclusion 
Two photoreactive probes were prepared consisting of a fluorescent dye 
(fluorescein) and TFMAD 4 linked by a PEG spacer. The difference between the 
probes was the introduction of an NLS sequence to mediate intra-nuclei 
targeting. Both probes, somewhat surprisingly, showed good cellular uptake 
properties, with an increase of 10-fold in fluorescence mean relative to cells 
treated with carboxyfluorescein which enters to the cell by simple diffusion. 
Furthermore, both probes showed no cytotoxicity for concentrations used for 
these studies, and despite the need of further studies, probes 41 and 46 
seemed to be localised into the cytoplasm and in the nucleus, respectively. 
On one hand, probe 41 was used to determine optimal conditions for 
cargo capture by irradiation of the diazirine moiety in the presence of a lysine-
like peptoid. The best cargo:probe ratios was found to be 1:1 and 2:1. On the 
other hand, probe 46 was used to capture the anticancer drug Colchicine, which 
has its effects in the nucleus, and these photo-adducts were compared to the 
drug itself. Unfortunately, the results showed a minimal increase in Colchicine 
activity for both probes and no additional effect could be attributed to drug 
localisation into the nucleus by the NLS sequence.  
Nevertheless, this approach opens up a new avenue for the rapid 
assessment and delivery of any desired compound into cells. The inclusion of the 
photoreactive moiety to the fluorescent probe construct provides a rapid way to 
tether compounds and allow analysis of their effects in cells before further 
studies are carried out or facilitate their cellular localization. Alternatively, these 
photoreactive probes could also be used for staining or fluorescent tagging 
specific tissues, cells or indeed cellular compartments by activation of the 
photoprobes once inside the cell. 
 
Microspheres for Gene Delivery  88 
 
Chapter IV: 





4.1. Introduction  
The main goal of gene therapy consists of delivering therapeutic genes 
into the nucleus of target cells to achieve expression of a deficient or incorrectly 
expressed gene product, thus curing genetic diseases and viral infections, 
slowing down tumour growth, and stopping neurodegenerative disease.319 
However, difficulties in developing safe and efficient gene delivery vectors able 
to sustain gene expression for long periods has limited broader clinical 
application of gene delivery.320 Viral vectors have been seen as the most efficient 
transfection method, however they have safety issues. For this reason, efficient 
non-viral methods for gene delivery are needed. Although a wide range of 
methods and techniques have been developed, there is the need to increase the 
efficiency and efficacy of gene transfer and reduce toxicity. Microspheres have 
proven to be a very successful delivery agent for a range of different 
biomolecules such as sensors, proteins and oligonucleotides.321-324 As a result, 
microspheres could perhaps also be used to deliver DNA into cells. In order to 
investigate the ability of microspheres to introduce plasmids into cells,     
TFMAD-functionalised microspheres were prepared and carbene insertion 
chemistry was used to capture DNA onto microsphere surfaces. 
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4.1.1. Gene Delivery 
The ability to introduce DNA encoding a gene of interest into cells 
efficiently has been of central importance in gene therapy and biological 
research. In gene therapy, the expression of a particular gene is desired to 
correct a genetically predetermined biochemical lack of that activity, to block cell 
division, or to effect cytotoxicity in tumour cells. In a research context, the aim 
is transfer DNA in order to increase expression of a gene product under study in 
transfected cells, or to to oblate completely expression of a particular gene 
product in order to establish its function.  
A plasmid contains trypically 103 to 104 base pairs with a molecular 
weight of 106 to 107 Da and has a supercoiled tertiary structure in aqueous 
solution with an effective hydrodynamic diameter greater than 100 nm.325  
Uptake of the exogeneous DNA by cells is greatly limited by its size and negative 
surface charge density.326 Therefore, it has to be condensed to a size that allows 
it to be taken up into cells and the negative charges have to be masked. 
Most of the DNA delivery systems operate at one of three general levels: 
DNA condensation and complexation, endocytosis, and nuclear targeting/entry. 
Negatively charged DNA molecules are usually condensed and/or complexed with 
cationic transfection reagents before delivery. These complexes are taken up by 
cells, usually through endocytosis, the route of uptake determines subsequent 
DNA release, trafficking, and lifetime in the cell. Endocytosis is a multistep 
process involving binding to specific receptors of the surface, internalisation, 
formation of endosomes, fusion with lysosomes, and lysis. The low pH and 
enzymes within endosomes and lysosomes usually bring about degradation of 
entrapped DNA and associated complexes. Finally, DNA that has survived both 
endocytotic processing and cytoplasmic nucleases must then dissociate from the 
condensed complexes and be transported through the nuclear pores and into the 
nucleus for transcription and expression to occur (Scheme 4.1).  
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Scheme 4.1: DNA is masked with the delivery system to increase the low uptake across the 
plasma membrane. The formed complex enter into the cell by endocytosis forming an 
endosome. The endosome can become a late endosome and the plasmid be degradated or 
be liberated into the cytoplasm from early endosomes. The plasmid needs to enter into the 
nucleus for expression.  
The low efficiency of DNA delivery from outside the cell to inside the 
nucleus is a natural consequence of this multistep process. As a result, the 
number of DNA molecules decreases at each step of the journey to the 
nucleus.327 Therefore, the three major barriers to be addressed for an efficient 
DNA delivery system are the low uptake across the plasma membrane, the 
inadequate release of DNA molecules in the cytoplasm, and the lack of nuclear 
targeting. Thus, some improvements in DNA delivery efficiency have been 
achieved via the optimisation of DNA condensation, the size of DNA complexes 
and cell and tissue targeting while controlling cytotoxicity. All these aspects have 
been discussed and reviewed elsewhere.328-331 
4.1.2. Delivery methods 
Delivery methods reported in the literature can be divided into viral and 
non-viral. Viral-mediated gene delivery uses the ability of viruses such as 
adenoviruses and retroviruses to enter and express their genomes in the host 
cell. As a result these systems have been found to be highly efficient for 
delivering DNA into cells.332 However, this type of vector also present several 
problems such as toxicity, immunogenicity, size limit of the exogenous DNA, 
difficulty of large-scale production, purification and storage, and the risk of 
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inducing oncogenic mutations or generating active viral particles through 
recombination mechanisms.333, 334 These limitations of viral vectors justify the 
interest on the development of improved non-viral gene delivery vectors, which 
have resulted in the development of a broad range of delivery systems.335  
The intent of chemical methods is to neutralise or obviate the issue of 
introducing negatively charged molecules into cells as well as to compact the 
DNA to facilitate its uptake. The main types of chemicals used for DNA delivery 
are cationic polymers, liposomes, nanoparticles and cell-penetrating peptides 
(CPPs) (Figure 4.1). The advantages of these gene transfer formulations are 
their ease of preparation (and scale-up) and their flexibility regarding the size of 








Figure 4.1: Reagents such as cationic polymers, cationic lipids or cell-penetreting peptides 
(CPPs) coat the DNA, neutralising or even creating an overall positive charge on the 
molecule. 
Cationic polymers tightly associate with negatively charged nucleic 
acids, providing an excess of positive charge which allows the uptake of the 
complex by endocytosis.336, 337 This method successfully delivers nucleic acids 
into cells for transient expression; that is, for short-term expression studies of a 
few days in duration. However, this technique is not generally useful for stable or 
long-term transfection studies that rely upon integration of transferred DNA into 
the chromosome.338 Synthetic cationic polymers that have been used to transfer 
DNA into cells include DEAE-dextran, polybrene339, and polyethyleneimine 
(PEIs)340. The biodegradable poly-L-lysine (PLL) has also been used as a delivery 
vehicle for DNA and small drugs for a long time. The advantages are the ease of 
its degradation by cells and the use of the epsilon amino group of lysine for 
covalently attaching ligands to the molecule to improve transfection efficiency.341 
However, PLL has a low level of transfection efficiency, primarily owing to lack of 
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rapid release of PLL-DNA complexes form endosomes, and suffers from 
immunogenicicty and toxicity.342, 343 
Polyamidoamine (PAMAM) dendrimers are non-linear polycationic 
hyperbranched polymers that can bind to DNA. The interaction of dendrimers 
and plasmid DNA induces condensation of the nucleic acid which facilitates their 
uptake by endocytosis.344-346 Commercially available PAMAM dendrimers include 
the SuperFect, and PolyFect transfection reagents (Qiagen). 
Cationic lipids have the ability to form lipid bilayers in aqueous medium 
called liposomes. The cationic portion of the lipid molecule associates with 
negatively charged nucleic acids, resulting in compaction of the nucleic acid in a 
liposome-nucleic acid complex,347, 348 which enters into the cell by endocytosis or 
fusion with the plasma membrane via the lipid moieties of the lipoplex.349 New 
formulations make use of various lipid mixtures and cationic peptides to improve 
transfection efficiency, for example the addition of L-dioleoyl 
phosphatidylethanolamine (DOPE) aims to help DNA release from endosomes 
once in the cytoplasm as well as to facilitate fusion with the outer cell 
membrane.350 Several cationic peptides have been used as a condensation agent 
to enhance uptake and facilitate the plasmid transfer to the nucleus.341, 351 
Liposome-mediated delivery offers advantages such as relatively high 
efficiency of gene transfer, in vitro and in vivo applications,352 and successful 
delivery of DNA of all sizes from oligonucleotides to yeast artificial 
chromosomes.261, 344, 353-355 Cells transfected using liposome techniques can be 
used for transient expression studies and long-term experiments. However, their 
transfection efficiency is still unsatisfactory, especially when compared with viral 
vectors, and little is known of the role of charged lipids in human gene therapy 
and the mechanism involved in the process of intracellular gene delivery.356 In 
addition, several in vivo studies have reported cytotoxicity of cationic lipids upon 
administration.357, 358 Nevertheless, the formulations of cationic lipids for DNA 
transfection such as Lipofectamine, Effectene and Attractene are commercially 
available. 
The use of CPPs for gene delivery is particularly interesting because they 
are able to efficiently condense DNA due to electrostatic interaction, improve 
cellular internalization and promote endosomal escape, and can provide nuclear 
localisation of condensates when short NLS peptides are used.265, 359-361 There 
are many examples of CPP-mediated delivery of plasmid DNA into cultured cells 
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and also in vivo.362, 363 However, their transfection efficiency improves when the 
peptide backbone is chemically modified by fatty tails such as stearic acid which 
increases efficiency of endosomal escape.364 Coupling of CPPs to other classes of 
non-viral gene delivery methods, such as liposomes,365, 366 PEI polymer367, 368 or 
nanoparticles369-371 contributes to enhance cellular association and increase 
nuclear delivery efficiency.372 
Alternatively, the main physical and mechanical methods include 
microinjection, electroporation and particle bombardment. In general, these 
methods involve making a transient hole in the membrane to facilitate the 
delivery of compounds that would not cross the membrane alone. Following 
permeation, the cell membrane can repair itself. Although efficient, these 
methods are slow, laborious and toxic. 
4.1.3. Microspheres as a Delivery Agent 
Microspheres are spherical mono-disperse polymeric particles, typically 
created by polymerisation techniques. The Bradley group has developed 
methods for the synthesis of amino functionalised cross-linked polystyrene 
microspheres of highly defined sizes that can be employed in solid phase multi-
step synthesis and have demonstrated to be an efficient delivery agent of 
biological cargos, including sensors,321, 373 proteins,323, 374 RNA,324 and dyes.322 
Microspheres have not only high uptake efficiency in a wide range of cells,373, 375, 
376 but they also show non-toxicity and may be easily functionalised. In addition, 
they are not trapped within endosomes, exhibiting cytoplasmic localisation. This 
is beneficial as the cargo is directly administered in the cytoplasm instead of 
being trapped within endosomes which can be trafficked to acidic lysosomes and 
can result in the degradation of the cargo. For all these traits, microspheres 
could be a very efficient delivery system for gene transfection. 
4.2. Aim of the Project 
The aim of this project was to investigate the potential of these 
microspheres as DNA delivery agents while using the reactivity of the TFMAD 
photophore synthesised in Chapter I. Specifically, functionalised microspheres 
with the TFMAD photophore would be used to attach plasmids randomly onto 
microsphere surface. In addition, the development of this general non-selective 
method could be used to immobilise other biomolecules, which could interact 
with a plasmid and therefore capture it non-covalently. To investigate the ability 
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of microspheres to deliver plasmid into the cells, a plasmid that encoded green 
fluorescent GFP protein (pEGFP-C1) was used as a reporter and the level of 
transfection was monitored by measuring the expression of GFP in cells 
(Scheme 4.2). 
 
Scheme 4.2: pEGFP is covalently immobilised after activation with UV light of the TFMAD-
functionalised microspheres. The plasmid-derivatised microspheres are then beadfected into 
cells. If the plasmid is successfully transfected into the nucleus, cells will become fluorescent 
as a result of the expresion of GFP protein encoded by the plasmid.  
4.3. Preparation of TFMAD-Functionalised Microspheres 
In order to study the ability of TFMAD-functionalised microspheres to 
capture DNA and efficiently transfer it into the cells, microspheres were 
synthesised and the influence of different factors such as spacer length, nature 
of linker and cargo were studied. These variables were chosen for several 
reasons. 
Firstly, the incorporation of spacers helps to reduces steric congestion 
between attached molecules and the microsphere surface, making them more 
accessible for further derivatisation. In addition, some spacers enhance 
biocompatibility and aid the interactions between microspheres and the cell 
surfaces.260 Microspheres were synthesised, with either one PEG spacer unit 
(51a and 56a) or two PEG spacer units (51b and 56b) (Figure 4.2). 
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Secondly, microspheres with a cleavable linker (51c and 56c) were also 
prepared by functionalising them with a disulfide linker which can be easily 
cleaved by naturally occurring enzymes or cellular factors.324 This would allow 
studies of the release effect of the DNA into the cytoplasm.  
And finally, the diazirine group was photolysed under “dry conditions” in 
order to achieve the maximum conjugation. However, the effect of drying the 
beads has not been studied before and could damage their morphology. For this 
reason, a set of microspheres with different length spacers were prepared but 
with the addition of Arginine (56a, 56b, and 56c microspheres) in order to add 
an overall positive charge to the microspheres. This positive charge would make 
them more attractive to the negatively charged DNA, concentrating the amount 
of DNA surrounding the microsphere surface and therefore increase the 
possibility of being captured in solution by the carbenes upon irradiation. The list 
of synthesised microspheres is shown in Figure 4.2. 
 
Figure 4.2: Microspheres were functionalised with TFMAD linked through different spacers 
with and without the presence of an Arginine to induce an overall positive charge. 
Amino-functionalised polystyrene microspheres (0.38 µm, 2% sc) were 
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prepared in chapter II. The step was repeated under the same conditions to 
give microspheres 51b in order to have a longer spacer. Microspheres 51c were 
derivatised first with adipic acid and then cystamine to introduce the disulfide 
bond into the structure (Scheme 4.3). Finally, deprotection of the Fmoc group 
was carried out if necessary and the TFMAD photophore 4 was introduced. 
 
 
Scheme 4.3: Synthetic route for the preaparation of microspheres without overall positive 
charge.  
For the preparation of positively charged microspheres,                   
Fmoc-Lys(Dde)-OH amino acid 35 (prepared in Chapter III) was used in order 
to introduce branches for derivatisation.316 Firstly, the free ε-amino group of 
Lysine was coupled to TFMAD and then, the α-amino group was used to 
introduce Fmoc-Arg(Boc)2-OH (Scheme 4.4). 
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Coupling and deprotection steps were monitored using the colorimetric 
ninhydrin test and zeta potential values in order to determine if they were 
successful. Ninhydrin test provides information about the presence of primary 
amino groups on the microspheres while the zeta potential value is an important 
particle characteristic which monitors the diffferent functional groups present on 
the surface.377 
 
Scheme 4.4: Synthesis of positively charged microspheres 56. 
To be able to remove the protecting Boc group of the guanidinium moiety, 
strong acidic treatment with TFA was needed. The effect of this treatment on 
microphere morphology was studied by SEM microscopy. As Figure 4.3 shows, 
microspheres did not lose their smooth and rounded form, demonstrating that 
the last step of the synthesis did not induce damage. 
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Figure 4.3: Scanning Electron Microscopy images of microspheres. a) microspheres 51a, 
which synthesis does not incude acid treatment and b) microspheres 56a after treatment 
with acid for Boc deprotection. Scale bar is 5 µm on the left and 10 µm on the right pictures. 
4.4. Microsphere Capture Optimisation  
In order to find out the best conditions for DNA capture, a 77-mer 
labelled oligonucleotide with Texas red (TxRd) on the 5’ anti-sense strand was 
chosen as a biological cargo. The capture of this oligonucleotide allowed the easy 
monitoring of the fluorescently-labelled microspheres by flow cytometry and 
quantification of the coupling reaction success. 
 As a first approach, the best conditions for sample irradiation were 
determined. Previous work using TFMAD showed that capture of molecules was 
successful when irradiation was carried out in dry conditions; however the effect 
of dryness as well as irradiation on microspheres needed to be determined. For 
this purpose, microspheres 51a and 56a were irradiated dry and in solution. 
Microspheres were mixed with the TxRd-oligonucleotide (1:10 equivalents), 
irradiated in an ice bath, washed and analysed by flow cytometry (Scheme 4.5). 
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Scheme 4.5: General process for capture of DNA or oligonucleotides onto TFMAD-
derivatised microspheres. Microspheres and DNA were mix together gently for 30 minutes. 
For irradiation in dry conditions solvent was evaportated from samples. Samples were 
irradiated in an ice bath for 40 minutes at 365 nm, resuspended in PBS and washed. 
Microspheres were analysed by flow cytometry or gel electrophoresis or added to cells to 
evaluate transfection abilities. 
 Flow cytometry showed a remarkable difference depending on the 
irradiation conditions for the two types of microspheres analysed (Graph 4.1). 
Samples irradiated under dry conditions showed a higher percentage of TxRd-
DNA loading, between 55 and 65 %, than microspheres irradiated in solution 
which showed a maximum of 12 % of labelled beads. The results also suggested 
that microspheres containing the Arginine residue captured TxRd-
oligonucleotides slightly better than microspheres without it; however the 
percentage of labelling in solution was still too low to be effective.  
 
Graph 4.1: Assessment of the capture of Texas Red-oligos by TFMAD-derivatised 
microspheres. Irradiation of microspheres with DNA (S) in solid phase and (L) in solution 
conditions with microspheres 51a and 56a.  
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In order to determine the effect of irradiation in dry conditions, the 
surface morphology of irradiated samples was examined by SEM microscopy 
(Figure 4.4). The results show that the morphology of microspheres was 
conserved after irradiation under dry conditions and in solution, demonstrating 
that irradiation at 365 nm for 40 minutes does not damage its structure. 
 
Figure 4.4: SEM images of microspheres. Irradiation of 56a microsphers a) in solution or b) 
under dry conditions. Scale bar is 5 µm on the left and 10 µm on the right pictures. 
Subsequently, the optimisation of DNA capture yields was studied where 
microspheres were irradiated with different amounts of pEGFP and the 
percentage of labelled microspheres was quantively assessed by cytometry using 
propidium iodide (PI), an intercalating agent that is used to stain nucleic 
acids.378 Samples treated in the same way but without irradiation where used as 
a negative control. Surprisingly, Graph 4.2 showed that microspheres mixed 
with the lowest amount of pEGFP had the highest yield. As in previous results, 
microspheres containing Arginine showed higher capture capacities than 
microspheres without it.  
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Graph 4.2: Microspheres 51a and 56a were used for the optimisation of the amount of DNA 
for efficient microsphere loading which was quantified by flow cytometry using propidium 
iodide (PI), a DNA stainer.  
 In conclusion, these experiments allowed determination of the best 
conditions for DNA capture onto microspheres. Results showed that the best 
photoreaction yields were obtained when samples were prepared under dry 
conditions. Results also showed that up to 70% of microspheres were labelled 
with DNA and the percentage did not increase with an increase in the DNA 
concentration. Finally, microsphere morphology examination by SEM microscopy 
demonstrated that irradiation of samples did not have any significant effect on 
their structure.  
4.5. Covalent Capture and Transfection of pEGFP-C1 
Once the optimal conditions for DNA capture were determined, the 
influence of other factors was studied by analysing the whole microsphere set 
under the same conditions. Not surprisingly, microspheres prepared in solution 
(L) showed a lower photoreactive yield compared to microspheres prepared 
under dry conditions (S) as previously observed (Graph 4.3). Nevertheless, the 
set of microspheres 56 containing Arginine in their structure showed higher 
percentages of DNA capture than the microspheres 51 that do not contained it. 
Arginine-containing microsphere with a cleavable linker (51c) showed the best 
capabilities for DNA capture.  
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Graph 4.3: Capture of DNA plasmid with different micropheres. Negative controls C1, C2 
and C3, represented microspheres treated with plasmid but without irradiation (C1), 
microspheres without plasmid and PI (C2), and microspheres with plasmid and PI (C3). 
Samples prepared in dryness are indicated with an S next to the microsphere type and those 
prepared in solution are indicated with an L.  
Complexation of DNA by cationic lipids is usually assessed by gel 
retardation assays due to a reduction of the DNA mobility on agarose as a result 
of the hidden negative DNA charge inside the liposomes that leads to the 
retention of DNA in the wells. Capture of DNA onto the prepared microsphere set 
was also assessed by gel retardation electrophoresis and compared with plasmid 
as a negative control and plasmid complexed with lipofectamine (Invitrogen) as 
a positive control. As expected, plasmid complexed by lipofectamine was partly 
retained in the well where sample was introduced although the signal was very 
faint. The reason for that might be the sensitivity of the liposome formation as 
they were not carried out under optimal conditions (Figure 4.5). In the case of 
microspheres, the same phenomenon occurred, thus a new band which does not 
migrate to the positive pole appeared very close to the starting gates where 
samples were introduced, but this time as a result of the impenetrability of 
microspheres through the agarose gel and not by complexation with liposomes 
(Figure 4.5). The results of the retardation assay basically showed similar 
results as to flow cytometry analysis, with higher intensity bands corresponding 
to microsphere-DNA complexes prepared dry. 
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Figure 4.5: Gel retardation assays. pEGFP-C1 attached onto microspheres was loaded in 
an agarose gel (0.7% agarose, 1 µg/ml ethidium bromide in TBE buffer) and run at 90 V for 
45 min. Lipofectamine  line corresponded to the positive control and plasmid line 
corresponded to the negative control, naked plasmid. Microspheres samples in black were 
prepared in solid conditions and in blue in solution phase. 
The transfection abilities of the microsphere set were evaluated on 
HEK293T cells after 48 and 72 h. Different microspheres bearing pEGFP-C1 were 
“beadfected” at three different concentrations (43, 86 and 172 µg/mL) and 
tested in triplicate. The expression of GFP was determined by microscopy and 
flow cytometry and compared to the values obtained by transfection with 
lipofectamine 2000 (Invitrogen). Unfortunately, none of the microspheres 
showed GFP expression (Graph 4.4). 
 
Graph 4.4: Results of transfection effciency of plasmid-microspheres complexes in different 
concentraions by flow cytometry. Cells transfected by lipofectamine reagent were used as a 
positive control (fluorescent mean values were 1620 and 1755 at 48 and 72 h, respectively). 
Negative controls corresponded to untreated cells and cells treated with microspheres 
without bearing a plasmid. X axes shows they type of microsphere used at three different 
concentrations: 21, 43, and 86 mg/mL. Each sample was assessed by triplicate. 
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The condensation of the plasmid has an important role on the efficiency of 
cellular uptake.351, 379 As a consequence of the conformation and large size of 
DNA plasmid which could limit its uptake,325, 326 microspheres were prepared with 
the same procedure but loaded with linear plasmid. For this purpose, DNA was 
treated with a restriction enzyme (StuI, which cut the plasmid in just one place 
and away from any important encoding area) to obtain the linear plasmid on the 
microspheres. As previously, capture of DNA onto microspheres was detected by 
two means, flow cytometry analysis using propidium iodide (Graph 4.5) and gel 
retardation assay (Figure 4.6). Flow cytometry analysis showed that 
microspheres having a net positive charge in their structure had the best capture 
abilities. Gel retardation assay allowed not only detection of DNA captured onto 
microspheres as a band in the starting gate, but also showed the shift in 
migration of the band corresponding to the plasmid after treatment with StuI 
restriction enzyme. 
 
Graph 4.5: Capture of linearised plasmid onto micropheres. Negative controls C1, C2 and 
C3, represented microspheres treated with plasmid but without irradiation (C1), 
microspheres without plasmid and PI (C2), and microspheres without plasmid and PI (C3). 
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Figure 4.6: Gel electrophoresis after treatment with Stu I. Circular plasmid corresponds to 
the plasmid without incubation with the restriction enzyme and the linear plasmid 
corresponds to the plasmid treated with Stu I. The rest are different microspheres irradiated 
with the circular plasmid and then treated with Stu I. 
However, the transfection abilities of microspheres bearing the linearised 
plasmid on HEK293T cells for 48 and 72 hr at three different concentrations 
showed no expression of GFP (Graph 4.6). 
 
Graph 4.6: Analysis of transfection effciency of plasmid-microspheres complexes. Positive 
control were cells transfected by lipofectamine and negative controls corresponded to 
untreated cells and cells treated with microspheres without bearing a plasmid. X axes shows 
they type of microsphere used at three different concentrations: 43, 86, and 129 mg/mL. 
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The absence of GFP expression led to a second verification of the 
presence of plasmid on the microspheres. Microspheres carrying a circular 
plasmid were treated with StuI and ApaI, which cut the plasmid in two different 
places generating two sequences of different lengths. If microspheres bearing a 
circular plasmid are treated with these two restriction enzymes, one of the 
sequences would be still attached onto the surface of the microsphere but the 
other would be free to move through the gel. With this aim, microspheres 
irradiated with plasmid were washed thoughtfully. Each sample was divided into 
two fractions, one was incubated with enzymes and the other without to be able 
to compare. Figure 4.7 showed that although microspheres were washed 
extensively, it was not enough to eliminate DNA that was not covalently attached 
to the microspheres as the band corresponding to the circular plasmid was still 
detected. Nevertheless, signal bands corresponding to microspheres treated with 
the two restriction enzymes did show a decrease in intensity in comparison with 
the band corresponding to the microspheres without treatment. Indeed, it was 
demonstrated that the band that stayed at the starting gate without migrating 
corresponded to the microspheres with plasmid attached onto their surface. 
 
Figure 4.7: Images of the electrophoresis gels carried out with the 6 different samples under 
the same conditions with (samples in green) and without restriction enzymes treatment 
(samples in black). P corresponds to the naked plasmid. The reduction of band intensity at 
the starting gate between samples treated with and without enzyme strongly demonstrate 
that the band corresponded to the plasmid attached onto micropheres. 
Although it was demonstrated that the plasmid could be cross-linked to 
microspheres making use of the TFMAD, expression of GFP after beadfection of 
HEK293T cells was not detected. Modification of the length and nature of the 
spacer did not improve the percentage of labelled beads and no transfection 
could be determined. These results suggest that the expression of the plasmid 
could be blocked due to covalent attachment to microspheres or as a result of 
the plasmid chemical modification by carbene insertion.  
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4.6. Non-covalent Gene Capture Approach 
The impact of random covalent attachment of the plasmid onto the 
microspheres by the carbene generated after irradiation is not known. It was 
hypothesised that if the plasmid was attached in an area where no important 
information was encoded, then the protein would be expressed. However, even 
so, we do not know if the plasmid stays for too long in the cytoplasm where 
there are DNA nucleases that can degradate it before being cleaved from the 
microspheres and moved into the nucleus.  
To rule out the effect in gene expression of chemical modification of the 
plasmid by covalent attachment, a new approach was developed where the DNA 
plasmid could be attached and disengaged from the microspheres by using 
peptide nucleic acid (PNA).380 Specific PNA sequences would be captured by 
TFMAD on the microspheres so they would be present onto the microsphere 
surface. These PNA sequence would have the ability to trap the double-stranded 
DNA onto their surface by hybridising on a specific area of the plasmid.292 
4.6.1. PNA-DNA Triplex Helix 
Binding of PNA to DNA is also very tight and occurs with a specificity 
similar to that observed in the formation of DNA duplexes.381 In fact, PNA·DNA 
duplexes are much more stable that DNA·DNA duplexes, and the introduction of 
a suitable strand of PNA can displace the corresponding DNA strand from a pre-
existing DNA duplex.382  
Peptide nucleic acid (PNA) recognition of nucleic acids occurs by a variety 
of mechanisms depending on the PNA sequence and nucleic acid target 
recognition.383 In general, triplex strand invasion by homopyrimidine PNAs is the 
preferred strategy for targeting double strand DNA by PNA.384 This mechanism 
involves the local dissociation of the low complementary DNA strands and 
binding of the sequence complementary PNA oligomers to one of the exposed 
strands forming extremely stable triplexes (Figure 4.8).  
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Figure 4.8: Triple strand invasion where PNA·DNA·PNA triple helix is formed with an 
antiparallel Watson-Crick duplex and a parallel bound Hoongsteen strand. 
 
For the capture of pEGFP-C1, two PNA-peptide conjugates able to form a 
triple helix PNA·DNA·PNA were prepared by members of the Bradley group.385 A 
poly-purine nucleotide sequence of 10 bases, 5’-GGAAGGGAAG-3’, was identified 
in the GFP non-codifying portion of the pEGFP-C1 (bases from 1993 to 2001). A 
complementary anti-parallel sequence (C-CCTTCCCTTC-NH2) and the parallel one 
(N-CCTTCCCTTC-C) of the corresponding PNA target sequence were designed 
containing rhodamine or fluorescein dyes at the N-terminus separated by a 
hydrophilic spacer, respectively (Figure 4.9). 
 
Figure 4.9: Sequence of the PNA used for targetting the DNA tagged sequence of the EGFP 
plasmid.  
4.6.2. Capture of PNA by TFMAD Photophore 
As with covalent attachment of the plasmid onto TFMAD-derivatised 
microspheres, dye-labelled PNA were captured by microspheres upon irradiation. 
Three different batches were prepared (Scheme 4.6), one with each dye-
labelled PNA and another with the same quantities of both PNA sequences.  
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Scheme 4.6: Synthesis of the different PNA conjugated microspheres. Microspheres were 
irradiated in the presence of a) both PNA sequences, b) FAM-labelled PNA, and c) Rho-
labelled PNA. 
The capture of fluorescently-labelled PNA onto microspheres was 
confirmed by flow cytometry where microsphere population clearly showed a 
shift in fluorescence for all three samples compared to microspheres irradiated 
without PNA (Figure 4.10).  
 
Figure 4.10: Flow cytometry analysis of the beads after irradiation under dry conditions with: 
no PNA (black), Rho-PNA (red), FAM-PNA (green), and both, Rho-PNA and FAM-PNAs at 
the same time. Histograms of fluorescent beads using a) a FITC filter, and b) a PE filter. 
 
a) b) 
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4.6.3. DNA Hybridisation and Transfection  
In order to find out the best conditions for non-covalent capture of DNA 
onto the PNA-functionalised microspheres, three different strategies were 
assessed. The first strategy consisted of using Mix microspheres directly for DNA 
hybridisation as these microspheres already contained both PNA sequences. For 
the second stratey, equal volumes of FAM- and Rho-microspheres were mixed 
and used to hybridised the plasmid. And finally, FAM-microspheres were 
hybridised with the plasmid and the addition of the same loading equivalents of 
Rho-PNA sense sequence (Scheme 4.7).  
 
Scheme 4.7: Hybridisation of double-stranded DNA onto PNA-functionalised microspheres 
by three different strategies: a) using Mix microspheres which contained both PNA 
sequences, b) using a mixture of Rho- and FAM-PNA functionalised microspheres, and c) 
using FAM-microspheres but with the addition of the complementary Rho-labelled PNA 
strand to the mixture. Hybridisation was carried out by heating all samples to 90 ºC and allow 
to cool down to RT slowly. 
DNA hybridiation on microspheres was carried out using different DNA 
amounts (10, 20, and 40 µL of plasmid solution) for each sample and  DNA 
capture efficiency was evaluated by gel migration assay (Figure 4.11). 
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Figure 4.11: Gel retardation assays of PNA-functionalised microspheres hybridised with 
different plasmid volumes: 10, 20, and 40 µL of plasmid solution (0.4 µg/mL in TE buffer). 
 Gel retardation assay showed a band at the starting gate corresponding 
to the double-stranded DNA complexed to microspheres for all samples and at all 
concentrations of plasmid. Microspheres were then beadfected for 48 and 72 h 
with HEK293T cells with 2 different concentrations (43 and 86 µg/mL). However 
no expression of GFP could be detected under any conditions (Graph 4.7). 
 
Graph 4.7: Results of transfection effciency of plasmid-microspheres complexes in different 
concentraions by flow cytometry. Positive control were cells treated with lipofectamine and 
negative controls corresponded to untreated cells and cells treated with each type of 
microsphere without bearing a plasmid. X axes shows each type of sample with the DNA 
amount used for the hybridisation, blue bars correspond to mean fluorescence after 48 hr 
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4.7. Conclusions 
No transfection was seen with the work shown above. Further 
experiments are needed to elucidate why the above strategies were not 
successful. Nevertheless, this work has developed a general loading method 
using a photo cross-linking reaction for cargos onto microspheres, for example a 
plasmid or PNA. Two strategies for DNA capture have been studied, by direct 
covalent immobilisation of the plasmid and by indirect non-covalent 
immobilisation using PNA-functionalised microspheres. Microspheres with 
different spacers showed slightly different effects on their ability to capture 
plasmid. As expected, positively charged microspheres showed better 
immobilisation abilities, having the highest yields when irradiation was 
performed under dry conditions. However, the effect of the different spacers on 
plasmid delivery could not be determined as no GFP expression could be 
detected. 
There are many reasons why plasmid attachment would not be 
expressed, thus further studies would help to elucidate why this methodology 
have not been successful. On one side, it would be prudent to find a way to 
determine the exact amount of plasmid per microsphere in order to know the 
amount of plasmid used for cell transfection. It could happen that no transfection 
is detected as a result of an insufficient plasmid quantity. On the other side, 
other applications that have been successfully developed using microspheres as 
a delivery vectors could be applied with this methodology in order to compare 
the applicability of TFMAD-functionalised microspheres.  
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Chapter V: 




5.1. General Information 
Solvents were dried by eluting through alumina columns. Unless 
otherwise noted, materials were obtained from a commercial supplier and were 
used without further purification. All reactions were performed in pre-dried 
glassware under nitrogen. All reactions involving diazirines were performed in 
dim red light. Microwave reactions were performed in sealed heavy-walled 
Pyrex tubes under controlled conditions in a safe and reproducible procedure 
using an Initiatior 2.0 Microwave (Biotage) fitted with a rotational mixing 
system. Single mode microwave irradiation was used at a fixed temperature, 
pressure and irradiation power during the reaction time by an automatic power 
control. Thin-layer chromatography (TLC) was carried out using precoated 
silica gel 60 F250 plates with thickness of 0.25 µm. TLC plates were visualised by 
short wavelength ultra-violet light (254 nm) and/or stained with DNP acetic 
anhydride. Flash column chromatography was performed using silica gel 60 
(230-400 mesh ASTM, Merck). 1H, 13C and 19F nuclear magnetic resonance 
(NMR) spectra were recorded on Bruker instruments: DMX500, DPX360 and 
ARX250, respectively. Chemical shifts (δ) are reported in parts per million (ppm) 
relative to internal solvent signal ((CH3)4Si, δ = 0.00 for 1H and 13C NMR and 
CCl3F for 
19F NMR) with coupling constants (J) in Hertz (Hz). Trifluoroacetic acid 
was used as a reference standard in some studies for 19F NMR (δ = -78.50 for 19F 
NMR). Analytical HPLC was performed on an analytical HPLCs HP Agilent 1100 
instrument using a 5 µm C18 reversed-phase Supelco Discovery column (5 cm 
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x 4.60 mm) at 1 mL/min eluent solvent and detecting by UV at 220, 254, 260, 
282 and 495 nm and evaporative light-scattering detection (ELSD) lamp. 
Different methods have been created for sample analysis: 
Method A: A 5 min method starting from water/MeCN/FA 95:5:0.1 and 
raising gradually to 5:95:0.1 after 3min, then 1 min isocratic and 1 min 
to go back to initial values. 
Method B: A 10 min method starting from water/MeCN/FA 95:5:0.1 and 
raising gradually to 5:95:0.1 after 8min, then 1 min isocratic and 1 min 
to go back to initial values. 
Method C: A 5 min method starting from water/MeOH/FA 95:5:0.1 and 
raising to gradually 5:95:0.1 after 3min, then 1 min isocratic and 1 min 
to go back to initial values. 
Mass spectrometric analysis was recorded on an Agilent 1100 series 
system. Mass spectra were obtained on a VG platform single Quadrupole mass 
spectrometer in electrospray positive (ES+) and negative (ES-) mode. High 
resolution mass spectra were recorded by the MS Department of the 
University of Edinburgh on a Finnigan MAT 900 XLP high resolution, double 
focussing mass spectrometer. MALDI mass spectra were acquired on a Voyager-
DETM STR MALDI-TOF MS (Applied Biosystems). Sinapic acid was used as a 
matrix solution (10 mg/mL) in 50% MeCN in water with 0.1% TFA. IR spectra 
were recorded on a Bruker Tensor 27 FT-IR with a golden SPECAC gate 
accessory with neat compounds. Sample Irradiation was carried out with a UVP 
Blak-Ray® lamp, model B100AP, 100 W, which emits a monochromatic light with 
a wavelength of 365 nm and 2.44 µW/cm2 of intensity. UV-Vis spectroscopy 
was performed on an Agilent 8453 UV-Vis spectrophotometer provided with UV-
Vis Chemstation software (Agilent). 
An Inkjet printer (Microdrop, GmbH, Norderstedt, Germany) equipped 
with a micro-pipette (AD-K-501, 70 µm diameter nozzle) was used for 
development of microarray preparation methods. The piezodispensing system 
Scienion S5 sciFLEXARRAYER (Scienion AG, Germany), operating at 230V AC, a 
temperature 15-30 ºC, 230V AC +/-10%, 50-60 Hz, relative humidity up to 85% 
was used to prepare the small molecule microarray. GeneMachines® Hyb4 
(Zinsser Analytic GmbH, Frankfurt, Germany) small scale hybridisation station 
was used for microarray hybridisations. Fluorescence readout of hybridised 
microarrays was conducted with either a BioAnalyser 4F/4S fluorescence 
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scanner (LaVision Biotec, Bielefeld, Germany) or an AutoLoader microarray 
scanner (Genetix 4200AL, Axon). Images were analysed using FiPS fluorescence 
imaging and processing software (LaVision Biotec, Bielefeld, Germany), the 
output of which was a background-corrected value of an integrated fluorescence 
intensity of each spot (“spot fluorescence”). 
Cell experiments were carried out in a HERAsafe KS 18 class II 
negative-flow cabinet from Heraeus. Cell cultures were performed in a HERAcell 
150 incubator form Heraeus. Flow cytometry was performed on a BD 
Biosciences FACSAria® system using the BD FACSDiva software for analysis or a 
DakoCytomation CyAnTM ADP system with Summit software for analysis. 
Scanning electron microscopy (SEM) analysis was performed on a Philips 
XL30CP with PGT Spirit X-ray analysis and HKL channel5 Electron Backscatter 
Diffraction (EBSD) system. ZetaSizer Nano (Malvern Instruments, United 
Kindom) was used for Z potential measurements. Cell viability was assessed 
using a Benchmark® Bio-Rad microplate reader measuring absorbance at 570 
nm. Microscopy was performed on a Leica DM IRB inverted fluorescent 
microscope and processed using Leica FW4000 v 1.2 imaging software (Leica 
Microsystems Imaging Solutions Ltd., UK). 
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5.2. General Methods 
5.2.1. Kaiser test:  
The test is based on the reaction of ninhydrin with primary amines which 
give a dark blue colour or a yellow colour when no free amino groups are 
present. Thus, the test is used to monitor the coupling reactions on solid support 
after each coupling or deprotection step.386 
On Solid Phase: A few resin beads were transferred to a small glass tube after 
extensive washing and drying. Then, 3 drops of ninhydrin reagent A and 1 drop 
of ninhydrin reagent B were added to the resin. The tube was introduced into a 
heater at 110 ºC for 3 minutes.  
On Microspheres: Microspheres were suspended in MeOH (25 µL, 2% sc) and 
solid particles obtained by centrifugation. Methanol was removed and ninhydrin 
reagent A (6 µL) and ninhydrin reagent B (2 µL) were added to the solid particles 
and sonicated before heating to 110 ºC for 3 min.  
5.2.2. Malachite Green Test:  
A few resin beads were transfer to a small glass vial after an extensive 
washing and drying. To this, 1 mL of a 0.25% solution of Malachita Green 
oxalate in ethanol was added followed by a single drop of pure triethylamine. 
After 2 min at room temperature the solution was discarded and the beads 
rinsed several times with EtOH (or MeOH) until the solution remained clear. In 
the presence of acid groups, the beads were coloured dark green; alternatively, 
they appeared as clear gel pearls.387  
5.2.3. Cell culture 
All cells were cultured in the appropriate culture medium at 37°C/5% CO2 
Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich) for HEK293T and 
Roswell Park’s Memorial Institute (RPMI-1640, Sigma-Aldrich) medium for HeLa, 
supplemented with 10% foetal bovine serum (FBS, Biosera), 100 U/mL penicillin 
and streptomycin and 4 mM L-glutamine (Gibco). Cells were cultured in T-75 
flasks (Nunc) until 70-80% confluency. At this time, the old growth media was 
removed and the cells were washed with PBS (10 mL) and harvested via 
trypsination (trypsin/EDTA, Gibco) (1 mL) at 37°C. The detached cells were 
collected in fresh growth media and diluted to the appropriate cell density for 
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experiments in fresh growth media. An aliquot was re-seeded to a T-75 flask for 
re-growth. 
5.2.4. Haemocytometry 
Cell densities were determined by haemocytometry. An aliquot (10 µL) of 
cells detached from a T-75 flask and collected in growth media (5 mL) was 
mixed with 0.2% trypan blue (40 µL, Sigma-Aldrich) and pipetted into a Bright 
Line TM haemocytometer (an etched glass device with an H-shaped moat 
forming two cell-counting areas (with 4 quadrants in each area), with surface 
features enhanced by Neubauer rulings, Sigma-Aldrich). Cell concentrations and 
the densities required for experiments were determined by Equations 5.1 and 
5.2, respectively. 
Concentration (cells/mL) = (N/Q) x 5 x 104 
Equation 5.1: Concentration of cells/mL by haemocytometry, where “N” is the total number 
of cells counted and “Q” is the number of quadrants counted. 
VExp (mL) = (VTot x CWell) x (1000/VWell)/CTot 
Equation 5.2: Volume of cells detached from T-25 flask (VExp) required in an experiment a 
total medium volume of VTot and a concentration per well of CWell. VWell is the volume required 
per well and CTot is the concentration of cells/mL as calculated in Equation 5.1. 
5.2.5. Flow cytometry analysis of cells 
In preparation for flow cytometric analysis, the old media was removed 
from cell cultures and the cells were washed with PBS and harvested by 
trypsination at 37°C (trypsin/EDTA). Detached cells were collected in growth 
media. Samples were analysed by flow cytometry using a 488 nm Coherent® 
SapphireTM solid state laser with the band pass filters according to the 
fluorophores under investigation: 
Filter name  Band pass Filter  Fluorophores 
   FITC-A         530/30           Fluorescein or GFP 
    PE-A        585/42             TAMRA and PI 
  PE-TxRed        610/20               Texas Red 
The BD Biosciences FACSDiva software was used to treat the data. 
Untreated cells were defined as having 0% uptake or transfection efficiency. 
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5.2.6. Cytotoxicity assay  
Cells were cultured and seeded onto a 96-well plate at a density of 1 x 
104 cells/well (volume per well: 100 µL). The first row of the well-plate was used 
as a blank without seeded cells. Cells were incubated (37 ºC/5% CO2) for 24 
hours prior to the addition of samples at different concentrations (10-100 µM). 
After 24 h, the old media was removed and replaced with 100 µL solution of 
fresh phenol red-free media (IMDM Iscovers Modified Medium supplemented with 
L-Glutamine and HEPES, FBS and Den/Stren Glu, GIBCO Invitrogen) containing 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-
Aldrich) at a concentration of 5 mg/mL. Cells were incubated for 3 h (37 ºC/5% 
CO2) before the addition of MTT solubilising solution (10% Triton-X, 0.1 N HCl in 
isopropanol) (100 µL). Once formazan crystals were dissolved, absorbance of 
each well was measured at 570 nm with a Bio-Rad microplate reader (version 
1.15). Untreated cells were considered to be 100% viable and cell viability was 
calculated from Equation 5.3.318 
% Viable Cells = (AbsExp/AbsCont) x 100 
Equation 5.3: Viability of cells by MTT assays, where “AbsExp” refers to the absorbance at 
570 nm of cells treated with microspheres and “AbsCont” refers to the absorbance at 570 nm 
of untreated control cells. 
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5.3. Experimental for Chapter 1 
5.3.1. Synthesis of aryl(trifluoromethyl)diazirine group 
tert-butyl (4-formyl-phenoxy)acetate (9): 
 
To a dried heavy-walled Pyrex tube containing a small stir bar was added 
4-hydroxibenzaldehyde (732 mg, 3 mmol), dry potassium carbonate (622 mg, 
4.5 mmol) and potassium iodide (74 mg, 0.45 mmol), and dry acetonitrile (1.2 
mL). Tert-butyl bromoacetate (415 µL, 3.75 mmol) was added dropwise. The 
tube containing the reaction mixture was sealed with an aluminium crimp cap 
fitted with a silicon septum and then it was exposed to microwave irradiation for 
40 min at a temperature of 120 ºC. After the irradiation, the reaction tube was 
cooled to room temperature with high-pressure air. The reaction progress was 
followed by TLC and DNP was used as a stain. Once the reaction was completed, 
water (10 mL) and DCM (10 mL) was added and the phases were separated. The 
aqueous layer was extracted with DCM (3 x 10 mL). The combined organic layers 
were dried over MgSO4, concentrated in vacuo and purified by column 
chromatography hexane/EtOAc (6:3) to give an orange solid (673 mg, 2.85 
mmol 95%).  
MS (ES+) m/z: 237 [M+H]+, 259 [M+Na]+; HRMS (ES+) for C13H17O4: 
237.11214 (calc.); 237.11241 (found); Mp: 52-53°C (lit.388 56-57°C); 1H NMR 
(CDCl3, 500 MHz): δ 9.89 (s, 1H), 7.84 (s, 2H), 6.99 (s, 2H), 4.60 (s, 2H), 1.48 
(s, 9H); 13C NMR (CDCl3, 90.6 MHz): δ 191.1, 167.5, 163.1, 132.3, 130.9 (2C), 
115.2 (2C), 83.3, 65.9, 28.4 (3C); IR (neat) υmax /cm-1: 2977, 1746, 1686, 
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Tert-butyl [4-(2,2,2-trifluoro-1-hydroxy-ethyl)phenoxy]acetate (10): 
 
To a mixture of 9 (673 mg, 2.85 mmol) and trifluoromethyl 
trimethylsilane (425 µm, 3.6 mmol) in THF (9.0 mL), TBAF (1.0 M solution in 
THF, 29 µL) was added at 0 ºC with stirring. After 15 min, methanol (21 mL) and 
aqueous 2M HCl solution (10.2 mL) were added to the mixture successively, and 
the whole mixture was stirred for an additional 10 min. Methanol and 
tetrahydrofuran were removed under reduced pressure, and the aqueous 
mixture was extracted with ether (20 mL x 3). The combined organic solutions 
were washed with brine, dried over MgSO4, and concentrated in vacuo. The 
residue was purified by column chromatography eluting with hexane/ EtOAc 
(4:1) to give a pale yellow solid (646 mg, 2.12 mmol, 74%).  
MS (ES+) m/z: 324.19 [M+NH4]
+; HRMS (ES+) for C14H21O4N1F3: 324.14172 
(calc.); 324.14229 (found); Mp:61-62°C; 1H NMR (CDCl3, 500 MHz): δ 7.41 (d, 
2H, J = 8.58 Hz), 6.92 (d, 2H, J = 8.3 Hz), 4.94 (q, J = 6.7 Hz, 1H), 4.53 (s, 
2H), 4.11 (q, J = 7.1 Hz, 1H, OH),1.52 (s, 9H); 13C NMR (CDCl3, 90.6 MHz): δ 
168.3, 159.0, 129.1, 127.6 (2C), 124.7 (q, 1J = 282.1), 115.0 (2C), 83.0, 72.6 
(q, 2J = 31.9 Hz), 65.8, 28.1 (3C); 19F NMR (CDCl3, 235.9 MHz): δ -79.77; IR 
(neat) υmax /cm-1: 3448, 1735, 1218, 1151 and 1122; HPLC (ELSD) tR/min: 
3.732 (method A), 7.161 (method B). 
tert-Butyl [4-(2,2,2-Trifluoro-acetyl)-phenoxy]acetate (11): 
 
 A mixture of 10 (590 mg, 1.93 mmol), Dess-Martin periodinane (2.5 g, 
8.55 mmol), and TFA (446 µL, 8.55 mmol) in DCM (20 mL) was stirred at RT for 
12 h. After the mixture was diluted with ether (20 mL), and the resulting mixture 
was poured into saturated aqueous NaHCO3. The organic layer was separated, 
washed with water, dried over MgSO4 and concentrated in vacuo. The residue 
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was purified by column chromatography eluting with hexane/EtOAc (6:4) to give 
the product 3 (469 mg, 1.54 mmol, 80%) as a mixture of ketone and hydrate 
forms (3:1).  
MS (ES+) m/z: 305 [M+H]+; HRMS (EI) for C14H15O4F3: 304.09170 (calc.); 
304.09110 (found); Mp: 57-58°C; 1H NMR (CDCl3, 500 MHz): δ 8.04 (d,            
J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 4.61 (s, 2H), 1.49 (s, 9H);  13C NMR 
(CDCl3, 90.6 MHz): δ 179.2 (q, 2J = 34.7), 167.7, 163.9, 133.0 (2C), 123.9, 
123.8, 117.2 (q, 1J = 291.0), 115.27 (2C), 83.5, 65.8, 28.3 (3C);  19F NMR 
(CDCl3, 235.9 MHz): δ -72.37, -77.19. IR (neat) υmax /cm-1: 1753, 1693, 1135; 
HPLC (ELSD) tR/min: 3.538 (method A), 6.724 (method B). 
tert-butyl [4-(2,2,2-trifluoro-1-hydroxyimino-ethyl)phenoxy]acetate (12): 
  
Ketone 11 (469 mg, 1.50 mmol) was dissolved in pyridine (3.5 mL) and 
placed in a microwave glass flask and sealed. Hydroxylamine hydrochloride 
(312.7 mg, 4.5 mmol) was added and the reaction was performed under 
microwave irradiation for 40 min at a temperature of 70 ºC. After cooling the 
reaction tube at room temperature, pyridine was removed in vacuo, and the 
remaining residue was dissolved in Et2O (20 mL) and washed with 0.01M HCl  
(20 mL). The organic layer was washed with H2O (3 x 20 mL) and dried with 
MgSO4, and the solvent was removed in vacuo to give a colorless liquid (311 mg, 
0.97 mmol, 65%), which was purified by flash column chromatography eluting 
with Et2O/Hexanes (6:4).  
MS (ES+) m/z: 342 [M+Na]+, 320 [M+H]+; HRMS (ES+) for C14H17O4N1F3: 
320.11042 (calc.); 320.11072 (found); Mp: 62-63°C; 1H NMR (CDCl3, 500 
MHz); δ 9.80 (bs, 1H), 7.42 (d, J = 8.7, 2H), 6.90 (d, J = 8.7, 2H), 4.53 (s, 2H), 
1.48 (s, 9H);  13C NMR (CDCl3, 90.6 MHz): δ 168.1, 159.7, 130.2 (2C), 129.1, 
119.8, 118.9 (q, 1J = 291.0), 114.8 (2C),  83.1, 66.3, 28.3 (3C);  19F NMR 
(CDCl3, 235.9 MHz): δ -67.22, -63.64; Multiple splitting patterns arise in 1H and 
19F NMRs due to anti/syn configurations of the oxime with a ratio of 3:2. IR 
(neat) υ/cm-1: 3309, 1735, 1247, 1139; HPLC (ELSD) Rt/min: 7.421 (method 
B), 4.228 (method C). 
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tert-butyl {4-[2,2,2-trifluoro-1-(O-toluensulfonyl)hydroxyimino-ethyl]-
phenoxy}acetate Oxime (13): 93 
 
Oxime 12 (162 mg, 0.51 mmol) was dissolved in pyridine (2 mL) and 
placed in a microwave glass flask and sealed. Tosyl chloride (145 mg,           
0.76 mmol) was added, and the reaction was performed under microwave 
irradiation for 40 min at 130 ºC. Subsequently, pyridine was removed in vacuo, 
and the remaining residue was dissolved in Et2O (20 mL) and washed with     
0.01 M HCl (10 mL). The organic layer was washed with H2O (3 x 20 mL) and 
dried with MgSO4 and the solvent removed giving an orange oil product (173 
mg, 0.37 mmol, 72%) which was purified by column chromatography from 20 to 
70% DCM in hexane. 
MS (ES+) m/z: 512 [M+K]+, 496 [M+Na]+, 491 [M+H2O]
+, 374 [M+H]+;  HRMS 
(ES+) for C21H26O6N2F3S1: 491.14582 (calc.); 491.14527 (found); Mp: 58-60°C; 
1H NMR (CDCl3, 500 MHz): δ 9.85 (bs, OH), 7.88 (d, J = 8.1, 2H), 7.44 (d,        
J = 8.9, 2H), 7.37 (d, J = 8.1, 2H), 6.94 (d, J = 8.9, 2H), 4.55 (s, 2H),1.48 (s, 
9H);  13C NMR (CDCl3, 90.6 MHz): δ  167.6, 160.7, 153.3 (q, 2J = 33.7), 146.4, 
131.5, 131.0 (2C), 130.2 (2C), 129.6 (2C), 120.1 (q, 1J = 277.7), 117.6, 115.1 
(2C), 83.2, 65.8, 28.3 (3C),22.1; 19F NMR (CDCl3, 235.9 MHz): δ -67.27; IR 
(neat) υmax /cm-1: 1741, 1143; HPLC (ELSD) tR/min: 4.437 (method A), 7.355 
(method B). 
tert-butyl {4-[3-(trifluoromethyl)diaziridin-3-yl]phenoxy}acetate (14):  
 
In a thick-walled screw-cap tube, compound 13 (173 mg, 0.37 mmol) 
was dissolved in Et2O (0.9 mL). The solution was cooled to -78 ºC, and liquid 
ammonia (0.2 mL) was added. The tube was screwed tightly closed, and the 
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solution mixture allowed rising to room temperature. The reaction was stirred for 
12h, and the solution was cooled to -78 ºC before removing the cap. Ammonia 
was removed by allowing the system to rise to RT. The solution was partitioned 
between Et2O (5 mL) and H2O (5 mL), the organic layer was dried with MgSO4, 
and the solvent was removed in vacuo to give an oil (106 mg, 0.33 mmol, 90%). 
The product was purified by column chromatography eluting from 10 to 50% 
EtOAc in hexane.93 
MS (ES+) m/z: 319 [M+H]+;  HRMS (ES+) for C14H18O3N2F3: 319.12640 (calc.); 
319.12661 (found); 1H NMR (CDCl3, 500 MHz): δ  7.52 (d, J = 8.7, 2H), 6.90 (d, 
J = 8.7, 2H), 4.52 (s, 2H), 2.78 (d, J = 8.7, 1H), 2.21 (d, J = 8.7, 1H), 1.48 (s, 
9H); 13C NMR (CDCl3, 90.6 MHz): δ 168.0, 159.5, 130.2 (2C), 124.9, 123.9 (q, 
1J = 278.4), 115.1 (2C), 83.0, 65.9, 57.9 (q, 2J = 36.0), 28.3 (3C);  19F NMR 
(CDCl3, 235.9 MHz): δ -76.97; IR (neat) υ/cm-1: 3257, 1748, 1514, 1143; HPLC 




A mixture of diaziridine 21 (266 mg, 0.84 mmol) and Et3N (201 µL, 1.44 
mmol) was stirred with iodine (235 mg, 0.924 mmol) in the dark for 10 min. 
After the solution was poured into aqueous 1 M NaOH solution and stirred for 5 
min. The organic layer was further extracted with NaOH solution and the 
combined aqueous solution was neutralised with HCl and extracted with EtO2. 
The organic layer was dried over magnesium sulfate and evaporated under 
vacuum to give a redish oil. The residue was purified by column chromatography 
from 0 to 20% EtOAc in hexane to give a colorless liquid (124 mg, 0.392 mmol, 
90%). 
MS (ES+) m/z: 317 [M+H]+, 339 [M+Na]+; HRMS (EI) for C14H15O3N2F3: 
316.10293 (calc.); 316.10389 (found); 1H NMR (CDCl3, 250 MHz): δ  7.12 (d,    
J = 8.8 2H), 6.89 (d, J = 9.0, 2H), 4.51 (s, 2H), 1.47 (s, 9H); 13C NMR (CDCl3, 
90.6 MHz): δ 167.8, 159.3, 128.5 (q, 3J = 1.3, 2C), 122.5 (q, 1J = 274.6), 122.2, 
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115.3 (2C), 83.0, 28.3 (3C), 65.9, 28.5 (q, 2J = 40.4), 28.3 (3C); 19F NMR 
(CDCl3, 235.9 MHz): δ -66.82; IR (neat) υ/cm-1: 1751, 1613, 1369 and 825; 
HPLC (ELSD) Rt/min: 4.442 (method A), 9.775 (method B), 4.458 (method C). 
{4-[3-(trifluoromethyl)-3H-diaziren-3-yl]phenoxy}acetic acid (4): 
 
Diazirine 15 (101 mg, 0.390 mmol) was dissolved in a solution of 50% 
TFA/CH2Cl2 (2 mL) and stirred for 20 min. The reaction progress was followed by 
TLC until it was completed. The solution was concentrated in vacuo and 
redissolved in Et2O, dried over magnesium sulfate and the solvent evaporated in 
vacuo to give a white solid (100 mg, 0.386 mmol, 99%). The product was pure 
enough to be used in the next step without further purification. 
MS (ES-) m/z: 259 [M-H]-, 519 [2M-H]-; HRMS (ES-) for C10H6O3N2F3: 
259.03360 (calc.); 259.03424 (found); Mp: 53-55°C; 1H NMR (CDCl3, 500 
MHz): δ  10.49 (bs, OH), 7.18 (d, J = 8.8, 2H), 6.85 (d, J =8.7, 2H), 4.71 (s, 
2H);  13C NMR (CDCl3, 90.6 MHz): δ 175.0, 159.4, 129.4 (q, 3J = 1.3, 2C), 
124.7, 123.2 (q, 1J = 274.6), 116.0 (2C), 65.7 (2C), 28.2 (q, 2J = 40.6);  19F 
NMR (CDCl3, 235.9 MHz): δ -66.19; IR (neat) υ/cm-1: 2909 (bs), 1748, 1610 




p-Bromophenol 16 (17.30 g, 100 mmol) was dissolved in anhydrous THF 
(30mL) followed by addition of Et3N. The reaction mixture was cooled in an 
ice/water bath and trimethylsilyl chloride (12.7 mL, 100 mmol) was added 
dropwise with stirring. The thick reaction mixture was stirred at RT for 1 h, and 
the white precipitate was filtered. The filtrate was diluted with hexane (20mL), 
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refiltered and evaporated to yield a colourless oil (24.50 g, 99.92 mmol, 99.9%) 
and used without further purification.  
MS (ES+) m/z: 244 and 246 [M+H]+; HRMS (EI) for C9H13OBrSi: 243.99136 
(calc.); 243.99176 (found); 1H NMR (CDCl3, 360 MHz): δ  7.20 (d, J = 8.9, 2H), 
6.60 (d, J =8.9, 2H), 0.13 (s, 9H); 13C NMR (CDCl3, 90.6 MHz): δ 154.6, 132.6 
(2C), 122.2 (2C), 114.1, 0.4 (3C); IR (neat) υ/cm-1: 1249, 824; HPLC (ELSD) 
Rt/min: 4.738 (method C). 
4-trifluoroacetyl phenol (18): 
 
nBuLi (80 mL of 2.5 M in hexanes, 150 mmol) was added to a stirred 
solution of 4-bromophenoxytrimethylsilane 17 (24.50 g, 99.9 mmol) and ethyl 
trifluoroacetate (17.85 mL, 150 mmol) in THF (500 mL) at -110 °C 
(cyclohexane/nitrogen cool bath) under argon. The mixture was stirred at          
-110 °C → -78 °C for 30min, and then the reaction was quenched with 1 M 
aqueous HCl (500 mL). The reaction mixture was extracted with Et2O                  
(2 x 100 mL) and the combined organic layer was washed with water (50 mL), 
brine (50 mL), dried over anhydrous MgSO4, filtered and concentrated. The 
product (12.77 g, 67.93 mmol, 68%) was used for the following steps without 
further purification.  
MS (ES-) m/z: 189 [M-H]-;  1H NMR (CDCl3, 500 MHz): δ  7.91 (d, J = 8.8, 2H), 
6.86 (d, J =8.9, 2H); 13C NMR (CDCl3, 90.6 MHz): δ 180.0 (q, 2J = 34.8), 163.1, 
133.7 (2C), 122.8, 117.2 (q, 1J = 291.1), 116.5 (2C); 19F NMR (CDCl3, 235.9 
MHz): δ -71.09; HPLC (ELSD) Rt/min: 3.524 (method C). 
5.3.2. Irradiation Studies 
Photolysis in solution followed by NMR spectroscopy: 
A 20 mM solution of TFMAD (52.034 mg) in deuterated methanol (10 mL) 
was prepared in a 10-mL microwave vial and sealded with a septum cap. 
Trifluoroacetic acid was added as a reference standard for 19F NMR. The sample 
was continuously irradiated with a 100-W black UV light lamp (UVP, model       
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B-100AP, 230 V) for 112 min at 20°C. Every 2 min, 0.5-mL samples were 
extracted until 18 min and then in increasing time scales. All samples were 
analysed by 1H- and 19F- NMR to follow the progress of the reaction. 
Photolysis in solution Recorded by UV-Vis Spectroscopy:  
A 3.5 mM solution of TFMAD in MeOH (1.5 mL) was added into a quatz 
cuvette (l = 1 cm) and irradiated at 365 nm above 10 cm at RT. At specific 
periods of time, the absorbance of the sample was recorded until no starting 
material was observed. 
Irradiation in Dry Conditions of TFMAD and Biotin: 
TFMAD (5.2 mg, 20 µmol) and biotin (7.33 mg, 30 µmol) were dissolved 
in deuterated DMSO in a 10-mL glass vial. A sample was collected and analysed 
by HPLC and NMR. Water was added (5 mL) and the sample was freezed dried to 
evaporate the solvent. Before irradiation at 365 nm for 10 min, the sample was 
cooled down to -196°C. The solid was redissolved with deuterated DMSO and 
analysed by 1H- and 19F-NMR. This operation was repeated two more times and 
the final solution was analysed further by HPLC and LCMS. 
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5.4. Experimental for Chapter 2 
Fluorescence polarisation solution assays of the 10 putative binding 
compounds to β-TrCP1 were performed by Douglas Houston from the center for 
cell Biology in the University of Edinburgh. 
5.4.1. Slide Preparation 
Slide cleaning:  
Glass slides were rinsed in acetone to remove manufacturing grease and 
residues before being etched by treating them for 2 h in a solution of 10% 
potassium hydroxide in methanol. Slides were then rinsed with water until no 
strips were visible on the surface. Slides were then washed with acetone and 
dried under a nitrogen stream and they were used immediately for 
functionalisation.117  
Masking process: 
Slides were printed with a solution of 20% (w/v) sucrose in water (12 
drops/spot) by an inkjet printing system (Microdrop Technology). The optimal 
printing voltage was 90 V, as a voltage greater than this resulted in drops 
breaking up to produce satellite drops, while a lower voltage was insufficient for 
drops to be generated. Subsequently, slides were dried for 5 min at 40 ºC in an 
oven before tridecafluoro-1,1,2,2-tetrahydrooctyl-dimethylchlorosilane (TFCS) 
(10 µL) was added and spread over the slide surface. Slides were incubated at 
110 ºC for 2hr in a sealed hybridisation chamber. Slides were then washed 
liberally, firstly with acetone followed by water, before curing them at 110 ºC for 
30 min.  
Amino functionalisation of slide:  
Aminosilanisation of the groups on the glass surface were carried out by 
incubating the slides in a solution of 2% 3-aminopropyltriethoxysilane (APTES) in 
acetonitrile (10 mL) for 30 min. Slides were washed with acetonitrile (2 x 10 
min) and ethanol (2 x 10 min) before being cured at 110 ºC for 30 min.  
Slide Fluorination: 
To a pre-cleaned slide, tridecafluoro-1,1,2,2-tetrahydrooctyl-1-
trimethoxysilane (10 µL) was added onto the slide and spread across the 
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surface. The slide was left for 2h at 110 ºC in a sealed hybridisation chamber. 
Slides were then washed with acetone and cured for 30 min at 110 ºC. 
5.4.2. PhotoSpacer synthesis 
5.2.2.1. Linker Synthesis 
Ethyl-4-(4’-formyl-phenol)-butyrate (22):  
 
A microwave vessel was prepared with hydroxybenzaldehyde (4.9 g, 40 
mmol), dried potassium carbonate (8.3 g, 60 mmol) and potassium iodide    
(996 mg, 6 mmol). The vessel was closed with a microwave septum cap and 
then acetonitrile (32 mL) and ethyl bromobutyrate (7.2 mL, 50 mmol) were 
added. The mixture was heated for 40 min at 120 ºC under microwave 
irradiation. After the reaction had been completed, the solution was filtered. 
Water (50 mL) and DCM (100 mL) were added and the phases were separated. 
The aqueous layer was extracted with DCM (3 x 100 mL) and the combined 
organic layer was washed with a saturated solution of sodium carbonate (200 
mL), dried over magnesium sulphate and evaporated under vacuum. The 
product was pure enough for the next step (9.19 g, 38.9 mmol, 97% yield).  
MS (ES+) m/z: 237  [M+H]+, 259 [M+Na]+; HRMS (ES+) for C13H17O4: 
237.11214 (calc.); 237.11211 (found); 1H NMR (CDCl3, 360 MHz): δ  9.74 (s, 
1H),7.67 (d, J =8.7, 2H), 6.82 (d, J = 8.7, 2H), 4.99 (q, J = 7.1, 2H), 3.94 (t,     
J = 6.2, 2H), 2.37 (t, J = 7.2, 2H), 1.96 (q5, J = 6.5, 2H), 1.10 (t, J = 7.2, 3H); 
13C NMR (CDCl3, 90.6 MHz): δ 190.1, 177.3, 165.8, 131.3 (2C), 129.5, 114.4 
(2C), 66.5, 59.6, 29.9, 27.1, 13.5; IR (neat) υ/cm-1: 2979 and 2941, 1728, 
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4-[4-(hydroxymethyl)phenoxy]butanoic acid (23):  
 
 Ethyl-4-(4’-formyl-phenol)-butyrate 22 (9.19 g, 38.9 mmol) was 
dissolved in ethanol (32 mL) and water (32 mL) was added. NaOH (2.5 g, 62.24 
mmol) was added portionwise over 20min. The reaction was stirred at room 
temperature for 30min. The solution was cooled to 0 ºC and sodium borohydride 
(1.104 g, 29.18 mmol) was added dropwise. After 1 h, the reaction was 
concentrated to approximately 30mL and the aqueous portion remaining was 
cooled to 0 ºC and the reaction quenched by the addition of 2 M HCl. The 
aqueous mixture was extracted with EtOAc (2 x 300 mL). The combined organic 
layers were washed with water and brine, dried over magnesium sulphate and 
concentrated under vacuum to give a greenish white solid (7.03 g, 33.46 mmol, 
86%).  
MS (ES-) m/z: 209 [M-H]-; HRMS (ES-) for C11H13O4: 209.08193 (calc.); 
209.08164 (found); 1H NMR (MeOD, 360 MHz): δ  7.13 (d, J =8.6, 2H), 6.76 (d, 
J =8.6, 2H), 4.91 (bs, OH), 4.40 (s, 2H), 3.86 (t, J = 6.2, 2H), 2.35 (t, J = 7.3, 
2H), 1.92 (q5, J = 7.0, 2H); 
13C NMR (MeOD, 90.6 MHz): δ 157.8, 132.8, 127.7 
(2C), 113.5 (2C), 66.0, 63.0, 29.5, 23.9; IR (neat) υ/cm-1: 3427, 2603, 1704 
and 1246; HPLC (ELSD) Rt/min: 3.294 (method C). 
5.2.2.2. PEG Spacer Unit Synthesis 
2-[(Dibenzylamino)ethoxy]ethanol (24):  
 
A mixture of 2-(aminoethoxy)ethanol (4.8 mL, 47.5 mmol), potassium 
carbonate (16.0 g, 118.75 mmol) and benzyl bromide (13.6 mL, 95 mmol) in 
acetonitrile (250 mL) was stirred at 50 ºC for 20 h. The solid was filtered and the 
solvent was removed from the filtrate. The residue was dissolved in hydrochloric 
acid (0.1 M, 50 mL) and washed with ethyl acetate (2 x 50 mL). The aqueous 
layer was then made basic (pH 9) with sodium hydroxide (4 M) and extracted 
with dichloromethane (4 x 50 mL). The solvent was dried over MgSO4 and 
Chapter V 
Experimental  130 
removed under vacuum to give a yellowish oil (13.0 g, 45.5 mmol, 96%). The 
product was used in the next step reaction without further purification.  
MS (ES+) m/z: 286.1 [M+H]+; HRMS (EI) for C16H19O6N3F3: 285.17233 (calc.); 
285.17246 (found); 1H NMR (CDCl3, 360 MHz): δ  7.75-7.25 (m, 10H), 3.75-
3.60 (m, 6H), 3.63 (t, J = 5.9, 2H), 3.55 (t, J = 4.9, 2H), 2.77 (t, J = 5.9, 2H);  
13C NMR (CDCl3, 90.6 MHz): δ139.0 (2C), 128.6 (4C), 128.0 (2C), 126.7 (2C), 
71.8, 69.3, 61.5, 58.6 (2C), 52.6; IR (neat) υmax/cm-1: 3360, 1475, 1366, 1244; 
HPLC (ELSD) tR/min: 3.521 (method C), 3.746 (method D). 
[2-(Dibenzylaminoethoxy)ethoxy]acetic acid (25):  
 
2-[(Dibenzylamino)ethoxy]ethanol (13.0 g, 45.5 mmol) was dissolved in 
dry THF (100 mL) and cooled to 0 ºC. Sodium hydride (7.30 g, 182.4 mmol; 
60% dispersion in oil) was added in portions followed by α-bromoacetic acid 
(9.44 g, 68.4 mmol). The suspension was refluxed under nitrogen overnight. 
Water (7 mL) was added carefully followed by stirring for 5 min. More water 
(200 mL) was added and the aqueous layer washed with a mixture of 
hexane/diethyl ether (3 x 100 mL) and then neutralised to pH 6-7 with sodium 
hydroxide (4 M).  Solid sodium chloride was added and the mixture was 
extracted with dichloromethane (5 x 150 mL). The solvent was dried over MgSO4 
and removed under vacuum. The crude colorless oil product was used in the next 
reaction without further purification (8.67 g, 25.2 mmol, 56%). 
MS (ES-) m/z: 342.1 [M-H]-; HRMS (EI) for C16H19O6N3F3: 343.17781 (calc.); 
343.17824 (found); 1H NMR (CDCl3, 250 MHz): δ  12.21 (bs, OH), 7.72-7.66 (m, 
4H), 3.60-7.50 (m, 6H), 4.45 (s, 2H), 4.35-4.28 (m, 2H), 3.98-3.87 (m, 4H), 
3.83-3.81 (m, 2H), 3.19 (t, J = 4.96, 2H); 13C NMR (CDCl3, 90.6 MHz): δ 173.7, 
133.2, 130.4 (2C), 128.6 (2C), 128.3, 70.5 (2C), 70.1 (2C), 68.0 (2C), 67.2 
(2C), 57.5 (2C), 53.4 (2C); IR (neat) υmax/cm-1: 2869, 1728, 1582, 1111,730, 
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[2-(2-aminoethoxy)ethoxy]acetic acid (26):  
 
Compound 25 (8.67 g, 25.2 mmol) was dissolved in MeOH (100 mL), 
palladium (3.0 g, 10% on carbon) was added and the mixture was stirred under 
hydrogen atmosphere (1 atm) at 45 ºC for 20 h. The catalyst was eliminated by 
filtration through a celite pad and the solvent removed under vacuum. The 
residue was triturated with diethyl ether (200 mL) to give a colorless oil (3.86 g, 
23.68 mmol, 94%) 
MS (ES+) m/z: 164 [M+H]+; MS (ES-) m/z: 162 [M-H]-; HRMS (EI) for 
C16H19O6N3F3: 163.08391 (calc.); 163.08402 (found); 
1H NMR (CDCl3, 600 
MHz): δ  4.68 (bs, OH), 4.25 (bs, NH), 4.13 (s, 2H), 3.96-3.70 (m, 6H), 3.36-
3.35 (m, 2H);  13C NMR (CDCl3, 90.6 MHz): δ 170.9, 70.4, 69.67, 67.9, 66.9, 
39.1; IR (neat) υmax/cm-1: ~2880, 1579, 1097; HPLC (ELSD) tR/min: 0.701 
(method C). 
{2-[(9H-Fluoren-9-ylmethoxycarbonylamino)-methoxy]-ethoxy}-acetic 
acid (27):  
 
The crude [(2-aminoethoxy)ethoxy]acetic acid (3.86 g, 23.68 mmol) was 
dissolved in water (120 mL) and sodium bicarbonate (3.98 g, 47.35 mmol) was 
added with stirring. The resulting solution was cooled in an ice bath and a 
solution of Fmoc-Cl (6.74 g, 26.04 mmol) in dioxane (240mL) was added 
dropwise. After stirring at 0°C for 1 h, the reaction mixture was allowed to warm 
to RT and stirred for a further 2 h. Water was added (50mL), and the aqueous 
solution was washed with diethyl ether (2 x 30 mL). The aqueous solution was 
acidified to pH 1-2 with concentrated hydrochloric acid and extracted with 
dichloromethane (5 x 30 mL). The solvent was dried and removed under vacuum 
to give an oily product (8.87 g, 23.02 mmol, 97%). 
MS (ES-) m/z: 384.0 [M-H]-; HRMS (EI) for C21H23NO6: 385.15199 (calc.); 
385.15294 (found); 1H NMR (CDCl3, 400 MHz): δ  7.73 (d, J = 7.5, 2H), 7.59 (d, 
J = 7.3, 2H), 7.37 (t, J = 7.3, 2H), 7.28 (t, J = 7.5, 2H), 5.63 (t, J = 5.4, 1H), 
4.37 (d, J = 6.9, 2H), 4.19 (t, J = 6.8, 2H), 4.13 (s, 2H), 3.75-3.70 (m, 2H), 
3.68-3.63 (m, 2H), 3.61-3.55 (m, 2H), 3.45-3.38 (m, 2H);  13C NMR (CDCl3, 
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90.6 MHz): δ 172.7, 156.8, 144.0, 141.3, 127.7, 127.0, 125.1, 120.0, 70.9 (2C), 
70.3, 68.3, 66.8, 47.2, 40.8; IR (neat) υmax/cm-1: 3324, 1716, 1531, 1253, 
1116, 887, 759; HPLC (ELSD) tR/min: 4.250 (method C), 7.630 (method D); 
5.2.2.3. Photospacer solid phase synthesis 
Linker coupling to amino PS resin (28): 
Amino polystyrene resin (1.0 g, 1.6 mmol) was swollen in DCM (10 mL). 
Hydroxymethyl phenyl butanoic acid 23 (1.018 g, 7.8 mmol) and HOBt (650 mg, 
4.8 mmol) were dissolved in DMF/DCM (1:1, 20 mL) and then DIC (743 µL, 4.8 
mmol) was added to the solution and stirred for 5 min. This solution was added 
to the resin and left shaking on the rotary wheel for 2.5 h. The resin was then 
washed with DMF (3 x 1 mL) and DCM (3 x 1 mL) and treated with 1.0 M 
NaOH(aq)/dioxane (1:1, 20 mL) for 1.5 h. This treatment was necessary to 
eliminate oligomers of the linker formed during the reaction. The resin was then 
washed with water (3 x 1 mL), DMF (3 x 1 mL), MeOH (3 x 1 mL), DMF (3 x 1 
mL), DCM (3 x 1 mL) and Et2O (2 x 1 mL) and allowed to dry for 30 min under 
vacuum. Complete coupling was assessed using the Green Malachita test which 
gave a positive result for free hydroxyl groups. 
Coupling of PEG spacer unit to the linker-Resin (29):  
Linker-resin (100 mg, 0.16 mmol) was swollen in DCM (1 mL) for 30 min. 
PEG spacer unit 27 (123.328 mg, 0.32 mmol) and HOBt (43.24 mg, 0.32 mmol) 
were dissolved in DCM with a few drops of DMF and stirred at RT. DIC (55 µL, 
0.352 mmol) and DMAP (6 mg, 0.048 mmol) were added the mixture and stirred 
for a further 5 min before addition to the resin. The resin was shaken at RT for 2 
h to allow complete esterification. The resin was washed with DMF (3 x 1 mL), 
DCM (3 x 1 mL), MeOH (3 x 1 mL) and Et2O (2 x 1 mL) and dried. Malachite 
Green test was done to check complete coupling of the spacer onto the resin and 
the absence of free hydroxyl groups. 
Fmoc deprotection (30):  
Fmoc removal was performed using 20% piperidine in DMF solution for 20 
min at RT. The resin was then filtered and washed with DMF (3 x 1 mL), DCM (3 
x 1 mL), MeOH (3 x 1 mL) and Et2O (2 x 1 mL) and dried under vacuum. A 
positive ninhydrin test result confirmed completion of the reaction. 
 
Chapter V 
Experimental  133 
TFMAD coupling to Spacer-Linker-Resin (31):  
The resin was swollen in DCM for 30 min and then washed with DMF (3 x 
1 mL). Meanwhile, TFMAD (48 mg, 0.183 mmol) and HOBt (25 mg, 0.183 mmol) 
were dissolved in DMF (1 mL) and stirred at RT for 10 min. DIC (29mL, 
0.183mmol) was added and the mixture stirred for a further 10 min before 
addition to the resin. The resin was shaken at RT overnight to affect coupling. 
The resin was washed with DMF (3 x 1 mL), DCM (3 x 1 mL), MeOH (3 x 1 mL) 
and Et2O (2 x 1 mL). The resin was dried under vacuum for 30 min. 
Acidic Cleavage from the Resin: 
The resin (100 mg) was swollen in DCM for 30 min. Then, an acidic 
cocktail containing DCM:TFA:TIS:water (4.8:4.8:2:2) was added and the resin 
was agitated on a rotary wheel at RT for 30 min. The resin was removed by 
filtration and the filtrate diluted with DCM (15 mL). The organic layer was 
extracted with NaOH 1 M aqueous solution, then acidified with concentrated HCl 
and extracted again with DCM. The organic solvent was dried over MgSO4 and 
evaporated under vacuum to give the different photospacer products. 
TFMAD-PEG-OH Photospacer (PS1):  
 
28 mg of yellow oil product (0.0691 mmol) was obtained with a yield of 36%. 
MS (ES-) m/z: 404  [M-H]-; MS (ES+) m/z: 406  [M+H]+;  HRMS (ES+) for 
C16H19O6N3F3: 406.12205 (calc.); 406.12182 (found); 
1H NMR (CDCl3, 600 
MHz): δ  7.17 (d, J = 8.6, 2H), 7.11 (bs, NH), 6.95 (d, J = 8.8, 2H), 4.53 (s, 2H), 
4.13 (s, 2H), 3.71 (m, 2H), 3.63 (m, 4H), 3.57 (m, 2H); 13C NMR (CDCl3, 150.9 
MHz): δ 175.5, 171.2, 160.7, 128.7 (2C), 122.9, 122.5 (q, 1J = 274.4), 115.5 
(2C), 71.5, 70.4, 70.0, 68.9, 67.4, 39.3, 28.0 (q, 2J = 40.7); 19F NMR (CDCl3, 
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TFMAD-(PEG)2-OH photospacer (PS2):  
 
33 mg of yellow oil product (0.06 mmol) was obtained with a yield of 30%. 
MS (ES-) m/z: 549  [M-H]-; MS (ES+) m/z: 551  [M+H]+, 573  [M+Na]+; 1H 
NMR (CDCl3, 360 MHz): δ  7.11 (d, J = 8.6, 2H), 7.02 (d, NH, J = 8.4, 1H), 6.89 
(m, 2H), 6.73 (d, NH, J = 8.5, 1H), 4.48 (s, 2H), 4.09 (s, 2H), 3.98 (s, 2H), 
3.70-3.35 (m, 16H); 13C NMR (CDCl3, 90.6 MHz): δ 173.1, 170.9, 170.0, 158.4, 
128.7 (2C), 122.8, 122.0 (q, 1J = 274.5), 115.4 (2C), 71.3, 70.8, 70.7, 70.5, 
70.3, 70.1, 70.0, 68.9, 67.4, 39.2, 39.1, 28.0 (q, 2J = 40.4); 19F NMR (CDCl3, 
235.9 MHz): δ -66.12; HPLC (ELSD) Rt/min: 4.112 (method C). 
TFMAD-(PEG)3-OH photospacer (PS3):  
 
38 mg of yellow oil product (0.055 mmol) was obtained with a yield of 27%. 
MS (ES-) m/z: 694  [M-H]-; MS (ES+) m/z: 696  [M+H]+; 1H NMR (CDCl3, 360 
MHz): δ  7.11 (d, J = 8.7, 2H), 7.00 (d, NH, J = 8.4, 1H), 6.88 (2H, d J = 8.8), 
6.71 (d, NH, J = 8.5, 1H), 4.47 (s, 2H), 4.07 (s, 2H), 3.96 (s, 2H), 3.95 (s, 2H), 
3.65-3.40 (m, 24H); 13C NMR (CDCl3, 90.6 MHz): δ 172.6, 171.1, 170.7, 168.6, 
158.4, 128.7 (2C), 122.7, 122.4 (q, 1J = 274.7), 115.4 (2C), 71.1, 71.0, 70.9, 
70.6 (2C), 70.5, 70.3, 70.2, 70.0, 69.9, 68.7, 67.4, 39.1, 39.0, 38.9, 28.4 (q, 2J 
= 40.5); 19F NMR (CDCl3, 235.9 MHz): δ -66.11; HPLC (ELSD) Rt/min: 4.158 
(method C), 7.338 (method D). 
5.4.3. Preparation of Fluorous tagged Photospacers 
General solution phase coupling procedure: 
To a solution of photospacer, carboxyfluorescein or biotin (1.1 equivalent) 
in DMF was added (benzotriazol-1-yloxy)trispyrrolidinophosphonium 
hexafluorophosphate (pyBOP) coupling agent (1.2 equivalent) and stirred at RT 
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for 45 min. 1-amino-1H,1H,2H,2H-perfluorodecane (1.0 equivalent) and DIEA 
(1.5 equivalent) in DMF were added and the reaction was irradiated in the 
microwave for 5 min at 50 ºC and then stirred at RT for 1 h. Evaporation of the 
product gave the crude which was purified through FSPE using FluoroFlash® 
silica gel starting with 20% MeOH in water as the wash fraction and 100% MeOH 
as the elution solution. 
Fluorous-tagged Biotin (32): 
 
50 mg of product was obtained with a yield of 71%. 
MS (ES+) m/z: 704  [M+H]+, 726  [M+Na]+; 1H NMR (d6-DMSO with CF3COOH 
traces, 500 MHz): δ  7.93 (t, J = 5.3, 1H), 6.96 (d, J = 7.4, 1H), 6.71 (d, J = 8.6, 
1H), 4.35-4.32 (m, 1H), 4.17-4.14 (m, 1H), 3.17-3.00 (m, 3H), 2.27-2.15 (m, 
2H), 2.07 (t, J = 7.4, 2H), 1.69-1.58 (m, 2H), 1.57-1.42 (m, 2H), 1.36-1.25 (m, 
2H), 0.88-0.77 (m, 2H); 13C NMR (d6-DMSO with CF3COOH traces, 125.9 
MHz): δ 172.4, 163.1, 132-108 (m), 61.3, 59.5, 55.5, 37.5, 35.3, 28.3, 28.1, 
25.4, 24.8, 20.3, 15.7; 19F NMR (d6-DMSO, 235.9 MHz): δ -126.23 (2F), -
123.54 (2F), -122.93 (2F), -122.90 (6F), -113.76 (2F), -80.66 (3F); HPLC 
(ELSD) Rt/min: 4.716 (method C). 
Fluorous-tagged 5-(6)-carboxyfluorescein (33): 
 
121 mg of product was obtained with a yield of 60% and a mixture of both, 5- 
and 6- substituted products. 
MS (ES+) m/z: 836  [M+H]+; 1H NMR (MeOD, 360 MHz): δ  8.10 (d, J = 8.0, 
1H), 8.03 (d, J = 7.0, 1H), 7.96 (d, J = 8.1, 1H), 7.19 (d, J = 8.1, 1H), 6.58 (s, 
2H), 6.50 – 6.40 (m, 3H), 3.27  (t, J = 6.8, 2H), 3.21 (s, 1H), 2.28–2.01 (m, 
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4H), 1.81 (q5, J
1 = 7.6, 2H); 13C NMR (MeOD, 90 MHz): δ 168.6 (168.6), 166.5 
(166.3), 158.0 (159.5), 152.1 (154.8), 135.7 (140.1), 133.6 (126.7), 128.3 
(2C), 126.4 (126.7), 125.3, 124.3, 123.8, 122.9, 122.0 (117.0), 116.7, 111.8, 
109.6 (108.9), 101.7, 40.8, 38.3, 35.1, 27.4 (t, J = 8.6, 1C), 19.5 (m, 1C); 1H 
and 12C NMRs describe those signals corresponding to 5-substituted product. 19F 
NMR (MeOD, 235.9 MHz): δ -127.72 (2F), -124.82 (2F), -124.19 (2F), -123.33 
(6F), -115.65 (2F),-82.77 (3F); HPLC (ELSD) Rt/min: 4.757 (method C). 
TFMAD-PEG-Ftag (FPS1): 
 
21 mg of product was obtained with a yield of 70%. 
MS (ES+) m/z: 865  [M+H]+, 887  [M+Na]+; 1H NMR (MeOD, 400 MHz): δ  7.24 
(d, J = 8.6, 2H), 7.10 (d, J = 9.0, 2H), 4.58 (s, 2H), 4.02 (s, 2H), 3.79-3.71 (m, 
2H), 3.68 (s, 4H), 3.65-3.60 (m, 2H), 3.54-3.48 (m, 2H), 2.30-2.20 (m, 2H), 
1.90-1.80 (m, 2H); 13C NMR (MeOD, 125.9 MHz): δ 171.6, 171.6, 169.2, 159.0, 
128.0 (2C), 122.3 (q, 1J = 273.0), 121.5, 115.2 (2C), 70.5, 69.9, 69.8, 69.1, 
66.7, 42.4, 38.5, 37.6, 28.0 (q, 2J = 28.0); 19F NMR (MeOD, 235.9 MHz): δ -
127.26 (2F), -124.38 (2F), 123.72 (2F), -122.89 (6F), -115.21 (2F),  -82.35 
(3F),  -67.44 (3F); HPLC (ELSD) Rt/min: 4.966 (method C). 
TFMAD-(PEG)2-Ftag (FPS2): 
 
51 mg of product was obtained with a yield of 72%. 
MS (ES-) m/z: 1008  [M-H]-, 1054 [M+FA]-; MS (ES+) m/z: 1010  [M+H]+, 
1032  [M+Na]+; 1H NMR (CDCl3, 500 MHz): δ  7.20 (d, J = 8.7, 2H), 7.07-7.02 
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(m, 3H, NHs), 6.96 (d, J = 8.9, 2H), 4.52 (s, 2H), 4.01 (s, 4H), 3.07-3.64 (m, 
4H), 3.64-3.56 (m, 8H), 3.54-3.49 (m, 2H), 3.42-3.38 (m, 2H), 2.21-2.11 (m, 
2H), 1.33-1.27 (m, 2H); 13C NMR (CDCl3, 125.9 MHz): δ 170.3, 170.2, 168.1, 
158.5, 128.8 (2C), 123.0, 122.1 (q, 1J = 274.5), 115.4 (2C), 70.8, 70.5, 70.1, 
70.0, 69.8, 67.3, 38.8, 38.4, 37.9, 20.9, 28.4 (q, 2J = 23.0); 19F NMR (CDCl3, 
235.9 MHz): δ -126.06 (2F), -123.50 (2F), 122.67 (2F), -121.28 (6F),               




30 mg of product was obtained with a yield of 69%. 
MS (ES-) m/z: 1153.8  [M-H]-; 1199.1  [M+FA]-; 1H NMR (CDCl3, 500 MHz): δ  
7.20 (d, J = 8.7, 2H), 6.97 (d, J = 9.0, 2H), 7.16-7.01 (m, NH, 4H), 4.533 (s, 
2H), 4.16 (s, 2H), 4.02 (s, 4H), 3.69-3.50 (m, 24H), 3.44-3.39 (m, 2H), 1.29-
1.25 (m, 2H), 1.16 (t, J = 4.3, 2H); 13C NMR (CDCl3, 125.8 MHz): δ 170.8, 
170.0, 170.0-169.8 (m), 167.7, 158.2, 128.45 (2C), 122.5, 115.2 (2C), 122.1  
(q, 1J = 274.9), 129.8, 70.8 (3C), 70.7, 70.6, 70.2, 70.1 (2C), 70.0, 69.9, 69.8, 
68.5, 67.4, 38.8, 38.6, 38.6, 38.5, 37.9, 29.7, 23.8 (q, 2J = 24.0); 19F NMR 
(CDCl3, 235.9 MHz): δ -126.04 (2F), -123.33 (2F), 121.67 (2F), -119.00 (6F),     
-114.23 (2F),  -80.73 (3F),  -65.58 (3F);  HPLC (ELSD) Rt/min: 4.938 (method 
C);  
5.4.4. Biotin-Streptavidin validation experiment 
Attachment of Photospacers by Strategy I 
A 15 µL solution of 0.3 M of PS1, PS2 or PS3 photospacer in DMF were 
transferred to a well plate and mixed with 15 µL of a solution of 0.3 M of HOBt in 
DMF. This was followed by addition of 15 µL solution of 0.3 M of DIC in DMF and 
mixing. 10 drops/spot were printed using this solution using a Microdrop printer 
(90 V and 60 µs). Printed slides were kept in a hybridisation chamber with DMF  
(1 mL) overnight at 30 ºC. The slides were washed with DMF (2 x 3 min), EtOH 
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(2 x 3 min), water and acetone and dry with nitrogen. If the slides were not used 
immediately, they were kept in the dark at 4 ºC. 
Attachment of Photospacers by Strategy II 
Solutions of 10 mM concentration of FPS1, FPS2 or FPS3 were prepared 
in DMF and used for printing 8-10 drops/spot onto fluorinated slides by inkjet 
printing at 90 V and 60 µs of pulse. The slides were left to dry overnight before 
small molecule solutions were printed on top. 
Biotin/Carboxyfluorescein Immobilisation: 
Four different concentration solutions of Biotin/carboxyfluorescein in 
DMSO (0.1 mM, 1 mM, 10 mM and 100 mM) were prepared and printed on the 
microarray slides by an inkjet printer (Microdrop). The slides were dried 
overnight under vacuum. They were then cool down to -196 ºC with liquid 
nitrogen and irradiated for 40 min at 365 nm with a 100W lamp. The slides were 
washed with DMSO, EtOH, water and acetone and dried with nitrogen for 
strategy I or with PBS buffer and distilled water for strategy II. In the case of 
carboxyfluorescein immobilisation, slides were ready to be scanned using a FITC 
filter. 
Hybridisation with Amersham CyTM5-Streptavidin (GE Healthcare): 
Slides were incubated with 150 µL of a 10 µg/mL streptavidin in PBS (pH 
7.4) buffer for 1 h at RT with a hybridisation station (Zinsser Analytic GmbH). 
Slides were then washed with PBS buffer (3 x 10 min), rinsed with distilled water 
and dried under a nitrogen stream. Slide scanning was performed using a Cy5 
filter by the bioanalyser microarrayer (La Vision BioTech). 
5.4.5. Small Molecule Microarray 
Small-Molecule Microarray Preparation: 
A small molecule microarray was prepared by printing 8 drops per spot of 
10 mM FPS1 solution in DMF (53 rows x 114 columns = 6,042 spots) at a 78 V 
and 64 µs of pulse using a Scienion S5 sciFLEXARRAYER (Scienion AG, 
Germany). The slides were left to dry overnight. Using the same settings for 
voltage and pulse, the 2,000 compounds from the SPECTRUM library (10 mM 
solutions in DMSO) were printed in triplicate at different locations, distributed 
along the slide, with 8 drops per spot for each compound. The final diameter per 
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spot was 200 µm. Slides were left to dry overnight and then irradiated for 40 
min at 365 nm from a distance of about 10 cm before washing in distilled water 
(3 x 10 min) and dried under a nitrogen stream. Slides were scanned with a 
microarray scanner (Genetix 4200AL, Axon) and analysed with FIPS software 
(LaVision Biotec, Bielefeld, Germany). If slides were not used immediately, they 
were kept in the dark at 4 ºC. 
Hybridisation with Human β-TrCP I Protein (University of Toronto): 
Slides were incubated with 150µL of a 2µM solution of β-TrCP I in TBS 
containing 0.5% of phosphoBLOCKERTM Blocking Reagent (Cell Biolabs, inc.). 
Hybridisation was carried out overnight at 4 ºC. Slides were then removed, 
washed with TBS buffer (3 x 10 min), rinsed with water and dried under a 
nitrogen stream. 
Hybridisation with mouse anti-β-TrCP I (Invitrogen, 37-3400): 
1 µL of monoclonal mouse anti-β-TrCP I solution (0.5 mg/mL in PBS, pH 
7.4, containing 0.1% sodium azide) was dissolved in 500 µL of TBS buffer 
containing 1% of phosphoBLOCKERTM Blocking Reagent (Cell Biolabs, inc.).    
150 mL of this solution was introduced to the hybridisation station and 
hybridisation was carried out for 4 h at RT. After that time, slides were removed, 
washed (3 x 10 min) in TBS buffer, rinsed with water and dried under a nitrogen 
stream. 
Hybridisation with Cy3 conjugated Donkey anti-Mouse IgG Secondary 
Antibody (Thermo Scientific, PA1-29773): 
1 µL of an affinity purified antibody solution (1.4 mg/mL, 500 µg in PBS, 
pH 7.6, containing 0.05% sodium azide) was dissolved in 500 µL of TBS buffer 
containing 1% of phosphoBLOCKERTM Blocking Reagent (Cell Biolabs, inc.).    
150 mL of this solution was introduced to the hybridisation station and 
hybridisation was carried out for 1 h at RT. After that time, slides were removed, 
washed (3 x 10 min) in TBS buffer, rinsed with water and dried under a nitrogen 
stream. 
Denaturising Wash for Slide reusal: 
Slides were washed for 1 h at 70 ºC with destilled water and gentle 
agitation. Slides were then washed with PBS (3 x 3 min) and rinsed with distilled 
water before drying under nitrogen stream. 
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5.5. Experimental for Chapter 3 
The 9-mer peptoid carrier system used in this chapter was provided by 
Geraldine Esher, a member of Bradley group. 
5.5.1. Photoprobe synthesis 
Synthesis of Dde-OH (34):  
 
Dimedone (2.06 g, 10 mmol), DMAP (122 mg, 1 mmol) and DCC (1.40 g, 
10 mmol) were dissolved in DMF (17 mL) and stirred at RT. Acetic acid (584 µL, 
142 mmol, 2 eq) was added to the solution and heated at 80 ºC under 
microwave irradiation for 1 h. The reaction mixture was filtered and the organic 
layer was poured into water (20 mL), which was then extracted with Et2O (3 x 
100 mL), dried with MgSO4 and then evaporated in vacuo. The crude was 
passed through a plug of silica to give 1.63 g of a yellowish solid (9 mmol, 
90%).  
MS (ES-) m/z: 181  [M-H]-; HRMS (ES+) for C10H15O3: 183.10157 (calc.); 
183.10154 (found); 1H NMR (CDCl3, 500 MHz): δ  2.59 (s, 3H), 2.52 (s, 2H), 
2.34 (s, 2H), 1.06 (s, 6H); 13C NMR (CDCl3, 150.9 MHz): δ 202.4, 197.9, 195.2, 
112.4, 52.5, 46.9, 30.7, 28.5, 28.2; IR (neat) υ/cm-1: 3324, 2957, 2930, 1665, 
1556, 1438; HPLC (220 nm) Rt/min: 3.776 (method C). 
Synthesis of Lys(Dde)-OH (35):  
 
Fmoc-Lys-OH·HCl (10 g, 24.70 mmol) was dissolved in distilled water and 
DIPEA (5 mL) was added dropwise until a white precipitate was formed. The 
solution was left to stir for 10 min at room temperature. The precipitate was 
obtained by filtration and dried under vacuum overnight (8.181 g, 21.17 mmol, 
86%).  
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Fmoc-Lys-OH (900 mg, 2.44 mmol) and Dde-OH (1.302 g, 7.32 mmol) 
were suspended in ethanol (12 mL) and TFA (18.8 µL, 0.25 mmol) was added 
dropwise. The mixture was heated under microwave irradiation for 60 min at   
120 ºC. Solvent was then removed and the resulting orange residue was 
dissolved in EtOAC and washed with 1 M aqueous KHSO4 (3 x 100 mL). The 
organic layer was dried over MgSO4 and evaporated by vacuum. Purification of 
the crude product was done by column chromatography in 8:1 DCM:MeOH to 
give 1.093 g of a yellowish powder (2.052 mmol, 84%). 
MS (ES-) m/z: 531  [M-H]-; MS (ES+) m/z: 533  [M+H]+, 555  [M+H]+; HRMS 
(ES+) for C31H36O6N2: 533.26571 (calc.); 533.26553 (found); 
1H NMR (CDCl3, 
500 MHz): δ  13.32 (br, 1H), 7.77 (d, J = 7.5, 2H), 7.61 (t, J = 8.4, 2H), 7.40 (t, 
J = 7.4, 2H), 7.30 (t, J = 7.3, 2H), 5.83 (s, 1H, NH), 4.47 (br, 1H), 4.38 (d, J = 
6.85, 2H), 4.21 (t, J = 6.9, 2H), 3.42 (s, 2H), 2.59 (s, 4H), 2.38 (m, 3H), 2.01-
1.70 (m, 4H), 1.60-1.47 (m, 2H), 1.03 (s, 6H); 13C NMR (CDCl3, 150.9 MHz): δ 
202.5, 198.0, 195.4, 174.1, 156.2, 143.8 (2C), 141.3 (2C), 127.7 (2C), 127.1 
(2C), 125.2 (2C), 120.0 (2C), 112.4, 67.1, 53.5, 52.5 (2C), 47.2, 43.3, 32.0, 
30.7, 30.2, 28.2 (2C), 22.4, 18.2; IR (neat) υ/cm-1: 3294, 2951, 2866, 1715, 
1567; HPLC (ELSD) Rt/min: 4.503 (method C). 
Microwave Coupling Reaction Procedure:  
The corresponding polystyrene resin (1.23 mmol/g, 1.0 eq) was swollen 
in DCM (15 mL) for 30 min. A 0.1M solution was prepared with an acidic building 
block (3.0 eq) and oxyma (3.0 eq) in DCM, and a few drops of DMF were added 
if necessary for complete dissolution. DIC (3.0 eq) was added to the solution and 
stirred for 10 min. The solution was then poured into the resin and the 
suspension was transferred to a microwave vial. The reaction was done at 60 ºC 
for 20 min. Resin was filtered and washed with DMF (3 x 15mL), DCM (3 x 
15mL), MeOH (3 x 15mL) and Et2O (3 x 15mL) and dried. The completion of the 
reaction was confirmed with a negative qualitative ninhydrin test. 
Room Temperature Coupling Reaction Procedure: 
 The corresponding polystyrene resin (1.23 mmol/g, 1.0 eq) was swollen 
in DCM for 30 min. A 0.1 M solution was prepared with the acidic building block 
(3.0 eq) and oxyma (3.0 eq) in DCM, and a few drops of DMF were added if 
necessary for complete dissolution. DIC (3.0 eq) was added to the solution and 
stirred for 10 min. The solution was then added to the resin and the mixture was 
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agitated in a rotary-wheel for 1 h. Resin was filtered and washed with DMF (3 x 
15 mL), DCM (3 x 15 mL), MeOH (3 x 15 mL) and Et2O (3 x 15mL) and dried. 
The completion of the reaction was confirmed with a negative qualitative 
ninhydrin test. 
6(5)-Carboxyfluorescein Coupling Reaction:  
The corresponding resin was swollen in DCM and a solution of 5(6)-
carboxyfluorescein (3.0 eq) and oxyma (3.0 eq) in DMF was prepared. DIC (3.0 
eq) was to this solution added and the mixture stirred for 10 min and then 
poured onto the resin which stirred overnight at room temperature. The resin 
was washed with DMF (3 x 15 mL), DCM (3 x 15 mL), MeOH (3 x 15 mL) and 
Et2O (3 x 15 mL) and dried. The completion of the reaction was confirmed with a 
negative qualitative ninhydrin test.  
Fmoc Deprotection Procedure: 
The corresponding resin was swollen in DCM and filtered. A freshly 
prepared solution of 20% piperidine in DMF was added to the resin and agitated 
in a rotary-wheel for 20 minutes. Resin was then filtered and washed with DMF 
(3 x 15 mL), DCM (3 x 15 mL), MeOH (3 x 15 mL) and Et2O (3 x 15 mL) and 
dried. The completion of the reaction was confirmed with a positive qualitative 
ninhydrin test. 
Dde Deprotection in Presence of Fmoc Group:  
Hydroxylamine hydrochloride (1.25 mg, 1.80 mmol) and imidazole (0.918 
g, 1.35 mmol) were suspended in NMP (5 mL) and the mixture was sonicated 
until complete dissolution. To this solution, DCM (1 mL) was added and the 
mixture added to the swollen resin with DCM (500 mg, 0.5 mmol) and stirred for 
3 h at room temperature. The resin was washed in DCM (3 x 1 mL), DMF (3 x 1 
mL), MeOH (3 x 1 mL) and Et2O (3 x 1 mL) and dried. Deprotection was 
confirmed with a positive qualitative ninhydrin test.  
Resin Cleavage:  
Resins 40 and 45 were swollen in DCM for 30 min, washed with DMF (2 x 
15 mL), 20% piperidine in DMF solution (3 x 15 mL), DMF (2 x 15 mL), and DCM 
(2 x 15 mL). A cocktail solution of TFA:TIS:water (90:5:5, 20 µL/mg) was added 
to the resin and the mixture stirred for 2 h at room temperature. The cleavage 
mixture was filtered and the resin rinsed with neat TFA (1 mL). The collected 
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acidic solution was added dropwise to a flask containing cooled diethyl ether 
(10mL ether/mL of cleavage cocktail) where product was precipitated. The 
precipitate was centrifuged for 10 min and the supernatant was changed for a 
new cooled diethyl ether solvent fraction. This action was repeated three times 
to eliminate TFA and scavengers presence from the flask. Finally, the solid was 
dried under vacuum. 
Photoreactive probe (41): 
 
Photoreactive probe 41 was obtained from the cleavage of 50 mg of resin 
to give 35 mg of an orange powder in 64% yield and 90% purity.   
MS (ES+) m/z: 891  [M+H]+; 913  [M+Na]+; HRMS (ES+) for C43H41O12N6F3: 
891.27884 (calc.); 891.27891 (found); 1H NMR (CDCl3, 500 MHz): δ  8.30-8.20 
(m, 2H), 7.97 (d, J = 7.4, 2H), 7.21 (d, J = 8.4, 2H), 7.09-7.00 (m, 5H), 6.91-
6.81 (m, 2H), 6.50 (dd, J = 6.5 and 2.4, 2H), 4.50 (d, J = 9.3, 2H), 4.44 (q, J = 
7.2, 2H), 4.03 (s, 2H), 3.74-3.57 (m, 8H), 3.27-3.19 (m, 2H), 1.88-1.62 (m, 
2H), 1.60-1.50 (m, 2H), 1.42-1.35 (m, 2H); 13C NMR (CDCl3, 150.9 MHz): δ 
175.8, 174.9, 171.1, 169.0, 166.9, 160.9, 158.9, 152.1, 139.3, 136.7, 132.2, 
132.6, 130.9, 129.5, 128.0, 122.3 (q, 1J = 273.8),121.4, 115.2, 114.4 (2C), 
105.7, 102.1, 99.9, 70.8, 69.6, 69.2, 69.0, 66.7, 54.2, 39.7, 38.4, 32.0, 28.6, 
27.9 (q, 2J = 40.3), 22.5; 19F NMR (CDCl3, 235.9 MHz): δ -66.05; HPLC (ELSD) 
Rt/min: 4.226 and puritiy: 90%.  
NLS photoreactive probe (46): 
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NLS photoreactive probe was obtained form the cleavage of 50 mg of 
resin to give 26 mg of pure product in 24% yield and 96% purity. 
MALDI-TOF MS m/z: 1728.9298 [(M+H)-N2]
+; 1952.9955 [(M+sinapic acid 
(SA))-N2]
+; HPLC (ELSD) Rt/min: 3.117 and puritiy: 96%. 
Measure of the sample concentration by UV-Vis spectroscopy: 
With the aim of facilitating the probe fluorescence measurement as a 
consequence of its pH dependency, all samples were dissolved with a solution of 
0.1 M NaOH aqueous solution in order to only detect the dianion form which 
absorbs at 499 nm with a coefficient extinction of 76,900 M-1cm-1 and have the 
best quantum yield (Φ= 0.93).389 The absorption spectrum was acquired with an 
8453 UV-Vis spectrophotometer (Agilent) and concentration calculated using the 
Beer-Lambert law. 
MALDI-TOF MS sample preparation: 
1 µL of Sinapinic acid (SA) matrix (10 mg/mL of SA in 50% MeCN in 
water with 0.1% TFA) was mixed with 1 µL of each sample (1mg/mL in water) 
on a gold target. Measurements were made using a laser-desorption time-of-
flight system (Applied Biosystems). For signal generation, 20-50 laser shots 
were added up in the single shot mode.  
5.5.2. Photoprobe Cellular Uptake 
Cellular Uptake experiment: 
Cells were suspended to the appropriate cell density in fresh growth 
media before seeding onto polystyrene well-plates. Cells were incubated          
(37 ºC/5% CO2) for 24 hours to allow adhesion. Two concentrations of 
photoreactive probes and carboxyfluorescein (10 and 20 µM) were added at 
different times and cells incubated (37 ºC/5% CO2) in their presence for 1-24 h 
prior analysis by FACS. 
Probes Cytotoxicity: 
Toxicity of probes 41 and 46 at different concentrations (10-100 µM) was 
assessed by the MTT assay described in Section 5.2.6. Samples of both probes 
at different concentrations were added to a 96 well-plate at a density of 104 
cells/well and assessed in quintuplicate. After 24 h incubation with the probes, 
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cell viability was measured by the formation of formazan crystals and compared 
to the positive and negative controls.  
 
Microscopy and Nuclei Staining with Hoechst 33342: 
Cells were seeded to the appropriate cell density in a 24-well plate in 
fresh growth media and incubated (37 ºC/5% CO2) for 24 h to allow adhesion. 
The two different probes and carboxyfluorescein were added in a concentration 
of 10 µM and incubated for 8h. Cells were washed with PBS before staining. 
Cells were fixed with a solution of 4% para-formaldheyde in PBS (300 µL) 
for 20 minutes at RT. Cells were washed carefully two more times with PBS  
(300 mL) before adding a solution of HOECHST dye (300 µL, 0.1 mg/mL) and 
incubated for 20 minutes at RT. Finally, cells were washed two times with PBS  
prior to microscopy. Microscopy was performed in PBS with a Leica DM IRB 
inverted fluorescent microscope or bright field as appropriate. Merged images 
were performed under identical exposure conditions using Leica FW4000 v 1.2 
software. 
5.5.3. Peptoid experiment 
Peptoid capture by photoreactive probes: 
On a 96 well-plate, the same volume of a peptoid solution (2.64 mM,   
150 µL/well) was placed into several wells. Different volumes of the 
photoreactive probe (14.67 mM) were added to achieve the different ratios 
between peptoid and probe. Also, the 3 highest volumes of probe used were 
added into empty wells as negative controls and treated as the others. Solvent 
was evaporated in the speed vac for 1 h, and then the well plate was irradiated 
from a distance of about 10 cm away for 40 min. Irradiated samples were 
redissolved in PBS, placed in eppendorfs and kept at 4 ºC until usage. Samples 
were analysed by MALDI-MS to see if conjugates had been formed. 
Peptoid Adduct Cellular Uptake: 
Cells were suspended to the appropriate cell density in fresh growth 
media before seeding onto polystyrene well-plates. Cells were incubated         
(37 ºC/5% CO2) for 24 hours to allow adhesion. Then, addition of peptoid 
conjugates solutions prepared previously were added to each well to have a 
concentration of 10 µM of peptoid or conjugated peptoid. Cells were incubated in 
the presence of peptoid-probe adducts (37 ºC/5% CO2) for 8 h prior to analysis. 
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5.5.4. Colchicine Adducts Toxicity 
Drug capture by photoreactive probes:  
1.5 mL of a 100 µM colchicine solution (60 mg) in distilled water were 
prepared and splitted into 3 wells of a 48-well plate. Then, 50 nmol of each 
photoreactive probe was added to two of the well plates in order to have the 
ratio 1:1 of drug-probe and same amounts of photoreactive probe were added to 
two empty wells as controls. The well plate solution was evaporated using the 
speed vac and then irradiated for 40 min. Solids were redissolved in distilled 
water and from these 100 µM solutions, solutions of 10 and 1 µM were prepared 
by diluting 10 and 100 times with distilled water. These solutions were used to 
carry out cytotoxicity MTT assays. 
Cell viability:  
Cells were incubated with colchicine, and conjugates of colchicine with 
probes 41 and 46 prepared in previous section for 24 h at three different 
concentrations (10, 1, and 0.1 µM). Each sample and concentration was 
assessed in quintuplet. Probes 41 and 46 were also added as negative controls 
for better comparison of samples at these three concentrations. After 24 h 
incubation, the cytotoxicity assay described in Section 5.2.6 was carried out 
and cell viability was determined. 
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5.6. Experimental for Chapter 4 
Amino-functionalised microspheres used in this chapter were provided by 
Juan Manuel Cardenas-Maestre, a member of the Sánchez-Martín group, with a 
diameter size of 380 nm and a solid content (sc) of 2%. 
5.6.1. TFMAD-Functionalised Microspheres Synthesis 
Preparation of PEG Microspheres (47 and 48):  
 
Amino functionalised microspheres (1 mL, solid content 2%, loading 27.6 
µmol/g, 1 eq, Z potential = -20.4 mV) were washed in DMF (3 x 1 mL) and 
suspended in DMF (0.5 mL). Separately, the Fmoc-O2Oc-OH spacer (2.13mg, 10 
eq) was dissolved in DMF (0.5 mL) with HOBt (746 µg, 10 eq) and mixed until 
complete dissolution had been achieved. Then, diisopropylcarbodiimide (DIC) 
(0.9 µL, 10 eq) was added to the solution and stirred for 5 min at 25 ºC. The 
solution was added to amino microspheres and the suspension mixed on a 
rotary-wheel at 25 ºC for 18h. Microspheres were washed with DMF (3 x 1 mL) 
and reaction completion was confirmed by a negative qualitative ninhydrin test 
and a change in Z potential value (-40.0 mV). 
Microspheres with a double PEG spacer unit were treated with 20% 
piperidine in DMF as described below and this step was repeated one more time. 
Fmoc Deprotection:  
 
Fmoc-protected microspheres (1 mL, solid content 2%, 1 eq) were 
centrifuged and DMF was exchange for 1 mL of 20% piperidine in DMF solution. 
The solution was sonicated and then mixed in a rotary-wheel for 20 min. The 
process was repeated one more time. Finally, microspheres were washed with 
DMF (3 x 1 mL) and reaction was confirmed by a positive qualitative ninhydrin 
test and a change in Z potential value (-0.8 mV). 
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Preparation of PEG-disulphide Microspheres (50):  
 
Fmoc-deprotected microspheres 49 (1 mL, solid content 2%, 1 eq) were 
centrifuged and resuspended into a solution of adipic acid (1.46 mg, 10 eq) and 
DIC (0.9 µL, 10 eq) that had been mixed for 10 min in DMF. DMAP was then 
added (0.61 mg, 5 eq) and the suspension was mixed on a rotary-wheel at      
25 ºC overnight for 1 h. Microspheres were washed with DMF (3 x 1 mL) and 
reaction completion was confirmed by a negative result on the ninhydrin test. 
Subsequently, microspheres were centrifuged and DMF was exchanged for a 
solution of cytamine (1.52 mg, 10 eq), HOBt (746 µg, 10 eq) and DMAP (0.61 
mg, 5 eq) that had been stirred for 10 min after the addition of DIC (0.9 µL, 10 
eq). The solution was mixed on a rotary-wheel for 1 h. Finally, microspheres 
were washed with DMF (3 x 1 mL) and reaction completion was confirmed by a 
negative qualitative ninhydrin test and a change in Z potential value (-22.0 mV). 
TFMAD Coupling onto Microspheres (51a):  
 
Fmoc-deprotected microspheres 47 (1 mL, solid content 2%, 1 eq) were 
centrifuged and resuspended into a solution of TFMAD-OH (1.44mg, 10eq) and 
HOBt (746 µg, 10 eq) that had been mixed for 10 min after addition of DIC (0.9 
µL, 10 eq). The suspension was mixed on a rotary-wheel at 25 ºC overnight. The 
resulting microspheres are washed with DMF (3 x 1 mL) and reaction completion 
was confirmed by a negative result on the ninhydrin test and a change in Z 
potential value (-35.5mV). The microspheres were washed with MeOH (3 x 1 
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Fmoc-Lys(Dde)-OH Coupling to PEG-Microspheres (53):  
 
Fmoc-deprotected microspheres 52 (0.5 mL, solid content 2%, 1 eq) 
were centrifuged and resuspended into a solution of Fmoc-Lys(Dde)-OH (823.4 
µg, 10eq) and oxyma (197 µg, 10 eq) that had been mixed for 10 min after 
addition of DIC (0.214 µL, 10 eq). The suspension was mixed on a rotary-wheel 
at 25 ºC overnight. The resulting microspheres are washed with DMF (3 x 1 mL) 
and reaction completion was confirmed by a negative result on the ninhydrin test 
and a change in Z potential value (-36.6 mV). 
Deprotection of Dde and TFMAD coupling (54):  
 
A freshly prepared solution of 1.25g hydroxylamine hydrochloride (1.80 
mmol, 1.33 eq) and 918 mg immidazole (1.35 mmol, 1 eq) in 5 mL of NMP was 
prepared and sonicated until complete dissolution had been achieved. Then, 5 
volumes of this solution (1000 µL) were mixed with 1 volume of DMF (200 µL) 
and the final solution was added to previously centrifuged microspheres 53 (0.5 
mL, solid content 2%, 1 eq). The resuspended microspheres were stirred at 
room temperature for 1.5 h and the procedure was repeated one more time. The 
resulting microspheres were washed with DMF (3 x 1 mL) and reaction 
completion was confirmed by a negative result on the ninhydrin test and a 
change in Z potential value (-8.9 mV). 
Dde-deprotected microspheres (0.5 mL, solid content 2%, 1 eq) were 
centrifuged and resuspended into a solution of TFMAD (388 µg, 10eq) and 
oxyma (197 µg, 10 eq) that had been mixed for 10 min after addition of DIC 
(0.214 µL, 10 eq). The suspension was mixed on a rotary-wheel at 25 ºC 
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overnight. The resulting microspheres are washed with DMF (3 x 1 mL) and 
reaction completion was confirmed by a negative result on the ninhydrin test and 
a change in Z potential value (-24.6 mV). 
Fmoc deprotection and Fmoc-Arg(Boc)2-OH coupling (55):  
 
Microspheres 54 (0.5 mL, solid content 2%, 1 eq) were centrifuge and 
DMF was exchanged for 20% piperidine in DMF solution (1 mL). The solution was 
sonicated and then mixed in a rotary-wheel for 20 min. The process was 
repeated one more time. Finally, microspheres were washed with DMF (3 x 1 
mL) and reaction was confirmed by a positive qualitative ninhydrin test and a 
change in Z potential value (-17.4 mV). 
Subsequently, microspheres were centrifuged and resuspended into a 
solution of Fmoc-Arg(Boc)2-OH (824 µg, 10eq) and oxyma (197 µg, 10 eq) that 
had been mixed for 10 min after addition of DIC (0.214 µL, 10 eq). The 
suspension was mixed on a rotary-wheel at 25 ºC overnight. The resulting 
microspheres were washed with DMF (3 x 1 mL) and reaction completion was 
confirmed by a negative result on the ninhydrin test and a change in Z potential 
value (-23.4 mV). 
Deprotection of Boc and Fmoc protecting groups of Arginine (56a):  
 
Microspheres 54 (0.5 mL, solid content 2%, 1 eq) were centrifuged and 
DMF was exchanged for DMF: TFA: TIS: water (64:32:2:2) solution (1 mL) 
Chapter V 
Experimental  151 
previously prepared and cooled on ice. Microspheres were resuspended and 
stirred for 1 h at room temperature. The process was repeated one more time. 
Microspheres were washed with DMF (3 x 1 mL) and deprotection was confirmed 
by a positive on ninhydrin test. Subsequently, microspheres were centrifuged 
and resuspended in of 20% piperidine in DMF (1 mL) and stirred for 20min at 
room temperature. The process was repeated one more time. Finally, 
microspheres were washed with DMF (3 x 1 mL) and reaction was confirmed by 
a change in Z potential value (-5.24 mV). 
Preparation of Samples for Scanning Electron Microscopy:  
Microspheres (25 µL, 2% sc) were dried on carbon-coated stubs under 
vacuum (50 ºC, 5 hours) and gold coated by sputtering (approximately 20 nm 
layer) prior to analysis. 
5.6.2. Oligos and pEGFP Covalent Capture on microspheres 
TxRd-Oligonucleotide Capture: 
Eppendorfs containing 40 µL of microspheres 56a or 51a (11.92 nmol of 
diazirine group, 1 eq) each were prepared and mixed with 10 µL of a 77-mer 
random sequence oligonucleotide with texas red at 5’ position solution (Sigma 
Aldrich)(100 nmol, 100 µM stock solution, 8.5 eq) and allowed to gently mix for 
30 min in the thermomixer. Solvent from one of each microsphere type was 
evaporated in a speedvac for 30 min at 25 ºC. All samples were placed in an ice 
bath and irradiated above 10 cm with a UV lamp for 40 min. Dry microspheres 
were resuspended with 40 µL of nuclease-free deionised water and all were 
centrifuged and washed three times with nuclease-free deionised water (40 µL) 
before analysis by flow cytometry. 
 1 µL of each microsphere sample was suspended into 500 mL of PBS 
buffer and analysed by flow cytometry using the filter for texas red fluorescence. 
Untreated microspheres of each type were used as negative controls. 
pEGFP Capture: 
To an eppendorf containing 15 µL of either 56a or 51a microsphere type 
(0.38 nm in size, 2% sc, 4.5 µmol of reactive group) were added different 
volumes of pEGFP-C1 stock solution (0.4 µg/mL of plasmid in TE buffer): 10, 25, 
50, and 100 µL of plasmid solution per reaction vessel. 51a microspheres were 
mixed with the higher volume (100 µL). All samples were left to mix gently in 
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the thermomixer for 30 min and solvent was then evaporated by speed vacuum 
for 30 min at 25 ºC. Samples were placed in an ice-water bath and irradiated 
above 10 cm with a UV lamp for 40 min. Beads were resuspended in nuclease-
free deionised water and centrifugated and washed three times before analysis. 
5.6.3. Flow Cytometry Analysis of beads Containing Plasmid 
DNA with Propidium Iodide 
For sample analysis, 1 µL of sample was placed in 300 µL of PBS and 6 µL 
of propidium iodide solution (50 µg/ml in PBS) was added and mixed. Samples 
were analysed by flow cytometry using Texas Red filter. Untreated microspheres, 
microspheres with the addition of DNA plasmid and PI or PI only were used as 
negative controls. 
5.6.4. Incubation of beads with Restriction Enzymes 
Digestion with FastDigest® StuI (Eco147I, Fermentas):  
10 µL of plasmid or 10 µL microspheres bearing plasmid (4 µg of plasmid)  
was diluted with 22 µL of nuclease-free deionised water and digested with 4 µL of 
StuI restriction enzyme for 10 min in 4 µL of 1 x Tango buffer at 37 ºC in a 
water buffer. Samples were washed with nuclease-free deionised water (10 µL). 
Double digestion with FastDifest® Stu I and ApaI (Fermentas): 
10 µL of plasmid (0.4 µg/mL) or 10 µL of microspheres containing plasmid 
were diluted with 14 µL of nuclease-free water. To this solution, 4 µL of StuI and 
4 µL of ApaI restriction enzymes were added with the subsequent addition of     
8 µL of 1 x Tango buffer. The final solution was incubated for 15 min at 37 ºC in 
a water bath. Samples containing microspheres were centrifuged and washed 
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5.6.5. Non-covalent Capture of pEGFP 
NLS-PNS Conjugate Capture: 
Three eppendorfs were prepared with a 100 µL of 51a microspheres (0.38 
µm in size, 2% sc) and mixed with solutions of Rho- or FITC-labelled PNA 
solutions (550 µM) as follows: 
MIX microspheres: 25 µL of Rho- + 25µL FAM-PNA solutions 
FAM microspheres: 50 µL of Rho-PNA solution  
Rho microspheres: 50 µL of FITC-PNA solution  
Solvent from samples was evaporated in a speedvac for 1 h at 25 ºC and 
samples were then irradiated at 365 nm above 10 cm with a UV lamp for 40 min. 
Samples were resuspended with nuclease-free deionised water (100 µL). The 
loading of each sample was determined by measuring the concentration of 
labelled-PNA left in the supernatant solution by UV-Vis spectrometry (Table 5.1 
and Appendix III). Finally, beads were washed three times with nuclease-free 
deionised water. 
Microspheres Loading in 100 µL microspheres Reaction Yield (%) 
Mix 
15.7 nmol Rho-PNA / 
20.4 nmol FAM-PNA 
65 
FAM 41.5 nmol FAM-PNA 74 
Rho 42.6 nmol Rho-PNA 76 
Table 5.1: Determination of the fluorescently-labelled PNA loading onto microspheres by 
UV-Vis spectrometry of the supernatant solutions. 
pEGFP Capture by NLS-PNA functionalised microspheres: 
Three different conditions were used for the hybridisation of plasmid onto 
the PNA-containing microspheres. First, microspheres containing the Rho- and 
FAM-labelled PNA sequences (Mix microspheres) were used directly for the 
hybridisation (57). Second, identical amounts of microspheres containing 
antisense (FAM microspheres) and sense sequences (Rho microspheres) were 
mixed and used for hybridisation with plasmid with no additions (58). And third, 
microspheres containing FAM-labelled PNA sequences (FAM microspheres) were 
incubated with the plasmid and the addition of the Rho-labelled PNA solution (8 
µL, 21 mM solution) containing the same equivalents of the antisense sequence 
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on the microsphere (59). Samples of 15 µL of each microsphere type were 
mixed with 10, 20, or 40 µL of pEGFP-C1 solution. Hybridisation was carried out 
in a TC-312 thermocycler (Techne, Wolf Lavoratoried Ltd.) with a program 
starting from 5 min at 95 ºC and then 1 min decreasing the temperature 3 ºC 
until reaching RT. Samples were washed three times with DNAase-free deionised 
water before analysis or beadfection. 
5.6.6. Gel Retardation Assays 
A 0.7% agarose gel in thickness was prepared with 243 mg of agarose I-
B in 35 mL 1 x TBE buffer and diluted by warming the solution into a water bath 
at 60 ºC for 20 min. Once 3.5 µL of GelRed Nucleic Acid Stain (10,000x in water, 
Biotium) were added to the solution and mixed, the mixture was poured into the 
mould and allowed to cool down to RT for 1 h. Meanwhile, microsphere solutions 
were prepared by diluting 5 µL of microsphere solutions obtained after irradiation 
in enzyme digestion with TBE buffer (20 µL) and addition of 4 µL of loading dye. 
Samples were mixed well before injecting them into the gel. Negative control 
samples were prepared by dilution of 1 µL of plasmid solution in TBE buffer and 4 
µL of loading dye. Positive samples were prepared by dissolving 1 µL of plasmid 
(0.4 µg/µl in TE buffer) with 1 µL of Lipofectamine in 25 µL of TBE buffer.  
Positive controls were left for 20 minute of gentle mixing before adding 4 µL of 
loading dye. The migration gel was run for 45 min at 90 V.  
5.6.7. Cell assays 
Lipofection with LipofectamineTM 2000:  
HeLa and HEK293T cells were seeded in the appropriate growth media to 
24-well plates at a density of 3 x 104 cell/well (well volume = 350 µL). After 24 
hours and with a confluence of 90%, the old media was removed from the cells, 
washed with PBS and replaced with fresh serum- and antibiotic-free Opti-MEM® I 
Reduced Serum Medium (500 µL). The well plate was incubated before addition 
of the complexes. 
For each transfection sample, LipofectamineTM 2000 (2 µL) was incubated 
in Opti-MEM® media (50 µL) at 25°C for 5 min. EGFP-plasmid (0.8 µg, 2 µL of a 
stock solution of 0.4 µg/µL of plasmid in TE buffer) was diluted in Opti-MEM® 
media (50 µL) and mixed gently. Then, the two diluted solutions were combined 
(100 µL) and incubated at 25°C for 20min. This solution was added to the well 
plate and mixed gently by rocking the plate back and forth. 
Chapter V 
Experimental  155 
After 24-72 hours cells were washed, harvested by trypsination and 
prepared for flow cytometric analysis as described in general procedures. 
Beadfection of HEK293T Cells:  
HEK cells were suspended to the appropriate cell density in fresh growth 
media before seeding onto polystyrene well-plates (Nunc). Cells were incubated 
(37°C/5% CO2) for 24 hours to allow adhesion.  
Separately, DNA plasmid-containing microspheres were dispersed in fresh 
growth media to a concentration of 43, 86, and 172 µg/mL. The old media was 
removed from cells and replaced with fresh media containing microspheres. Cells 
were incubated in the presence of microspheres (37°C/5% CO2) for 48 and 72 
hours prior to analysis by flow cytometry and microscopy. 
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Appendix I 
NMR Spectres of TFMAD 4 Photolysis: 
 
 
Figure A.1: Photoreaction of 4 in CD3OD at room temperature monitored by 
1H-NMR 
(Arx250, CD3OD, 250MHz, 20 °C). 
 
 Appendix   157 
 
Figure A.2: Photoreaction of 4 in CD3OD at room temperature monitored by 
19F-NMR 
(Arx250, CD3OD, 235.9MHz, 20 °C) using TFA as an external standard (δ = 69.987 ppm). 
 




Figure A.3: Photoreaction of 4 and biotin in dry conditions and at -196 ºC monitored by 1H-
NMR (Arx250, d6-DMSO, 250MHz). 
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Figure A.4: Photoreaction of 4 and biotin in dry conditions and at -196 ºC monitored by     
19F-NMR (Arx250, d6-DMSO, 235.9MHz). 
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Appendix II 
List of the compounds generated from the top 25 potential binders from 
SPECTRUM library found on the three binding assays carried out towards          
β-TrCP1. The list also includes compounds that were not found active as negative 
controls. Highlighted compounds corresponded to those compounds found active 
towards β-TrCP1 by solution binding assays. 
1 Pyrromycin 41 Juglone 
2 Pyrvinium Pamoate 42 Pomiferin 
3 Doxorubicin 43 Tyrothricin 
4 Dehydrovariabilin 44 Thiridazine Hydrochloride 
5 Bisanhydrotutilantinone 45 Dalbergione 
6 Fenofibrate 46 Ethisterone 
7 Rutilantinone 47 Apigenin 
8 Dichlorophene 48 Haematoporphyrin 
9 Naphazoline Hydrochloride 49 2001-039 
10 Hexachlorophene 50 Quinacrine Hydrochloride 
11 Bithionate Sodium 51 Derrubone 
12 Auraptene 52 Chlorhexidine 
13 Pararosaniline Pamoate 53 Purpurin 
14 Tannic Acid 54 Perillyl Alcohol 
15 Benzbromarone 55 Thiostrepton 
16 Daunorubicin 56 Indapamide 
17 Gentian Violet 57 Epirubicin Hydrochloride 
18 Gambogic Acid Amide 58 Carbetapentane Citrate 
19 3,4’-Dimethoxyflavone 59 Ornidazole 
20 Probucol 60 2001-039 
21 Trazodone Hydrochloride 61 Methyl Robustone 
22 Dibutyl Phthalate 62 Triamterene 
23 Pyrimethamine 63 Adenosine Phsophate 
24 Gossypol 64 Danthron 
25 Grayanotoxin I 65 Physcion 
26 Pimozide 66 Acriflavinium Hydrochloride 
27 Curcumin 67 1770-173 
28 Methyl 7-Deshydroxypyrogallin-4-
ccarcarboxylate 
68 Colistin sulphate 
29 Nisldipine 69 Polymyxin B sulfate 
30 Phloretin 70 Sulfacetamide 
31 Theaflavin Digallate 71 Scopolamine Hydrobromide 
32 Temefos 72 Mecamylamine Hydrochloride  
33 Propranolol Hydrochloride (+/-) 73 Sisomicin sulphate 
34 Resveratrol 74 Mephenesin 
35 Aristolochich acid 75 Pirenzepine Hydrochloride 
36 Eugenyl Benzoate 76 Dropropizine 
37 4’-methoxychalcone 77 Methylbenzethonium Chloride 
38 Gossypetin 78 Bambuterol Hydrochloride 
39 Oxidopamine Hydrochloride 79 Quinine Sulfate 
40 Theaflavin Monogallates 80 Chlormezanone 
 
 
Table A.1: List of 80 selected compounds form SPECTRUM library. Highlighted compound 
were found active for inhibition of β-TrCP1 by fluorescence polaritsation assays. 
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Appendix III 
Calibration and determination of the extinction coefficient of FAM-PNA 
conjugate at 501 and 560 nm: 
 
Figure A.5: Absorbance spectra of three different concentrations of FAM-labelled PNA 
sequence. 
 
Graph A.1: Determination of the extinction coefficient of fluorescein at 501 nm with the 
absorbance values obtained for each concentration. 
 
FAM-labelled PNA sequence has an ε of 16,117 M-1cm-1 at 501 nm and a 
null value at 560 nm. 
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Calibration and determination of the extinction coefficient of  Rho-labelled 
PNA sequence at 501 and 560 nm 
 




Graph A.2: Determination of the extinction coefficient of Rhodamine at 501 and 560 nm with 
the absorbance values obtained for each concentration. 
 
Rho-labelled PNA sequence has an ε of 3,570 M-1cm-1 at 501 nm and 




 Appendix   163 
Measurements with supernatant samples: 
λ (nm) Rho Mix FAM
501 0.02282 0.224532 0.157685





Figure A.7: Absorbance spectra of the three supernatant samples collected after irradiation 
at 365 nm with TFMAD-functionalised microspheres. The number of nmols present in the 
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